

CITATION REPORT

List of articles citing

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

DOI: 10.1016/s1470-2045(14)70442-5
Lancet Oncology, The, 2014, 15, e538-48.

Source: <https://exaly.com/paper-pdf/59205260/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2256	Das Multiple Myelom [Was ist bei der Diagnostik und Erstellung eines Behandlungskonzepts zu beachten?]. 2015 , 44, 456-466		
2255	Acute graft-versus-host disease and bronchiolitis obliterans after autologous stem cell transplantation in a patient with multiple myeloma. 2015 , 3, 370-5		3
2254	Advances in the pathogenesis and diagnosis of multiple myeloma. 2015 , 37 Suppl 1, 108-14		33
2253	Multiple Myeloma. 2015 , 537-561		
2252	Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. 2015 , 126, 1996-2004		76
2251	The cellular origin and malignant transformation of Waldenström macroglobulinemia. 2015 , 125, 2370-80		51
2250	Pathogenesis beyond the cancer clone(s) in multiple myeloma. 2015 , 125, 3049-58		181
2249	Macro-quest. 2015 , 125, 2318-9		2
2248	How I treat fragile myeloma patients. 2015 , 126, 2179-85		57
2247	Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). 2015 , 100, 1214-21		34
2246	Incidental Discovery of Multiple Myeloma, Presenting as an Amyloid Tumor with Plasmacytic Elements of the Thoracic Wall. 2015 , 53, 267-72		
2245	Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay. 2015 , 47, 564-9		7
2244	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. 2015 , 3, 47-68		11
2243	High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. 2015 , 8, 77		21
2242	Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. 2015 , 5, 1		4
2241	Time to redefine Myeloma. 2015 , 171, 1-10		14
2240	Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. 2015 , 35, 1173-88		39

2239	Multiple myeloma: is it time for biomarker-driven therapy?. 2015 , e493-503	10
2238	La Situaciin Del CCncer En Espaaa: Informe 2015 (The Situation of Cancer in Spain: Report 2015). 2015 ,	1
2237	Orbital Plasmablastic Plasmacytoma in Multiple Myeloma. 2015 , 06,	
2236	Positron Emission Tomography with Integrated Computed Tomography in Multiple Myeloma: A Silent Revolution. 2015 , 03,	
2235	Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model. 2015 , 2, 76	36
2234	Differential Expression of Non-Shelterin Genes Associated with High Telomerase Levels and Telomere Shortening in Plasma Cell Disorders. 2015 , 10, e0137972	5
2233	PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. 2015 , 10, e0139867	55
2232	Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy". 2015 , 2015, 742762	1
2231	Facial Swelling as a Primary Manifestation of Multiple Myeloma. 2015 , 2015, 319231	2
2230	Light Chain Escape in 3 Cases: Evidence of Intraclonal Heterogeneity in Multiple Myeloma from a Single Institution in Poland. 2015 , 2015, 809840	4
2229	Nonsecretory Multiple Myeloma and AL Amyloidosis Presenting with Nephrotic Range Proteinuria. 2015 , 2015, 635974	
2228	Smoldering multiple myeloma: when to observe and when to treat?. 2015 , e484-92	5
2227	Paraprotein-related Bleeding as a First Symptom of Multiple Myeloma. 2015 , 03,	2
2226	Hyponatraemia in patients with multiple myeloma. 2015 , 2015,	1
2225	Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis. 2015 , 2015,	1
2224	Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. 2015 , 11, 1643-58	
2223	Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. 2015 , 5, e296	73
2222	Extramedullary Soft Tissue Involvement and Discrepant Osseous Uptake on Tc-99m MDP and Ga-67 Citrate Scintigraphy in a Patient With Multiple Myeloma: A Case Report and Literature Review. 2015 , 94, e995	1

2221	A Bone to Pick Regarding Use of Magnetic Resonance Imaging to Begin Treatment in Patients With Asymptomatic Multiple Myeloma. 2015 , 33, 2925-6	2
2220	Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. 2015 , 5, e364	70
2219	Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma. 2015 , 5, e363	26
2218	Evolving diagnostic criteria for multiple myeloma. 2015 , 2015, 272-8	35
2217	Multiple myeloma and atopic eczema in an adult. 2015 , 8, 58-63	0
2216	Smoldering multiple myeloma: to treat or not to treat. 2015 , 16, 785-90	1
2215	Managing multiple myeloma in the over 70s: a review. 2015 , 80, 148-54	6
2214	Risk of progression in MGUS. 2015 , 2, e6-7	2
2213	Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. 2015 , 5, e271	13
2212	The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. 2015 , 21, 1068-73	36
2211	Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. 2015 , 87, 8268-74	19
2210	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. 2015 , 1, 174-5	6
2209	IgG subclass distribution in patients with monoclonal gammopathy. 2015 , 444, 167-9	2
2208	Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. 2015 , 15, 737-48	43
2207	Handbook of Multiple Myeloma. 2015 ,	3
2206	Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis. 2015 , 8, 264-8	11
2205	Peptide-based immunotherapy in multiple myeloma. 2015 , 46, 248-253	
2204	American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. 2015 , 8, 273-5	5

2203	A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma. 2015 , 100, 818-25	31
2202	Treatment of patients with multiple myeloma who are not eligible for stem cell transplantation: position statement of the myeloma foundation of Australia Medical and Scientific Advisory Group. 2015 , 45, 335-43	4
2201	Multiple asymptomatic colon plasmacytomas: a diagnostic and therapeutic dilemma. 2015 , 94, 1061-2	1
2200	Tailoring treatment in myeloma: are there clues from biology?. 2015 , 8, 11-15	0
2199	Imaging myeloma and related monoclonal plasma cell disorders using MRI, low-dose whole-body CT and FDG PET/CT. 2015 , 3, 95-109	1
2198	Smoldering multiple myeloma. 2015 , 125, 3069-75	159
2197	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2015. 2015 , 46, 159-211	
2196	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. 2015 , 126, 9-16	1005
2195	PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. 2015 , 21, 4384-90	108
2194	High incidence of intact or fragmented immunoglobulin in urine of patients with multiple myeloma. 2015 , 56, 3348-56	2
2193	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. 2015 , 7, 985-1001	23
2192	Interpretation of cytogenetic results in multiple myeloma for clinical practice. 2015 , 5, e365	121
2191	Reply to D.L. Cooper. 2015 , 33, 2926-7	
2190	Letter: Monoclonal gammopathy of HEV infection. When is it significant?. 2015 , 41, 1027-8	1
2189	V. Smoldering multiple myeloma. 2015 , 33 Suppl 1, 33-7	4
2188	European Myeloma Network guidelines for the management of multiple myeloma-related complications. 2015 , 100, 1254-66	222
2187	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. 2015 , 6, 7213	54
2186	Whole body diffusion weighted MRI--a new view of myeloma. 2015 , 171, 29-37	63

2185	Clinical and prognostic significance of bone marrow abnormalities in the appendicular skeleton detected by low-dose whole-body multidetector computed tomography in patients with multiple myeloma. 2015 , 5, e329	20
2184	Clinical treatment of newly diagnosed multiple myeloma. 2015 , 8, 595-611	7
2183	Trends in survival of multiple myeloma: a thirty-year population-based study in a single institution. 2015 , 39, 693-9	17
2182	Panobinostat for the Treatment of Multiple Myeloma. 2015 , 21, 4767-73	150
2181	Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment. 2015 , 12, 71-2	5
2180	Polycythaemia: an unusual presentation of multiple myeloma. 2016 , 2016,	1
2179	Role of stem cell transplant and maintenance therapy in plasma cell disorders. 2016 , 2016, 504-511	2
2178	Immunochemical Characterization of Immunoglobulins in Serum, Urine, and Cerebrospinal Fluid. 2016 , 89-100	
2177	. 2016 ,	
2176	13. Molecular pathogenesis of multiplemyeloma. 2016 , 245-256	
2175	Kinase inhibitors as potential agents in the treatment of multiple myeloma. 2016 , 7, 81926-81968	13
2174	POEMS SYNDROME: an Update. 2017 , 9, e2017051	17
2173	Solitary Plasmacytoma. 2017 , 9, e2017052	24
2172	Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. 2016 , 8, 6295	6
2171	Single Best Answers. 2016 , 101-154	
2170	Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes. 2016 , 6, 21-35	0
2169	Non-Secretory Myeloma: Ready for a new Definition?. 2017 , 9, e2017053	9
2168	Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?. 2016 , 9, 4843-58	4

2167	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. 2016 , 35, e400-6	1
2166	Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons. 2016 , 35, e425-30	11
2165	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. 2016 , 7, 47127-47133	5
2164	Updated Diagnostic Criteria and Staging System for Multiple Myeloma. 2016 , 35, e418-23	110
2163	The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. 2016 , 35, e407-17	29
2162	Assessing the Driving Forces Influencing World City Formation in Shanghai Based upon PLS-SEM Approach. 2016 ,	
2161	Light chain multiple myeloma: when the response will it be evaluated by serum free light chains?. 2016 , 22, 393-394	
2160	Massive Retroperitoneal Hemorrhage as an Initial Presentation of a Rare and Aggressive Form of Multiple Myeloma. 2016 , 2016, 8206826	
2159	Imaging Findings of Plasmacytoma of Both Breasts as a Preceding Manifestation of Multiple Myeloma. 2016 , 2016, 6595610	3
2158	The Diagnosis and Treatment of Multiple Myeloma. 2016 , 113, 470-6	73
2157	Non-secretory multiple myeloma: from biology to clinical management. 2016 , 9, 7583-7590	25
2156	Three cases of systemic amyloidosis successfully diagnosed by subcutaneous fat tissue biopsy of the hip. 2016 , 11, 1061-6	
2155	Towards Stratified Medicine in Plasma Cell Myeloma. 2016 , 17,	6
2154	New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma. 2016 , 6, 287-90	25
2153	Multiple myeloma in the very elderly patient: challenges and solutions. 2016 , 11, 423-35	23
2152	A retrospective analysis of cytogenetic alterations in patients with newly diagnosed multiple myeloma: a single center study in Korea. 2016 , 51, 122-6	4
2151	Multiple myeloma: Looking beyond standards. 2016 , 02, 023-028	
2150	Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. 2016 , 25, 127-37	43

2149	The Prognostic Significance of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Patients With Multiple Myeloma. 2016 , 30, 1208-1213		17
2148	Effective use of panobinostat in combination with other active agents in myeloma in a novel five-drug combination: Case report and interesting observations. 2016 , 91, E5-6		3
2147	Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma. 2016 , 174, 127-35		21
2146	Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers. 2016 , 97, 201-7		3
2145	Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients. 2016 , 16, 2676-83		4
2144	Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1127-1136	21.7	100
2143	Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients. 2016 , 91, 700-4		21
2142	Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study. 2016 , 97, 217-8		
2141	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. 2016 , 51, 41-48		3
2140	Prevalence, incidence and survival of smoldering multiple myeloma in the United States. 2016 , 6, e486		34
2139	Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. 2016 , 54, 907-19		40
2138	Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. 2016 , 128, 2941-2948		39
2137	MGUS to myeloma: a mysterious gammopathy of underexplored significance. 2016 , 128, 2599-2606		83
2136	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. 2016 , 1, e000097		59
2135	Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. 2016 , 6, e454		42
2134	Pee no more? Urine light chains down the drain. 2016 , 128, 2873-2874		1
2133	Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. 2016 , 128, 2757-2764		56
2132	Plasma Cell Neoplasms. 2016 ,		

2131	Role of stem cell transplant and maintenance therapy in plasma cell disorders. 2016 , 2016, 504-511	13
2130	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. 2016 , 14, 389-400	44
2129	Utility of flow cytometry studies in the management of patients with multiple myeloma. 2016 , 28, 511-517	15
2128	Robust estimates of overall immune-repertoire diversity from high-throughput measurements on samples. 2016 , 7, 11881	44
2127	Primary amyloidosis. 2016 , 147, 121-126	
2126	Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation. 2016 , 23, 254-259	4
2125	Measurement of free light chains with assays based on monoclonal antibodies. 2016 , 54, 1005-14	14
2124	Elotuzumab for treating myeloma. 2016 , 4, 215-222	
2123	Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies. 2016 , 38, 37-43	2
2122	MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings. 2016 , 7, 553-69	63
2121	Multiple myeloma and multiple plasmacytomas associated with free gamma heavy chain, free kappa light chain and IgGk paraproteins: an unusual triple gammopathy. 2016 , 53, 706-711	4
2120	Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents. 2016 , 57, 640-5	26
2119	Treatment of relapsed and refractory multiple myeloma. 2016 , 101, 396-406	84
2118	A man with a short history of lower back pain. 2016 , 353, i1722	
2117	Diagnostic Advances in Multiple Myeloma. 2016 , 11, 111-7	4
2116	Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. 2016 , 9, 101-16	6
2115	Nuances in the Management of Older People With Multiple Myeloma. 2016 , 11, 241-51	11
2114	Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. 2016 , 96, 610-7	18

2113	Quantification of I region IgA paraproteins - should we include immunochemical "heavy/light chain" measurements? Counterpoint. 2016 , 54, 1059-64	4
2112	Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. 2016 , 54, 1095-104	87
2111	Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. 2016 , 30, 1869-76	6
2110	[Primary amyloidosis]. 2016 , 147, 121-6	1
2109	Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902). 2016 , 95, 921-9	3
2108	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. 2016 , 30, 2026-2031	17
2107	Audit of Use and Overuse of Serum Protein Immunofixation Electrophoresis and Serum Free Light Chain Assay in Tertiary Health Care: A Case for Algorithmic Testing to Optimize Laboratory Utilization. 2016 , 145, 531-7	9
2106	Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease. 2016 , 54, 1039-43	2
2105	Discrepancy between FLC assays: only a problem of quantification?. 2016 , 54, 1111-3	4
2104	Laboratory testing in monoclonal gammopathy of renal significance (MGRS). 2016 , 54, 929-37	27
2103	Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. 2016 , 54, 997-1003	18
2102	Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. 2016 , 104, 300-9	43
2101	Myeloma imaging: time to move on!. 2016 , 57, 1499-500	3
2100	How I treat extramedullary myeloma. 2016 , 127, 971-6	103
2099	Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. 2016 , 127, 1151-62	49
2098	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. 2016 , 127, 2955-62	463
2097	VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. 2016 , 127, 2569-74	167
2096	A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. 2016 , 6, e467	47

2095	Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. 2016 , 14, 259	13
2094	Progression of a solitary plasmacytoma to multiple myeloma. A population-based registry of the northern Netherlands. 2016 , 175, 661-667	36
2093	77-Year-Old Man With a Painful Left Knee, Anemia, and Renal Insufficiency. 2016 , 91, e149-e153	
2092	Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. 2016 , 29, 187-193	4
2091	Maintenance lenalidomide after transplantation: How much is enough?. 2016 , 122, 3762-3764	
2090	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. 2016 , 23, 214-220	5
2089	The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. 2016 , 33, 1896-1920	11
2088	Extracorporeal Removal of Serum-Free Light Chains in Patients with Multiple Myeloma-Associated Acute Kidney Injury. 2016 , 143-148	
2087	Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports. 2016 , 12, 2363-2370	2
2086	Progress in Myeloma - A Monoclonal Breakthrough. 2016 , 375, 1390-1392	33
2085	Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis. 2016 , 23, 221-224	4
2084	MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. 2016 , 169, 3-12	23
2083	New investigational drugs with single-agent activity in multiple myeloma. 2016 , 6, e451	54
2082	61-Year-Old Man With Right Knee Pain and Chronic Anemia. 2016 , 91, 1640-1644	
2081	Baseline characteristics, chromosomal alterations, and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. 2016 , 91, E473-E477	23
2080	Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. 2016 , 91, 719-34	279
2079	Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. 2016 , 90, 81-90	37
2078	Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions. 2016 , 245, S113-8	5

2077	Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate. 2016 , 146, 207-14	28
2076	Aggressive and extramedullary plasma cell myeloma evade bone marrow flow cytometric minimal residual disease detection. 2016 , 173, 947-9	2
2075	Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. 2016 , 38 Suppl 1, 110-22	30
2074	Multiple myeloma in the marrow: pathogenesis and treatments. 2016 , 1364, 32-51	83
2073	Myeloma today: Disease definitions and treatment advances. 2016 , 91, 90-100	105
2072	Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service. 2016 , 90, 54-60	13
2071	Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model. 2016 , 172, 64-79	13
2070	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. 2016 , 270, 95-112	197
2069	Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. 2016 , 2, 1261-1262	
2068	Current Trends of Renal Impairment in Multiple Myeloma. 2016 , 1, 241-57	41
2067	Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. 2016 , 11, 2273-2279	33
2066	Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance. 2016 , 11, 2280-2287	29
2065	Treatment of high-risk smoldering myeloma. 2016 , 43, 695-696	2
2064	Erythropoietin treatment in murine multiple myeloma: immune gain and bone loss. 2016 , 6, 30998	13
2063	Consensus on Surgical Management of Myeloma Bone Disease. 2016 , 8, 263-9	10
2062	Current treatments for renal failure due to multiple myeloma. 2016 , 17, 2165-2177	17
2061	Multiple myeloma: managing a complex blood cancer. 2016 , 25, S18-28	9
2060	Evaluation of the Impact of Renal Failure on Correlation and Concordance Between 2 Free Light Chain Assays. 2016 , 16, 693-704	6

2059	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	21.7	1155
2058	Managing renal complications in multiple myeloma. 2016 , 9, 839-50		11
2057	Imaging of Multiple Myeloma. 2016 , 30, 843-65		8
2056	Reducing Mortality in Acute Kidney Injury. 2016 ,		
2055	Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. 2016 , 175, 448-456		35
2054	Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis. 2016 , 29, 702-709		14
2053	Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). 2016 , 49, 33-50		23
2052	Multiple myeloma epidemiology and survival: A unique malignancy. 2016 , 43, 676-681		255
2051	Progress and Paradigms in Multiple Myeloma. 2016 , 22, 5419-5427		96
2050	New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. 2016 , 22, 5428-5433		62
2049	Imaging Measurable (Minimal) Residual Disease in Multiple Myeloma. 2016 , 4, 1		
2048	Plasma Cell Disorders. 2016 , 43, 677-691		11
2047	Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology. 2016 , 29, 735-746		14
2046	Baseline bone involvement in multiple myeloma - a prospective comparison of conventional X-ray, low-dose computed tomography, and 18flourodeoxyglucose positron emission tomography in previously untreated patients. 2016 , 101, e415-e418		18
2045	Controversies in multiple myeloma: Evidence-based update. 2016 , 43, 666-675		6
2044	Genetic interrogation of circulating multiple myeloma cells at single-cell resolution. 2016 , 8, 363ra147		93
2043	Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment. 2016 , 101, e419-e422		12
2042	Section 4: Single Best Answers Answers to Questions 1-20 with Feedback. 2016 , 101-154		

2041	Current Controversies in the Management of Myeloma Bone Disease. 2016 , 231, 2374-9	26
2040	Excessive diagnostic testing in acute kidney injury. 2016 , 17, 9	9
2039	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. 2016 , 43, 1995-2004	50
2038	Multiples Myelom. 2016 , 11, 28-33	
2037	Multiple myeloma-associated skin light chain amyloidosis: A case of misdiagnosis. 2016 , 11, 3617-3620	1
2036	Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. 2016 , 67, 2941-8	60
2035	Prognostic Effect of Low Subcutaneous Adipose Tissue on Survival Outcome in Patients With Multiple Myeloma. 2016 , 16, 434-41	20
2034	PET-CT in the UK: current status and future directions. 2016 , 71, 673-90	14
2033	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. 2016 , 47, 39-85	8
2032	Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma. 2016 , 186, 2171-2182	26
2031	Circulating aberrant plasma cells allows risk stratification of patients with myeloma. 2016 , 91, E353-E355	9
2030	Diagnostic reference range of κ/λ free light chain ratio to screen for Bence Jones proteinuria is not significantly influenced by GFR. 2016 , 96, 527-31	1
2029	Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study. 2016 , 97, 303-9	41
2028	Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. 2016 , 97, 568-575	20
2027	Implemented myeloma management with whole-body low-dose CT scan: a real life experience. 2016 , 57, 1539-45	8
2026	Myeloma. 2016 , 89-100	
2025	Multiple qualitative and quantitative methods for free light chain analysis are necessary as first line tests for AL amyloidosis. 2016 , 54, 981-4	0
2024	Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features. 2016 , 27, 81-91	21

2023	Osteolytica: An automated image analysis software package that rapidly measures cancer-induced osteolytic lesions in in vivo models with greater reproducibility compared to other commonly used methods. 2016 , 83, 9-16	7
2022	Is accuracy of serum free light chain measurement achievable?. 2016 , 54, 1021-30	26
2021	Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. 2016 , 44, 342-351.e5	3
2020	Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. 2016 , 5, e1093721	15
2019	To biopsy or not to biopsy, that is the question in myeloma cast nephropathy. 2016 , 31, 1-3	41
2018	State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias. 2016 , 54, 581-96	9
2017	Measurement of free light chains - pros and cons of current methods. 2016 , 54, 1015-20	14
2016	A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine. 2016 , 11, 1073-82	5
2015	Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. 2016 , 38, 113-20	5
2014	Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014. 2016 , 6, e409	8
2013	Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma. 2016 , 57, 2516-25	13
2012	A systematic study comparing aspirate versus trephine for quantifying plasma cell infiltration in newly-diagnosed myeloma. 2016 , 174, 818-20	4
2011	Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology. 2016 , 26, 3939-3948	21
2010	Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics. 2016 , 11, 102-10	8
2009	Risk Stratification in Multiple Myeloma. 2016 , 11, 137-47	11
2008	Is it possible to cure myeloma without allogeneic transplantation?. 2016 , 54, 63-70	8
2007	Bone Disease in Myeloma: The Claws of CRAB. 2016 , 22, 1301-3	1
2006	Recurrent Subepidermal Blistering Dermatitis heralding disease relapse in IgA Kappa Multiple Myeloma: Report of a Case and a Review of the Literature. 2016 , 16, e1-5	

2005	Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging. 2016 , 57, 1114-21	22
2004	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. 2016 , 21, 333-42	21
2003	International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. 2016 , 34, 1544-57	204
2002	Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. 2016 , 57, 1534-8	5
2001	The effects of proteasome inhibitors on bone remodeling in multiple myeloma. 2016 , 86, 131-8	29
2000	Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques. 2016 , 101, 169-83	19
1999	Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. 2016 , 6, e396	18
1998	Bone marrow invasion in multiple myeloma and metastatic disease. 2016 , 58 Suppl 1, 81-93	1
1997	Low immunoglobulin A levels detected via the tissue transglutaminase assay can reveal previously undetected monoclonal proteins. 2016 , 53, 409-11	1
1996	Screening immunofixation should replace protein electrophoresis as the initial investigation of monoclonal gammopathy: Point. 2016 , 54, 963-6	6
1995	Should routine laboratories stop doing screening serum protein electrophoresis and replace it with screening immune-fixation electrophoresis? No quick fixes: Counterpoint. 2016 , 54, 967-71	3
1994	Fibronectin on the Surface of Myeloma Cell-derived Exosomes Mediates Exosome-Cell Interactions. 2016 , 291, 1652-1663	156
1993	Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. 2016 , 16, 29-35	12
1992	Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. 2016 , 216, 128-134	
1991	Multiple Myeloma: Diagnosis and Treatment. 2016 , 91, 101-19	290
1990	New pharmacotherapy options for multiple myeloma. 2016 , 17, 181-92	11
1989	New Approaches to Molecular Imaging of Multiple Myeloma. 2016 , 57, 1-4	30
1988	Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20. 2016 , 30, 409-16	45

1987	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. 2016 , 32, 191-205	3
1986	Laboratory guidelines for the diagnosis and follow-up of patients with monoclonal gammopathies. 2016 , 216, 128-34	1
1985	18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. 2016 , 30, 417-22	96
1984	Search for familial clustering of multiple myeloma with any cancer. 2016 , 30, 627-32	31
1983	A Pooled Analysis of Reproductive Factors, Exogenous Hormone Use, and Risk of Multiple Myeloma among Women in the International Multiple Myeloma Consortium. 2016 , 25, 217-21	4
1982	Gradual increase of chronic lymphocytic leukemia incidence in Korea, 1999-2010: comparison to plasma cell myeloma. 2016 , 57, 585-9	8
1981	Minimal residual disease testing after stem cell transplantation for multiple myeloma. 2016 , 51, 2-12	15
1980	Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry. 2017 , 35, 323-328	16
1979	Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. 2017 , 21, 212-227	9
1978	Management of multiple myeloma in older adults: Gaining ground with geriatric assessment. 2017 , 8, 1-7	17
1977	Activity of aldehyde dehydrogenase in B-cell and plasma cell subsets of monoclonal gammopathy patients and healthy donors. 2017 , 98, 19-25	2
1976	Solitary Extramedullary Plasmacytoma of the Orbital Apex and Dura Masquerading as Idiopathic Inflammation. 2017 , 33, S92-S94	1
1975	Bone mineral density utilization in patients with newly diagnosed multiple myeloma. 2017 , 35, 703-710	7
1974	Potential therapeutic targets in plasma cell disorders: A flow cytometry study. 2017 , 92, 145-152	10
1973	Developments in the Field of Myeloma in the Last Decade. 2017 , 33, 3-7	2
1972	A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. 2017 , 116, 705-710	3
1971	Correlation of multiparameter flow cytometry and bone marrow trephine immunohistochemistry in the identification and characterization of neoplastic plasma cells. 2017 , 179, 499-501	2
1970	expressing CD14CD16 monocytes expand in multiple myeloma patients leading to increased osteoclasts. 2017 , 102, 773-784	26

1969	Nodular mucinosis associated with light-chain monoclonal gammopathy of uncertain significance. 2017 , 108, 272-273	
1968	Incidental findings of monoclonal proteins from carbohydrate-deficient transferrin analysis using capillary electrophoresis. 2017 , 55, e133-e136	1
1967	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). 2017 , 102, e112-e114	32
1966	Amyloidosis of the Lung. 2017 , 141, 247-254	53
1965	Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study. 2017 , 177, 67-71	27
1964	Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. 2017 , 56, 1722-1732	22
1963	Safety issues and management of toxicities associated with new treatments for multiple myeloma. 2017 , 10, 193-205	5
1962	Pulmonary-renal syndrome as a clinical expression of multiple myeloma. 2017 , 37, 445-446	
1961	Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma. 2017 , 177, 395-403	13
1960	Restoration of renal function in patients with newly diagnosed multiple myeloma is not associated with improved survival: a population-based study. 2017 , 58, 1-9	8
1959	RGS1 expression is associated with poor prognosis in multiple myeloma. 2017 , 70, 202-207	17
1958	Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma. 2017 , 7, e530	23
1957	Diagnostic Liquid-Based Cytology. 2017 ,	13
1956	Prise en charge des lésions osseuses du myélome multiple : quelles particularités ? 2017 , 84, 197-204	
1955	How I manage the toxicities of myeloma drugs. 2017 , 129, 2359-2367	28
1954	PET/MR Imaging of Multiple Myeloma. 2017 , 25, 351-365	15
1953	An Evidence-Based Approach to Myeloma Bone Disease. 2017 , 12, 109-118	9
1952	Multiple myeloma. 2017 , 78, C21-C27	10

1951	Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. 2017 , 70, 775-780	35
1950	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. 2017 , 98, 563-568	6
1949	Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. 2017 , 17, 13	51
1948	Acute Anuric Renal Failure in an 80-Year-Old Man. 2017 , 317, 1471-1472	
1947	Osteolytic-variant POEMS syndrome: an uncommon presentation of "osteosclerotic" myeloma. 2017 , 46, 817-823	4
1946	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. 2017 , 13, 1181-1193	19
1945	The Value of Anti-Angiogenics in Multiple Myeloma Therapy. 2017 , 1-19	
1944	A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role?. 2017 , 209, 152-158	20
1943	Multiple myeloma of the spine. 2017 , 30, 259-268	18
1942	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. 2017 , 23, 3980-3993	51
1941	Plasmacytoma of the Temporal Bone, a Great Imitator: Report of Seven Cases and Comprehensive Review of the Literature. 2017 , 38, 400-407	9
1940	Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone. 2017 , 14, 1382-1384	6
1939	Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. 2017 , 96, 987-993	10
1938	A first Czech analysis of 1887 cases with monoclonal gammopathy of undetermined significance. 2017 , 99, 80-90	5
1937	Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance. 2017 , 58, 2962-2965	4
1936	How is patient care for multiple myeloma advancing?. 2017 , 10, 551-561	9
1935	CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy. 2017 , 99, 186-189	13
1934	Safety and cost-effectiveness of outpatient autologous transplantation for multiple myeloma in Asia: single-center perspective from Singapore. 2017 , 52, 1044-1046	10

1933	The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. 2017 , 58, 2582-2587	7
1932	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. 2017 , 23, 1549-1554	21
1931	Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure. 2017 , 13, 2490-2494	22
1930	Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. 2017 , 92, 838-850	65
1929	Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma. 2017 , 108, 187-192	8
1928	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. 2017 , 178, 196-208	13
1927	Glomerular Diseases Associated with Malignancies. 2017 , 1-40	
1926	The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. 2017 , 92, 772-779	71
1925	Novel investigational drugs active as single agents in multiple myeloma. 2017 , 26, 699-711	10
1924	Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017 , 28, iv52-iv61	426
1923	Epigenetic repression of miR-375 is the dominant mechanism for constitutive activation of the PDPK1/RPS6KA3 signalling axis in multiple myeloma. 2017 , 178, 534-546	19
1922	Cancer Cytogenetics. 2017 ,	4
1921	Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting. 2017 , 44, 332-341	8
1920	Recurrent Cytogenetic Abnormalities in Multiple Myeloma. 2017 , 1541, 295-302	6
1919	High apelin levels could be used as a diagnostic marker in multiple myeloma: A comparative study. 2016 , 17, 391-396	12
1918	Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy. 2017 , 31, e403-e405	1
1917	Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. 2017 , 130, 974-981	312
1916	Tumors of the Sacrum. 2017 ,	2

1915	Diffusion-weighted whole-body MRI for evaluation of early response in multiple myeloma. 2017 , 72, 850-857	28
1914	[Current Aspects in Diagnosis and Therapy of Plasma Cell Myeloma]. 2017 , 142, 800-804	
1913	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. 2017 , 99, 216-222	19
1912	Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. 2017 , 99, 223-233	31
1911	Therapy assessment in multiple myeloma with PET. 2017 , 44, 111-117	12
1910	Monitoring of light chain myeloma - time for a change. 2017 , 178, 177-178	3
1909	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. 2017 , 25, 1317-1320	12
1908	Performance Evaluation of Serum Free Light Chain Analysis: Nephelometry vs Turbidimetry, Monoclonal vs Polyclonal Reagents. 2017 , 147, 611-622	15
1907	Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. 2017 , 178, 781-793	11
1906	Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. 2017 , 148, 517-523	
1905	Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. 2017 , 96, 1053-1056	1
1904	Nodular Mucinosi s Associated With Light-Chain Monoclonal Gammopathy of Uncertain Significance. 2017 , 108, 272-273	
1903	A systematic review of health-related quality of life in longitudinal studies of myeloma patients. 2017 , 99, 3-17	38
1902	The Critical Role of Imaging in the Management of Multiple Myeloma. 2017 , 12, 168-175	8
1901	Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. 2017 , 7, 45681	26
1900	Myeloma and MGUS. 2017 , 45, 311-317	1
1899	Musculoskeletal Imaging Findings of Hematologic Malignancies. 2017 , 37, 881-900	38
1898	Re: Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis. 2017 , 30, 265	

1897	IgM myeloma: A multicenter retrospective study of 134 patients. 2017 , 92, 746-751		21
1896	Monitoring multiple myeloma by quantification of recurrent mutations in serum. 2017 , 102, 1266-1272		34
1895	Which therapies will move to the front line for multiple myeloma?. 2017 , 10, 383-392		7
1894	Extracellular matrix protein Reelin promotes myeloma progression by facilitating tumor cell proliferation and glycolysis. 2017 , 7, 45305		13
1893	Role of F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2017 , 18, e206-e217	21.7	275
1892	Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances. 2017 , 23, 1193-1202		6
1891	Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. 2017 , 55, 1598-1604		6
1890	Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma. 2017 , 46, 733-750		28
1889	Imagerie des lésions osseuses du myélome. 2017 , 84, 187-195		
1888	Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. 2017 , 98, 388-392		10
1887	Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum IgA and Immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. 2017 , 55, 424-434		18
1886	Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib. 2017 , 96, 449-459		14
1885	Free light chains: Eclectic multipurpose biomarker. 2017 , 451, 11-19		24
1884	DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma. 2017 , 40, 315-322		9
1883	Predictors of Prognosis in Light-Chain Amyloidosis and Chronological Changes in Cardiac Morphology and Function. 2017 , 120, 2041-2048		4
1882	Current applications of multiparameter flow cytometry in plasma cell disorders. 2017 , 7, e617		26
1881	Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. 2018 , 91, 20170344		18
1880	Whole-Body MRI: Current Applications in Oncology. 2017 , 209, W336-W349		49

1879	Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. 2017 , 7, 12885	6
1878	Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients. 2017 , 17, 825-833	5
1877	Evolutionary biology of high-risk multiple myeloma. 2017 , 17, 543-556	119
1876	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. 2017 , 12, 643-654	16
1875	Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. 2017 , 7, e599	83
1874	Pleural Effusion in Multiple Myeloma: A Liquid State. 2017 , 138, 67-68	2
1873	HIF-2 β Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1. 2017 , 77, 5452-5463	33
1872	Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. 2017 , 52, 1602-1608	12
1871	The treatment of paraprotein-related kidney disease. 2017 , 26, 477-483	4
1870	The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies. 2017 , 99, 449-458	5
1869	Myeloma and Bone Disease. 2017 , 15, 483-498	35
1868	Multiple myeloma. 2017 , 3, 17046	484
1867	POEMS syndrome: An elusive diagnosis. 2017 , 92, 1269-1270	1
1866	Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience. 2017 , 101, e337-e342	13
1865	Evidence-Based Guidelines for Preventing and Managing Side Effects of Multiple Myeloma. 2017 , 33, 332-347	2
1864	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. 2017 , 99, 409-414	24
1863	PD-1/PD-L1 inhibitors in haematological malignancies: update 2017. 2017 , 152, 357-371	85
1862	Guidelines for the use of imaging in the management of patients with myeloma. 2017 , 178, 380-393	77

1861	Standardisation of minimal residual disease in multiple myeloma. 2017 , 26, e12732	8
1860	Możliwości leczenia indukcyjnego chorych na szpiczaka plazmocytozowego kwalifikujących się do chemioterapii wysokodawkowanej wspomaganą autologiczną transplantacją komórek krwiotwórczych a aktualne zalecenia Polskiej Grupy Szpiczakowej. 2017 , 48, 104-111	
1859	Management of smoldering myeloma: Recommendations of the Spanish Myeloma Group. 2017 , 148, 517-523	3
1858	How I treat myeloma with new agents. 2017 , 130, 1507-1513	53
1857	The Experience of Myeloma Caregivers During Home-Based Oral Chemotherapy Treatment: A Qualitative Study. 2017 , 33, 362-371	5
1856	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. 2017 , 96, 1707-1714	4
1855	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. 2017 , 96, 1693-1698	4
1854	Hematuria as the first sign of multiple myeloma. 2017 , 5, 1358-1361	2
1853	Secondary Hypertension Post Bone Marrow Transplant: A Long Winding Road. 2017 , 39, 77-79	0
1852	Asymmetric Deep Stromal Keratopathy in a Patient With Multiple Myeloma. 2017 , 36, 372-374	3
1851	Multiple Myeloma in an 8-Year-Old Child With HIV Infection. 2017 , 39, 77	3
1850	Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. 2017 , 92, 1146-1155	22
1849	[Multiple Myeloma - Current Status in Diagnostic Testing and Therapy]. 2017 , 155, 575-586	16
1848	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. 2017 , 47, 938-951	13
1847	Diagnostik lymphatischer Neoplasien. 2017 , 41,	0
1846	Diagnostik und Therapie des Multiplen Myeloms. 2017 , 20, 44-52	
1845	A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients. 2017 , 6, 2058460117738809	6
1844	Pulmonary-renal syndrome as a clinical expression of multiple myeloma. 2017 , 37, 445-446	

1843	[Multiple myeloma : What has been confirmed in therapy?]. 2017 , 58, 1250-1257	2
1842	Smoldering Multiple Myeloma: Who and When to Treat. 2017 , 17, 716-722	10
1841	Epibulbar Plasmacytoma Masquerading as Subconjunctival Hemorrhage in a Patient With Multiple Myeloma. 2017 , 36, 249-251	4
1840	Pathobiology and Diagnosis of Multiple Myeloma. 2017 , 33, 225-236	64
1839	Toward a GEP-based PET in myeloma. 2017 , 130, 2-3	20
1838	Strategies for Selecting the Optimal Treatment in Newly Diagnosed Multiple Myeloma Patients. 2017 , 33, 254-264	1
1837	Percorso di laboratorio raccomandato nella diagnosi, prognosi e follow-up delle gammopatie monoclonali. 2017 , 13, 10-23	1
1836	Milestones in myeloma. 2017 , 10, 13-17	
1835	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. 2017 , 7, e581	27
1834	Living with Multiple Myeloma: A Continuum-Based Approach to Cancer Survivorship. 2017 , 33, 348-361	12
1833	Safety of ixazomib for the treatment of multiple myeloma. 2017 , 16, 973-980	14
1832	An unusual presentation of multiple myeloma with unilateral sudden vision loss: A case report. 2017 , 96, e7277	3
1831	Panobinostat for the management of multiple myeloma. 2017 , 13, 477-488	32
1830	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management. 2017 , 35, 432-439	4
1829	Assessment of Total Lesion Glycolysis by F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma. 2017 , 23, 1981-1987	57
1828	Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response. 2017 , 176, 222-233	33
1827	FAM46C Serves as a Predictor of Hepatic Recurrence in Patients with Resectable Gastric Cancer. 2017 , 24, 3438-3445	19
1826	Comparison of Fully Automated and Semiautomated Systems for Protein Immunofixation Electrophoresis. 2017 , 31,	3

1825	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. 2017 , 282, 484-493	61
1824	Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. 2017 , 27, 2333-2347	16
1823	Treatment response evaluation with F-FDG PET/CT and F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. 2017 , 44, 50-62	30
1822	Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. 2017 , 35, 734-740	5
1821	Waldenström Macroglobulinemia. 2017 ,	
1820	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS). 2017 , 143-167	
1819	Epidemiology of Hematologic Malignancies. 2017 , 543-569	7
1818	Polychromatic flow cytometry is more sensitive than microscopy in detecting small monoclonal plasma cell populations. 2017 , 92, 136-144	3
1817	Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. 2017 , 31, 130-135	46
1816	Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma. 2017 , 23, 262-268	25
1815	Polyclonal Immunoglobulin G N-Glycosylation in the Pathogenesis of Plasma Cell Disorders. 2017 , 16, 748-762	24
1814	Practical Considerations in Managing Relapsed Multiple Myeloma. 2017 , 17, 69-77	7
1813	The achievements of clinical chemistry testing: 1967-2017. 2017 , 50, 165-167	
1812	A clinical picture of pulmonary embolism revealing light-chain myeloma. 2017 , 5, 2044-2046	1
1811	Free Immunoglobulin Light Chains as Criteria of Extracorporeal Hemocorrection in Patients with Monoclonal Gammopathies. 2017 , 163, 493-496	1
1810	The therapeutic effect of modified Huangqi Guizhi Wuwu Tang for multiple myeloma: An 18-year follow-up case report. 2017 , 96, e9074	5
1809	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. 2017 , 19, 972-981	12
1808	Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. 2017 , 4, e584-e594	3

1807	[Monoclonal gammopathy of undetermined significance and multiple myeloma]. 2017 , 76, 33-37	1
1806	Response: Re: Primary Care Patients' Willingness to Participate in Comprehensive Weight Loss Programs: From the WWAMI Region Practice and Research Network. 2017 , 30, 264.2-265	
1805	Immunogenicity and persistence of the 13-valent Pneumococcal Conjugate Vaccine (PCV13) in patients with untreated Smoldering Multiple Myeloma (SMM): A pilot study. 2017 , 3, e00441	9
1804	Das multiple Myelom. 2017 , 14, 51-63	
1803	Extramedullary Solitary Plasmacytoma: Demonstrating the Role of F-FDG PET Imaging. 2017 , 11, XD01-XD03	7
1802	Serum Free Light Chain Assay and κ/λ Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for κ/λ Ratio. 2017 , 9, 46-57	28
1801	The therapeutic potential of cell cycle targeting in multiple myeloma. 2017 , 8, 90501-90520	24
1800	Abbildungs- und Tabellennachweis. 2017 , xiv-xvii	
1799	IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up. 2017 , 23, 312-324	0
1798	POEMS syndrome in a patient with rheumatoid arthritis. 2017 , 2017,	1
1797	Shall we treat smoldering multiple myeloma in the near future?. 2017 , 2017, 194-204	18
1796	Direct evidence for a polygenic etiology in familial multiple myeloma. 2017 , 1, 619-623	13
1795	Should minimal residual disease negativity be the end point of myeloma therapy?. 2017 , 1, 522-525	3
1794	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. 2017 , 1, 1911-1918	31
1793	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. 2017 , 1, 2186-2192	23
1792	Serum Free Light Chain (FLC) Analysis: A Guiding Light in Monoclonal Gammopathy Management. 2017 , 2, 98-106	3
1791	PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients. 2017 , 18,	19
1790	Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases. 2017 , 18,	4

1789	Solitary Extramedullary Plasmacytoma of the Cricoid Cartilage-Case Report. 2017 , 7, 284	3
1788	A First Report on [F]FPRGD PET/CT Imaging in Multiple Myeloma. 2017 , 2017, 6162845	2
1787	My Patient with Monoclonal Gammopathy of Undetermined Significance has a Kidney Problem. 2017 , 1, 18-23	3
1786	Cytokines in Endocrine Dysfunction of Plasma Cell Disorders. 2017 , 2017, 7586174	2
1785	Extrasosseous Multiple Myeloma: Case Report of Presentation in the Lower Extremity Soft Tissues with Literature Review. 2017 , 2017, 9159035	7
1784	C-Methionine-PET in Multiple Myeloma: A Combined Study from Two Different Institutions. 2017 , 7, 2956-2964	41
1783	Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. 2017 , 11, 2399-2408	23
1782	Molecular Characteristics of High-Dose Melphalan Associated Oral Mucositis in Patients with Multiple Myeloma: A Gene Expression Study on Human Mucosa. 2017 , 12, e0169286	7
1781	Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature. 2017 , 12, e0179406	5
1780	Diagnostic utility of whole body Dixon MRI in multiple myeloma: A multi-reader study. 2017 , 12, e0180562	24
1779	Primary solitary plasmacytoma of the liver - successful treatment with fractionated stereotactic radiotherapy (Cyberknife®): a case report. 2017 , 11, 193	2
1778	MGUS ¶n concetto evidence-based?. 2017 , 13, 194-198	0
1777	Response: Re: Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis. 2017 , 30, 265.2-265	
1776	Whole-Body Low-Dose Computed Tomography (WBLDCT) in Assessment of Patients with Multiple Myeloma - Pilot Study and Standard Imaging Protocol Suggestion. 2017 , 82, 356-363	9
1775	High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. 2017 , 8, 48350-48361	5
1774	Electrophoresis test prevalence, requesting patterns, yield and related bone marrow biopsy findings at a South African tertiary hospital: A 5-year retrospective audit. 2017 , 107, 270-273	
1773	Persistent Back Pain and Normal Serum Immunofixation in an Older Gentleman. 2017 , 2, 269-272	
1772	Management of multiple myeloma in the newly diagnosed patient. 2017 , 2017, 498-507	46

1771	Coexisting multiple myeloma, lymphoma, and non-small cell lung cancer: a case report and review of the literature. 2017 , 10, 373-376	2
1770	Exploiting Exosomes for Differential Diagnosis of Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance. 2017 ,	1
1769	[Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016]. 2017 , 27, 262	3
1768	Crohn's disease and smoldering multiple myeloma: a case report and literature review. 2017 , 15, 249-254	3
1767	Considering renal risk while managing cancer. 2017 , 9, 167-178	6
1766	Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era. 2017 , 9, 6887	12
1765	Concomitant HIV infection in newly diagnosed multiple myeloma patients is hard to recognise and should be tested for routinely in areas of high endemicity. 2017 , 107, 781-787	5
1764	Light Chain Amyloidosis. 2018 , 10, e2018022	37
1763	Should minimal residual disease negativity be the end point of myeloma therapy?. 2017 , 1, 517-521	8
1762	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. 2017 , 1,	8
1761	Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. 2017 , 35, 2911-2918	172
1760	Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. 2017 , 8, 35863-35876	62
1759	Panoramic and skull imaging may aid in the identification of multiple myeloma lesions. 2018 , 23, e38-e43	3
1758	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. 2017 , 35, 2900-2910	175
1757	Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. 2017 , 8, 24031-24044	59
1756	Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico. 2018 , 124, 1946-1953	12
1755	Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels. 2018 , 103, e162-e164	3
1754	Proteasome 20S in multiple myeloma: comparison of concentration and chymotrypsin-like activity in plasma and serum. 2018 , 78, 253-257	2

1753	The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. 2018 , 18, 319-329	15
1752	Unexpected discovery of multiple myeloma following cardiomyopathy. 2018 , 6, 86-90	3
1751	CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. 2018 , 56, 1071-1080	28
1750	Prostate carcinoma presenting with diffuse osteolytic metastases and supraclavicular lymphadenopathy mimicking multiple myeloma. 2018 , 6, 253-257	10
1749	Rare Undiagnosed Primary Amyloidosis Unmasked During Surgical Treatment of Primary Hyperparathyroidism: A Case Report. 2018 , 2, 112-116	1
1748	A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy. 2018 , 97, e9920	1
1747	Metastatic prostate cancer with bone marrow infiltration mimicking multiple myeloma. 2018 , 6, 269-273	4
1746	Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients With Multiple Myeloma With Deep Responses. 2018 , 18, 293-296	1
1745	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. 2018 , 32, 1815-1818 ₁₂	
1744	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. 2018 , 93, 739-746	16
1743	The multiple myelomas - current concepts in cytogenetic classification and therapy. 2018 , 15, 409-421	121
1742	Clinical characteristics and prognosis of multiple myeloma with bone-related extramedullary disease at diagnosis. 2018 , 38,	5
1741	Multiple myeloma and macro creatine kinase type 1: the first case report. 2018 , 56, e239-e242	
1740	Disulfiram/copper targets stem cell-like ALDH population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. 2018 , 119, 6882-6893	24
1739	How We Manage Patients with Plasmacytomas. 2018 , 13, 227-235	7
1738	Short overview on the current standard of treatment in newly diagnosed multiple myeloma. 2018 , 11, 59-64	7
1737	Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. 2018 , 7, e1458809	46
1736	Combined Selection System to Lower the Cutoff for Plasma Cell Enrichment Applied to iFISH Analysis in Multiple Myeloma. 2018 , 11, 647-652	1

1735	Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark. 2018 , 101, 21-27	13
1734	Epidemiology of multiple myeloma in 17 Latin American countries: an update. 2018 , 7, 2101-2108	19
1733	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. 2018 , 32, 1811-1815	18
1732	Other Complications of Multiple Myeloma. 2018 , 141-156	1
1731	Multiple Myeloma. 2018 , 463-483	
1730	Epidemiology and Pathophysiology of Multiple Myeloma. 2018 , 1-15	1
1729	Diagnosis and Staging of Multiple Myeloma and Related Disorders. 2018 , 17-28	2
1728	Treatment of Elderly Patients with Multiple Myeloma. 2018 , 61-71	1
1727	Bone Disease. 2018 , 111-140	
1726	Discriminating Depth of Response to Therapy in Multiple Myeloma Using Whole-body Diffusion-weighted MRI with Apparent Diffusion Coefficient: Preliminary Results From a Single-center Study. 2018 , 25, 904-914	17
1725	Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop. 2018 , 59, 2305-2317	9
1724	Functional and molecular MRI of the bone marrow in multiple myeloma. 2018 , 91, 20170389	17
1723	Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. 2018 , 100, 518-525	10
1722	Current developments in immunotherapy in the treatment of multiple myeloma. 2018 , 124, 2075-2085	42
1721	Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. 2018 , 59, 2546-2556	21
1720	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. 2018 , 180, 821-830	23
1719	Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters. 2018 , 94, 500-508	2
1718	Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. 2018 , 378, 241-249	216

1717 Plasma Cell Neoplasms. **2018**, 103-116

1716 Renal recovery after severe acute kidney injury in critically ill myeloma patients: a retrospective study. **2018**, 11, 20-25 5

1715 The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe. **2018**, 11, 219-237 21

1714 Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies. **2018**, 17, 1326-1333 25

1713 Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). **2018**, 25, 62-67 63

1712 N-terminal B-type natriuretic peptide (NT-proBNP) is associated with disease severity in multiple myeloma. **2018**, 48, e12905 6

1711 Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. **2018**, 32, 1427-1434 36

1710 Whole-body ultra-low dose CT using spectral shaping for detection of osteolytic lesion in multiple myeloma. **2018**, 28, 2273-2280 16

1709 Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. **2018**, 124, 1710-1721 24

1708 Can Dual-Energy CT Challenge MR Imaging in the Diagnosis of Focal Infiltrative Bone Marrow Lesions?. **2018**, 286, 214-216 7

1707 Screening and Diagnosis of Monoclonal Gammopathies: An International Survey of Laboratory Practice. **2018**, 142, 507-515 20

1706 Can dentists detect multiple myeloma through oral manifestations?. **2018**, 40, 43-49 5

1705 DANFIN functions as an inhibitor of transcription factor NF- κ B and potentiates the antitumor effect of bortezomib in multiple myeloma. **2018**, 495, 2289-2295 8

1704 Gastrointestinal perforation in light chain amyloidosis in the era of novel agent therapy - a case series and review of the literature. **2018**, 25, 11-17 4

1703 Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. **2018**, 32, 979-985 19

1702 Erythrocyte deformability and hemorheological profile in multiple myeloma. **2018**, 68, 25-34 2

1701 Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. **2018**, 355, 350-356 1

1700 Multiple Myeloma: The Case of the Disappearing Band. **2017**, 49, 87-91 1

1699	Monoclonal gammopathies: Electronic subspecialty consultation. 2018 , 100, 351-355	2
1698	Severe abdominal pain and diarrhea - unusual multiple myeloma presentation with a severe prognosis: a case report. 2018 , 12, 70	2
1697	Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. 2018 , 9, 1691	103
1696	The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression. 2018 , 9, 1649	15
1695	Nanotherapeutics for multiple myeloma. 2018 , 10, e1526	7
1694	Frail Patients with Newly Diagnosed Multiple Myeloma. 2018 , 539-549	
1693	Radiographic patterns of multiple myeloma in the jawbones of patients treated with intravenous bisphosphonates. 2018 , 149, 382-391	8
1692	The Complexity and Heterogeneity of Monoclonal Immunoglobulin-Associated Renal Diseases. 2018 , 29, 1810-1823	79
1691	Monoclonal Gammopathy of Undetermined Significance. 2018 , 525-530	
1690	Going the distance: Are we losing patients along the multiple myeloma treatment pathway?. 2018 , 126, 19-23	6
1689	Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database. 2018 , 21, 622-628	10
1688	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or F-fluorodeoxyglucose positron emission tomography/CT (F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. 2018 , 124, 66-72	31
1687	Strong immunoexpression of dickkopf-1 is associated with response to bortezomib in multiple myeloma. 2018 , 59, 2670-2678	4
1686	Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy. 2018 , 11, 423-435	15
1685	Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?. 2018 , 35, 289-302	1
1684	Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma. 2018 , 103, 1047-1053	29
1683	Additional Clinical Value for PET/MRI in Oncology: Moving Beyond Simple Diagnosis. 2018 , 59, 1028-1032	11
1682	Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients. 2018 , 551-571	

1681	Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. 2018 , 118, 1013-1019	20
1680	Monoclonal gammopathy in rheumatic diseases. 2018 , 37, 1751-1762	15
1679	Plasma cell diseases and organ transplant: A comprehensive review. 2018 , 18, 1046-1058	7
1678	IgM κ IgM λ pair quantitation in the clinical laboratory practice. 2018 , 51, 56-60	4
1677	Serum free light chain quantitative assays: Dilemma of a biomarker. 2018 , 32,	5
1676	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. 2018 , 36, 3-14	11
1675	Age-related health care disparities in multiple myeloma. 2018 , 36, 224-231	1
1674	Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. 2018 , 51, 38-47	25
1673	Quantitative MRI and spectroscopy of bone marrow. 2018 , 47, 332-353	117
1672	Molecular mechanisms, current management and next generation therapy in myeloma bone disease. 2018 , 59, 14-28	16
1671	Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with The Binding Site FreeLite assay on the SPA. 2018 , 51, 90-96	11
1670	Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. 2018 , 59, 288-299	9
1669	A man with generalized weakness. 2018 , 51, e7-e8	
1668	A mandibular lesion revealing multiple myeloma. 2018 , 11, 157-162	
1667	Monoclonal protein reference change value as determined by gel-based serum protein electrophoresis. 2018 , 51, 61-65	7
1666	Candidate recommendations for protein electrophoresis reporting from the Canadian Society of Clinical Chemists Monoclonal Gammopathy Working Group. 2018 , 51, 10-20	17
1665	Minimal residual disease in multiple myeloma: Benefits of flow cytometry. 2018 , 40, 12-20	5
1664	Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapy. 2018 , 59, 1756-1758	6

1663	Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. 2018 , 93, 179-186	29
1662	Personalized Therapy for Multiple Myeloma. 2018 ,	1
1661	Synoptic reporting for protein electrophoresis and immunofixation. 2018 , 51, 21-28	7
1660	Minimal residual disease analysis in myeloma - when, why and where. 2018 , 59, 1772-1784	14
1659	CD5+ B lymphoproliferative disorder with subsequent development of plasma cell leukaemia: Diagnostic and aetiologic reasoning. 2018 , 94, 688-694	1
1658	Cast Nephropathy and Deceptively Low Absolute Serum Free Light Chain Levels: Resolution of a Challenging Case and Systematic Review of the Literature. 2018 , 18, e1-e7	6
1657	'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma. 2018 , 59, 1514-15168	
1656	RhPDCD5 combined with dexamethasone increases antitumor activity in multiple myeloma partially via inhibiting the Wnt signalling pathway. 2018 , 45, 140-145	2
1655	IgE monoclonal gammopathy: A case report and literature review. 2018 , 51, 103-109	6
1654	Presence of fluorescent in situ hybridization abnormalities is associated with plasma cell burden in light chain amyloidosis. 2018 , 11, 105-111	6
1653	Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. 2018 , 51, 72-79	16
1652	AYA-Myeloma: Real-World, Single-Center Experience Over Last 5 Years. 2018 , 7, 120-124	7
1651	¹⁸ F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma. 2018 , 45, 77-84	26
1650	Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. 2018 , 65, 104-118	125
1649	Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma. 2018 , 180, 60-70	7
1648	Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. 2018 , 191, 110-115	35
1647	Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. 2018 , 78, 471-478.e4	10
1646	How I manage monoclonal gammopathy of undetermined significance. 2018 , 131, 163-173	49

1645	Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. 2018 , 103, 336-343	13
1644	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. 2018 , 378, 518-528	568
1643	The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma. 2018 , 13, 39-47	22
1642	[Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis]. 2018 , 58, 72-78	2
1641	Epigenetic silencing of EVL/miR-342 in multiple myeloma. 2018 , 192, 46-53	12
1640	Rare manifestations of extramedullary myeloma: testicular plasmacytomas. 2018 , 59, 2002-2004	3
1639	Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. 2018 , 180, 71-81	22
1638	Risk Stratification in Newly Diagnosed Smoldering Multiple Myeloma. 2018 , 1-13	
1637	Dysproteinemias and Glomerular Disease. 2018 , 13, 128-139	37
1636	Bone marrow Dkkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma. 2018 , 183, 812-815	5
1635	Monoclonal gammopathy of renal significance presenting as monotypic plasma cell interstitial nephritis in two patients with Sjögren's syndrome. 2018 , 472, 865-869	2
1634	What is the place of POEMS syndrome in the current classification of monoclonal gammopathies of renal significance?. 2018 , 50, 383-384	2
1633	A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma. 2018 , 180, 296-298	6
1632	Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. 2018 , 56, 312-322	15
1631	Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. 2018 , 59, 941-949	21
1630	Plasma cell neoplasm as a risk factor for early thrombosis of arteriovenous fistula. 2018 , 22, 176-179	1
1629	Multiple Myeloma and Dual-Energy CT: Diagnostic Accuracy of Virtual Noncalcium Technique for Detection of Bone Marrow Infiltration of the Spine and Pelvis. 2018 , 286, 205-213	69
1628	Serum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)/CCND1-immunoglobulin heavy chain fusion gene: A report of three cases . 2018 , 21, 56-69	

1627 Plasma Cell Neoplasms: an overview. **2018,**

1626 Comparison of Immuno-PET of CD138 and PET imaging with CuCl and F-FDG in a preclinical syngeneic model of multiple myeloma. **2018, 9, 9061-9072** 20

1625 Phosphatidylserine-exposing cells contribute to the hypercoagulable state in patients with multiple myeloma. **2018, 52, 1981-1990** 4

1624 Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. **2018, 36, 2012-2016** 1

1623 Bones in Multiple Myeloma: Imaging and Therapy. **2018, 38, 638-646** 19

1622 Practical Considerations for Antibodies in Myeloma. **2018, 38, 667-674** 5

1621 Caso clinico di mieloma multiplo IgG kappa secernente in cui la misura delle catene leggere libere sieriche (sFLC) ha evidenziato la ripresa della malattia di tipo I light chain escape con localizzazione extramidollare della patologia. **2018, 14, 168-170**

1620 Value and Cost of Myeloma Therapy. **2018, 38, 662-666** 27

1619 Combination of acquired von Willebrand syndrome (AVWS) and Glanzmann thrombasthenia in monoclonal gammopathy of uncertain significance (MGUS), a case report. **2018, 16, 30**

1618 Coexistence of primary colorectal follicular lymphoma and multiple myeloma: a case report. **2018, 11, 363-367** 3

1617 [Multiple myeloma associated with a secondary amyloidosis. Report of one case]. **2018, 146, 1351-1355** 1

1616 Advances in Oncology Imaging. **2018,**

1615 A Case of Multiple Myeloma Misdiagnosed as Seronegative Rheumatoid Arthritis and Review of Relevant Literature. **2018, 2018, 9746241** 1

1614 From carcinoma through lymphoma to myeloma: a gastric mass diagnostic rollercoaster ride. **2018, 2018,** 1

1613 Multiple Myeloma. **2018,**

1612 Multiples Myelom. **2018, 47, 418-425**

1611 Toothache as the initial symptom of plasma cell myeloma. **2018, 12, 443-445**

1610 Can 18F-FDG PET/MR Imaging Contribute to the Assessment of Bone Lesions in Patients with Plasma Cell Dyscrasias?. **2018, 08,**

1609	An Incidental Finding of AL-associated Amyloidosis Presenting as Gastric Ulcers. 2018 , 09, 019-021	
1608	LIGHT/TNFSF14 as a New Biomarker of Bone Disease in Multiple Myeloma Patients Experiencing Therapeutic Regimens. 2018 , 9, 2459	12
1607	Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. 2018 , 8, 107	9
1606	Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma. 2018 , 9, 2431	61
1605	Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. 2018 , 18, 1152	9
1604	Prevention Is the Best Treatment: The Case for Understanding the Transition from Monoclonal Gammopathy of Undetermined Significance to Myeloma. 2018 , 19,	5
1603	Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). 2018 , 8, 117	35
1602	Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MIM-CAT study. 2018 , 8, 102	17
1601	Increasing therapy-related myeloid neoplasms in multiple myeloma. 2019 , 49, e13050	8
1600	Molecular Expression of Bone Marrow Angiogenic Factors, Cell-Cell Adhesion Molecules and Matrix-Metallo-Proteinases in Plasmacellular Disorders: a Molecular Panel to Investigate Disease Progression. 2018 , 10, e2018059	2
1599	Venous thromboembolic events during warm autoimmune hemolytic anemia. 2018 , 13, e0207218	29
1598	Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. 2018 , 8, 533	36
1597	Osteoprotective medication in the era of novel agents: a European perspective on values, risks and future solutions. 2018 , 103, 755-758	4
1596	The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. 2018 , 8, 566	21
1595	Peripheral Blood Lymphocyte-to-Monocyte Ratio as a Useful Prognostic Factor in Newly Diagnosed Multiple Myeloma. 2018 , 2018, 9434637	7
1594	A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. 2018 , 11, 141	252
1593	PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma. 2018 , 13, e0207908	8
1592	An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring. 2018 , 10, e3148	9

1591	Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome. 2018 , 8, 125	17
1590	Classification of Solitary Plasmacytoma, Is it more Intricate than Presently Suggested? A Commentary. 2018 , 9, 3894-3897	5
1589	Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial. 2018 , 5, e628-e640	11
1588	Special problems in the management of elderly patients with multiple myeloma. 2018 , 58, 64-69	
1587	Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. 2018 , 8, 95	34
1586	Multiple Myeloma: Criteria for Diagnosis and Response to Therapy. 2018 , 651-658	
1585	Multiple Myeloma: The Role of Imaging in Staging and Restaging. 2018 , 659-669	
1584	Ultrastructural identification of a proximal tubulopathy without crystals in a relapsed multiple myeloma patient. 2018 , 42, 458-463	4
1583	Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study. 2018 , 8, e021376	5
1582	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. 2018 , 18, 693-702	3
1581	Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites. 2018 , 124, 4358-4365	3
1580	Whole-Body Imaging in Multiple Myeloma. 2018 , 26, 509-525	12
1579	Smoldering Myeloma Presenting with Renal Histopathology of Monoclonal Gammopathy of Renal Significance: Adding to the Complexity. 2018 , 29, 2901	4
1578	Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. 2018 , 12, 11343-11354	43
1577	Clinical Electrophoresis. 2018 , 128-128	
1576	Successful eradication of leptomeningeal plasma cell disease. 2018 , 2018, omy038	0
1575	Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. 2018 , 2018, 3029650	1
1574	Light-chain monoclonal gammopathy and cast nephropathy in a horse with multiple myeloma. 2018 , 253, 1177-1183	2

1573	Pseudohyperphosphatemia in a patient with incidentally identified progression of smoldering myeloma. 2018 , 487, 306-308	2
1572	Myeloma Bone Disease and Other Hematological Malignancies. 2018 , 760-767	0
1571	Impact of renal impairment on outcomes after autologous stem cell transplantation in multiple myeloma: a multi-center, retrospective cohort study. 2018 , 18, 1008	15
1570	Lambda Light Chain Non-crystalline Proximal Tubulopathy with IgD Lambda Myeloma. 2018 , 57, 3597-3602	2
1569	Abducens Nerve Palsy as Initial Presentation of Multiple Myeloma and Intracranial Plasmacytoma. 2018 , 7,	4
1568	Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders. 2018 , 18, 822-828	3
1567	Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells. 2018 , 42, 2676-2688	7
1566	Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis. 2018 , 16, 635-641	3
1565	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. 2018 , 93, 1518-1523	15
1564	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. 2018 , 103, 1772-1784	46
1563	Backache could be an indication of multiple myeloma: An unusual case report. 2018 , 17, 311-315	
1562	The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma. 2018 , 18, 829-835	1
1561	National survey of imaging practice for suspected or confirmed plasma cell malignancies. 2018 , 91, 20180462	3
1560	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study. 2018 , 20, 859-870	24
1559	Multiple myeloma associated with IgA lambda gammopathy and multiple myeloma oncogene 1 in a Yorkshire terrier. 2018 , 63, 187-192	
1558	Ubiquitination and DNA Repair in Multiple Myeloma. 2018 ,	
1557	Timing of treatment of smoldering myeloma: early treatment. 2018 , 2, 3045-3049	9
1556	Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. 2018 , 2018, 103-109	1

1555	Treatment approach for young, fit, newly diagnosed multiple myeloma patients. 2018 , 2018, 97-102	4
1554	Prognostic significance of bone marrow abnormalities in the appendicular skeleton of patients with multiple myeloma. 2018 , 2, 1032-1039	14
1553	Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. 2018 , 2, 1120-1128	11
1552	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. 2018 , 2, 1470-1479	22
1551	Timing of treatment of smoldering myeloma: delay until progression. 2018 , 2, 3050-3053	3
1550	Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma. 2018 , 2, 2607-2618	21
1549	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. 2018 , 2, 3149-3154	17
1548	[Rapidly progressive proliferative glomerulonephritis with monoclonal immunoglobulin G deposits despite the mild histological changes. Case report]. 2018 , 159, 1567-1572	
1547	Bizarre multilobated myeloma cells mimicking megakaryocytes. 2018 , 11, 248-250	
1546	Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'. 2018 , 32, 2083-2085	2
1545	Multiples Myelom Update 2018. 2018 , 39, 235-238	
1544	Immunochemical Diagnosis of Multiple Myeloma. 2018 , 165, 84-87	2
1543	The difficult business of assessing new therapies for smouldering multiple myeloma. 2018 , 182, 463-464	
1542	The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. 2018 , 182, 86-92	12
1541	Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. 2018 , 97, 1869-1877	10
1540	A predictive model for risk of early grade B infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. 2018 , 32, 1404-1413	28
1539	Role of oral examination in newly diagnosed multiple myeloma patients: A safe and simple way to detect light chain amyloidosis. 2018 , 24, 1343-1348	5
1538	Multiple Myeloma and Plasmacytoma. 2018 , 781-788	

1537	Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. 2018 , 182, 495-503	23
1536	Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. 2018 , 14, 2149-2160	2
1535	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. 2018 , 97, 1671-1682	7
1534	Is a 500-Cell Count Necessary for Bone Marrow Differentials?: A Proposed Analytical Method for Validating a Lower Cutoff. 2018 , 150, 84-91	4
1533	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. 2018 , 24, 2360-2364	13
1532	Prevalence of Monoclonal Gammopathy of Undetermined Significance in India-A Hospital-based Study. 2018 , 18, e345-e350	3
1531	Quantification of bone-marrow plasma cell levels using various International Myeloma Working Group response criteria in patients with multiple myeloma. 2018 , 108, 371-374	2
1530	How I treat the young patient with multiple myeloma. 2018 , 132, 1114-1124	28
1529	Multiple Myeloma of the Central Nervous System: 13 Cases and Review of the Literature. 2018 , 2018, 3970169	18
1528	High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS. 2018 , 97, 1879-1887	0
1527	Clinical PET/MRI: 2018 Update. 2018 , 211, 295-313	36
1526	Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. 2018 , 101, 794-808	67
1525	Serum vascular endothelial growth factor (VEGF) level can be used as a diagnostic marker in POEMS syndrome. 2018 , 50, 674-676	1
1524	Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series. 2018 , 43, 1263-1272	12
1523	Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients. 2018 , 183, 60-67	16
1522	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. 2018 , 183, 375-384	7
1521	Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent. 2018 , 57, 221-229	10
1520	Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. 2018 , 97, 2447-2454	3

1519	Bildgebung beim multiplen Myelom. 2018 , 24, 584-595	
1518	Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. 2018 , 65, 585-591	1
1517	Impact of hemodialysis on the prognosis of multiple myeloma: A nationwide population-based study and single-institute analysis. 2018 , 16, 1991-2002	3
1516	The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma. 2018 , 75, 55-66	2
1515	Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. 2018 , 18, 650	3
1514	Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. 2018 , 132, 1478-1485	93
1513	Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential. 2018 , 11, 67	48
1512	Combined Coagulopathy Can Induce Both Hemorrhagic and Thrombotic Complications in Multiple Myeloma. 2018 , 57, 3303-3306	5
1511	Applications of PET-MRI in musculoskeletal disease. 2018 , 48, 27-47	28
1510	Myc protein overexpression is a feature of progression and adverse prognosis in multiple myeloma. 2018 , 101, 585	10
1509	The histopathology of myeloma in the bone marrow. 2018 , 58, 61-67	7
1508	Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold. 2018 , 13, 220-226	11
1507	Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. 2018 , 11, 10	89
1506	Smoldering Multiple Myeloma. 2018 , 531-538	
1505	Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions. 2018 , 8, 21-31	5
1504	Advanced Imaging of Multiple Myeloma Bone Disease. 2018 , 9, 436	11
1503	Genomic patterns of progression in smoldering multiple myeloma. 2018 , 9, 3363	99
1502	Comparative analysis of the surgical treatment results for multiple myeloma bone disease of the spine and the long bone/soft tissue. 2018 , 15, 10017-10025	4

1501	Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. 2018 , 93, 981-1114	115
1500	High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. 2018 , 20, 777-788	5
1499	Automated enumeration of lymphoid and plasma cells in bone marrow to establish normal reference ranges. 2018 , 71, 916-925	4
1498	IRF4 in multiple myeloma-Biology, disease and therapeutic target. 2018 , 72, 52-58	22
1497	Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. 2018 , 35, 76-83	1
1496	Moderne Diagnostik des multiplen Myeloms. 2018 , 24, 609-612	1
1495	Multiples Myelom und seine Vorstufen. 2018 , 24, 625-631	
1494	Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. 2018 , 8, 59	115
1493	Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma. 2018 , 7, e1444411	6
1492	Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. 2018 , 58, 57-63	9
1491	Multiple Myeloma and Other Plasma Cell Neoplasms. 2018 , 383-403	
1490	Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns. 2018 , 28, 5083-5090	31
1489	Bone Health and Survival in Women With Multiple Myeloma. 2018 , 18, 597-602.e1	3
1488	Novel biomarkers in multiple myeloma. 2018 , 201, 49-59	21
1487	Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study. 2018 , 58, 100-107	11
1486	Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. 2019 , 60, 477-482	3
1485	Improving serum calcium test ordering according to a decision algorithm. 2019 , 72, 232-236	0
1484	Dysproteinemias or light chain diseases. 2019 , 267-278	

1483	Daratumumab proves safe and highly effective in AL amyloidosis. 2019 , 185, 342-344	33
1482	Monoclonal gammopathy of undetermined significance in Chinese population: A prospective epidemiological study. 2019 , 37, 75-79	5
1481	Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma. 2019 , 54, 587-594	7
1480	Monoclonal Gammopathies. 2019 , 1079-1093.e1	
1479	Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. 2019 , 185, 347-350	3
1478	Five cases of orbital extramedullary plasmacytoma: diagnosis and management of an aggressive malignancy. 2019 , 38, 218-225	9
1477	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. 2019 , 60, 163-171	8
1476	Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay. 2019 , 65, 1327-1329	
1475	Lower respiratory tract amyloidosis: Presentation, survival and prognostic factors. A multicenter consecutive case series. 2019 , 94, 1214-1226	6
1474	Immunoglobulin abnormalities in 1677 solid organ transplant recipients. Implications for posttransplantation follow-up. 2019 , 57, 101229	3
1473	Longitudinal preclinical magnetic resonance imaging of diffuse tumor burden in intramedullary myeloma following bortezomib therapy. 2019 , 32, e4122	
1472	The hypercoagulable state in multiple myeloma: The contribution of thrombin generation test. 2019 , 41, 684-690	1
1471	A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. 2019 , 6, e521-e529	138
1470	Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example. 2019 , 19, 635-644.e2	1
1469	Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review. 2019 , 8, 215-221	4
1468	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. 2019 , 381, 727-738	266
1467	Bleeding diathesis in canine multiple myeloma and prognostic implications: A cohort study in 156 dogs. 2019 , 125, 305-308	2
1466	Blastic variant of plasma cell myeloma mimicking squamous cell carcinoma of the uterine cervix in a super-morbidly obese female. 2019 , 29, 34-37	1

1465	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. 2019 , 5, 1293-1301	33
1464	Palliative Care in Patients With Multiple Myeloma. 2019 , 58, 1113-1118	4
1463	[Differential diagnoses of osteoporosis]. 2019 , 52, 414-420	1
1462	Premalignant Clonal Hematopoietic Proliferations. 2019 , 152, 347-358	3
1461	Bone Pathology for Hematopathologists. 2019 , 12, 831-847	1
1460	Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. 2019 , 39, 1077-1097	28
1459	Multiple Myeloma: Clinical Aspects. 2019 , 1-13	1
1458	FDG PET in Multiple Myeloma. 2019 , 27-38	2
1457	Role of Standard Magnetic Resonance Imaging. 2019 , 39-72	
1456	Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A New Era for Whole Body Imaging in Myeloma?. 2019 , 73-85	1
1455	Therapeutic Targets and Signaling Pathways for Diagnosis of Myeloma. 2019 ,	
1454	Towards quantitative imaging biomarkers of tumor dissemination: A multi-scale parametric modeling of multiple myeloma. 2019 , 57, 214-225	4
1453	Combination bone marrow imaging using positron emission tomography (PET)-MRI in plasma cell dyscrasias: correlation with prognostic laboratory values and clinicopathological diagnosis. 2019 , 1, 20180020	1
1452	Sequence variation at the MTHFD1L-AKAP12 and FOPNL loci does not influence multiple myeloma survival in Sweden. 2019 , 9, 57	1
1451	Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma. 2019 , 54, 2051-2059	1
1450	Heavy/light chain assay in the monitoring of multiple myeloma. 2019 , 51, 507-511	3
1449	Hypercalcemia and Altered Mental Status. 2019 , 65, 833-836	
1448	Molecular Imaging in Multiple Myeloma. 2019 ,	1

1447 What Does a Clinician Need from New Imaging Procedures?. **2019**, 15-26

1446 Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. **2019**, 134, 668-677 59

1445 Medullary Abnormalities in Appendicular Skeletons Detected With F-FDG PET/CT Predict an Unfavorable Prognosis in Newly Diagnosed Multiple Myeloma Patients With High-Risk Factors. **2019**, 213, 918-924 6

1444 Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. **2019**, 14, 391-403 5

1443 PET-Computed Tomography in Myeloma: Current Overview and Future Directions. **2019**, 14, 411-418

1442 Evolving Roles of Fluorodeoxyglucose and Sodium Fluoride in Assessment of Multiple Myeloma Patients: Introducing a Novel Method of PET Quantification to Overcome Shortcomings of the Existing Approaches. **2019**, 14, 341-352 7

1441 An approach to the diagnosis and management of multiple myeloma. **2019**, 109, 723 1

1440 Flow Cytometric Immunophenotypic Analysis in the Diagnosis and Prognostication of Plasma Cell Neoplasms. **2019**, 96, 338-350 9

1439 Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. *Lancet Oncology, The*, **2019**, 20, 1760-1772 21.7 62

1438 Use of an Extremely Biodiverse Probiotic and a Supplement Based on Microbial Chondroitin Sulfate is Associated with a Significant Decrease of Serum Free Kappa Light Chains as well as a Trend Toward Normalization of Kappa/Lambda Ratio and of Plasma Cell Bone Marrow Infiltration in a Case of Multiple Myeloma. **2019**, 15, 5-9 1

1437 [Molecular cytogenetic analyses of patients with plasma cell myeloma in Tolna and Baranya counties in Hungary]. **2019**, 160, 944-951

1436 Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. **2019**, 12, 135 3

1435 The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. **2019**, 19, 889-898 3

1434 Full Issue PDF. **2019**, 1, I-CXLVII

1433 Identification of High Serum Apolipoprotein A1 as a Favorable Prognostic Indicator in Patients with Multiple Myeloma. **2019**, 10, 4852-4859 6

1432 Haematologists usually over-estimate the percentage of CD138+ plasma cells in marrow biopsies. **2019**, 51, 647-648 2

1431 Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?. **2019**, 2019, 9401717 3

1430 Liquid Biopsies in Multiple Myeloma. **2019**,

1429	Is urine immunofixation electrophoresis necessary for monitoring myeloma patients who have undergone hematopoietic stem cell transplantation?. 2019 , 58, 102660	0
1428	Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach. 2019 , 121, 108739	14
1427	Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance - Relationship With Selected Immune And Clinical Parameters. 2019 , 14, 1741-1749	5
1426	Elevated serum lncRNA TUG1 levels are a potential diagnostic biomarker of multiple myeloma. 2019 , 79, 47-55.e2	20
1425	Monoclonal immunoglobulin-mediated kidney disease: What is beyond amyloidosis in real practice?. 2019 , 3, 105-112	1
1424	[Multiple myeloma: New criteria for diagnosis and treatment, strong therapeutic hopes]. 2019 , 48, 825-831	1
1423	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. 2019 , 19, 855	1
1422	The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. 2019 , 10, 740	3
1421	A Case of Aggressive Multiple Myeloma with Extramedullary Involvement of the Female Reproductive System, Thyroid and Breasts. 2019 , 2019, 7348504	1
1420	Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. 2019 , 9, 71	5
1419	Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis. 2019 , 14, e0222522	0
1418	Epidemiology of Multiple Myeloma. 2019 ,	1
1417	Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma. 2019 , 21, 100159	4
1416	Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy. 2019 , 74, 42-46	4
1415	Renal crystal-storing histiocytosis involving glomeruli - A comprehensive clinicopathologic analysis. 2019 , 43, 151403	5
1414	AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. 2019 , 1, 117-130	15
1413	Laboratory assessment of multiple myeloma. 2019 , 89, 1-58	10
1412	Long Non-Coding RNAs in Multiple Myeloma. 2019 , 5,	17

1411	Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. 2019 , 92, 20180822	3
1410	Systematic overestimation of human serum albumin by capillary zone electrophoresis method due to monoclonal immunoglobulin interferences. 2019 , 491, 74-80	4
1409	Multiples Myelom und renale Beteiligung. 2019 , 14, 59-72	
1408	26 Musculoskeletal Tumors. 2019 ,	
1407	Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data. 2019 , 14, 100215	14
1406	Mylbmes. 2019 , 43, 161-165	
1405	Non-odontogenic Bone Pathology. 2019 , 555-626	1
1404	Comparison of bone lesion distribution between prostate cancer and multiple myeloma with whole-body MRI. 2019 , 100, 295-302	6
1403	Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. 2019 , 19, 183-189.e1	8
1402	Cyclophosphamide + Thalidomide + Dexamethasone Versus Melphalan + Dexamethasone for the Treatment of Amyloid Light-chain Amyloidosis With Kidney Involvement: A Retrospective Study in Chinese Patients. 2019 , 41, 1186-1198	3
1401	Smoldering Multiple Myeloma: To Treat or Not to Treat. 2019 , 25, 65-71	12
1400	The therapeutic role of natural killer cells in multiple myeloma. 2019 , 2, e49	1
1399	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. 2019 , 185, 11-24	12
1398	Primary extramedullary plasmacytoma with diffuse lymph node involvement: a case report and review of the literature. 2019 , 13, 153	3
1397	Improved contrast for myeloma focal lesions with T2-weighted Dixon images compared to T1-weighted images. 2019 , 100, 513-519	15
1396	Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia. 2019 , 19, 560-569	10
1395	Gerinc diffúziónosztott mágneses rezonancia vizsgálatok myeloma multiplexes betegek kósmében és kóretében. 2019 , 52, 37-44	
1394	Skeleton on FDG PET/CT. 2019 , 9-32	

1393	Monoclonal gammopathy of "ocular" significance. 2019 , 15, 100471		5
1392	Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. 2019 , 60, 2968-2974		5
1391	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. 2019 , 19, e465-e469		2
1390	MAGE genes: Prognostic indicators in AL amyloidosis patients. 2019 , 23, 5672-5678		4
1389	The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and of renal significance. 2019 , 34, 1440-1452		5
1388	Use of carbon monoxide breath test to assess red blood cell lifespan in newly diagnosed multiple myeloma patients. 2019 , 13, 046008		1
1387	Red blood cell distribution width is a simple and novel biomarker for survival in light-chain amyloidosis. 2019 , 110, 431-437		3
1386	Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. 2019 , 65, 1015-1022		18
1385	Comparison of Whole-Body DWI and F-FDG PET/CT for Detecting Intramedullary and Extramedullary Lesions in Multiple Myeloma. 2019 , 213, 514-523		23
1384	STAT3: A Promising Therapeutic Target in Multiple Myeloma. 2019 , 11,		29
1383	International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. <i>Lancet Oncology, The</i> , 2019 , 20, e302-e312	21.7	166
1382	Multiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging. 2019 , 191, 998-1009		10
1381	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. 2019 , 380, 2104-2115		435
1380	Long term outcomes in monoclonal gammopathy of renal significance. 2019 , 186, 706-716		9
1379	Rapid discrimination of multiple myeloma patients by artificial neural networks coupled with mass spectrometry of peripheral blood plasma. 2019 , 9, 7975		14
1378	Presentation and survival of multiple myeloma patients in Ghana: a review of 169 cases. 2019 , 53, 52-58		8
1377	Response to pneumococcal vaccination in multiple myeloma. 2019 , 8, 3822-3830		13
1376	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. 2019 , 54, 1898-1907		0

1375	Gene Co-expression Network and Copy Number Variation Analyses Identify Transcription Factors Associated With Multiple Myeloma Progression. 2019 , 10, 468	7
1374	Imaging of Multiple Myeloma. 2019 , 191, 805-816	8
1373	Multiple myeloma: Every year a new standard?. 2019 , 37 Suppl 1, 62-65	75
1372	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. 2019 , 54, 2039-2050	6
1371	Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients. 2019 , 186, 695-705	6
1370	Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. 2019 , 134, 421-431	80
1369	Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma. 2019 , 110, 69-76	4
1368	Difficult�et d'harce de diagnostic du my�lome pauci-s�cr�tant. 2019 , 2019, 67-70	
1367	Circulating microRNAs and Their Role in Multiple Myeloma. 2019 , 5,	5
1366	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. 2019 , 14, e0211600	16
1365	Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. 2019 , 2019, 5652935	6
1364	State of the science in smoldering myeloma: Should we be treating in the clinic?. 2019 , 46, 112-120	7
1363	Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. 2019 , 14, 187-196	6
1362	Potential of NK cells in multiple Myeloma therapy. 2019 , 12, 425-435	10
1361	Activin A: a novel urinary biomarker of renal impairment in multiple myeloma. 2019 , 39,	6
1360	Diffuse alveolar hemorrhage caused by IgA deposition associated with multiple myeloma. 2019 , 7, 1049-1052	1
1359	Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. 2019 , 57, 1397-1405	3
1358	Incidence and risk factors for acute kidney injury following autologous stem cell transplantation for multiple myeloma. 2019 , 8, 3278-3285	13

1357	Biology and therapy of multiple myeloma. 2019 , 210, 375-380	29
1356	When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. 2019 , 19, e251-e258	3
1355	The use of mean platelet volume for distinguishing the causes of thrombocytopenia in adult patients. 2019 , 11, 7732	5
1354	A Case Report of Multiple Myeloma Associated With Myeloperoxidase and Proteinase-3 Antibodies Posing a Diagnostic Dilemma. 2019 , 7, 2324709619843944	4
1353	Effects of triptolide on bone marrow-derived mesenchymal stem cells from patients with multiple myeloma. 2019 , 17, 3291-3298	0
1352	Eculizumab as a treatment for atypical hemolytic uremic syndrome secondary to carfilzomib. 2019 , 39, 86-88	5
1351	Comparison of two serum free light chain assays for the diagnosis of primary plasma cell malignant proliferative disease. 2019 , 2, e113	6
1350	Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. 2019 , 98, 1703-1711	6
1349	Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?. 2019 , 2019, 2186494	2
1348	New insights in the treatment of patients with solitary bone plasmacytoma. 2019 , 60, 2810-2813	5
1347	Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma. 2019 , 16, 17	10
1346	Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. 2019 , 116, 9543-9551	161
1345	A niche-dependent myeloid transcriptome signature defines dormant myeloma cells. 2019 , 134, 30-43	54
1344	Autologous Hematopoietic Cell Transplantation Versus Chemotherapy Alone for Immunoglobulin Light Chain Amyloidosis: A Retrospective Study. 2019 , 19, 413-422.e5	1
1343	Testing and management for monoclonal gammopathy of uncertain significance and myeloma patients presenting with osteoporosis and fragility fractures. 2019 , 58, 1142-1153	4
1342	Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens. 2019 , 24, 387-391	2
1341	Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice. 2019 , 316, R678-R686	6
1340	Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma. 2019 , 25, 3772-3775	28

1339	The transcriptomic profile of CD138 cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged. 2019 , 104, e465-e469	7
1338	Free light chains and autoimmunity. 2019 , 18, 484-492	25
1337	Serum protein N-glycosylation changes in multiple myeloma. 2019 , 1863, 960-970	16
1336	Differential diagnosis between bone relapse of breast cancer and lambda light chain multiple myeloma: role of the clinical biochemist. 2019 , 105, NP17-NP19	
1335	Dual-tracer PET/CT scan after injection of combined [F]NaF and [F]FDG outperforms MRI in the detection of myeloma lesions. 2019 , 37, 193-201	5
1334	Glomerular Diseases Associated with Malignancies. 2019 , 691-734	
1333	Oral Signs of Systemic Disease. 2019 ,	
1332	Oral Signs of Hematologic Disease. 2019 , 25-43	1
1331	Low hexokinase-2 expression-associated false-negative F-FDG PET/CT as a potential prognostic predictor in patients with multiple myeloma. 2019 , 46, 1345-1350	18
1330	Timing treatment for smoldering myeloma: is earlier better?. 2019 , 12, 345-354	4
1329	F-fluoro-ethyl-tyrosine (F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. 2019 , 23, 23-31	4
1328	Natural history of multiple myeloma with de novo del(17p). 2019 , 9, 32	22
1327	Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy. 2019 , 11,	35
1326	[Free light chains assay: Indications and methods]. 2019 , 40, 297-305	3
1325	PLASMA CELL NEOPLASMS. 2019 , 487-536	
1324	Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients. 2019 , 11,	12
1323	Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma. 2019 , 9, 9	5
1322	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. 2019 , 6, e217-e228	46

1321	Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study. 2019 , 98, 1435-1440	21
1320	Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. 2019 , 98, 1441-1447	10
1319	Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations. 2019 , 50, 381-389	6
1318	Evaluation of the safety and efficacy of daratumumab outside of clinical trials. 2019 , 109, 665-672	11
1317	Multiple myeloma in elderly patients-a Portuguese multicentric real-life study. 2019 , 98, 1689-1701	6
1316	Evaluation of renal function in clinical practice: the basics. 2019 , 13, 32-37	
1315	Retrospective analysis of the efficacy and influencing factors of autologous hematopoietic stem cell transplantation for multiple myeloma. 2019 , 43, 1028-1034	2
1314	Interest of Pet Imaging in Multiple Myeloma. 2019 , 6, 69	15
1313	Classification OMS 2017 des tumeurs plasmocytaires. 2019 , 2019, 34-40	
1312	Le urgenze ematologiche. 2019 , 1-100	
1311	JSH practical guidelines for hematological malignancies, 2018: III. Myeloma-1. Multiple myeloma (MM). 2019 , 109, 509-538	11
1310	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. 2019 , 37, 1228-1263	104
1309	Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary. 2019 , 15, 279-286	4
1308	Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. 2019 , 104, 2456-2464	6
1307	Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. 2019 , 19, e228-e237	4
1306	Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial. 2019 , 54, 1482-1488	7
1305	Lymphomas of the head and neck region: an update. 2019 , 474, 649-665	16
1304	Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry. 2019 , 109, 377-381	11

1303	Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. 2019 , 94, 539-545	3
1302	Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). 2019 , 291, 5-13	117
1301	Myeloma Associated Glomerular Disease. 2019 , 617-631	
1300	Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. 2019 , 14, 70-82	10
1299	Un cas familial complexe de maladie de l'hémoglobine. 2019 , 2019, 69-71	
1298	Evaluating the role of Tregs in the progression of multiple myeloma. 2019 , 60, 2134-2142	10
1297	Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. 2019 , 94, E146-E149	7
1296	Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. 2019 , 41, 477-493.e7	7
1295	Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma. 2019 , 33, 1273-1277	7
1294	Insights on Multiple Myeloma Treatment Strategies. 2019 , 3, e163	23
1293	PKP/PVP combine chemotherapy in the treatment of multiple myeloma patients with vertebral pathological fractures: minimum 3-year follow-up of 108 cases. 2019 , 14, 42	4
1292	Physicians, paraproteins and progress: diagnosis and management of myeloma. 2019 , 80, 91-98	4
1291	Targeted Management Strategies in Multiple Myeloma. 2019 , 25, 59-64	4
1290	Acute kidney injury in the patient with cancer. 2019 , 38, 295-308	28
1289	Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27. 2019 , 20, 2410-2418	3
1288	Systemic AL amyloidosis with high bone marrow plasma cells (BMPCs) infiltration: a case report and literature review. 2019 , 4, 130-30	
1287	Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. 2019 , 25, 6781-6787	3
1286	Intelligent Microarray Data Analysis through Non-negative Matrix Factorization to Study Human Multiple Myeloma Cell Lines. 2019 , 9, 5552	7

1285	Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. 2019 , 3, e300	11
1284	Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study. 2019 , 3, 751-760	4
1283	Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. 2019 , 3, 744-750	15
1282	Pathophysiology and management of monoclonal gammopathy of renal significance. 2019 , 3, 2409-2423	26
1281	Laboratory testing in the evaluation of a monoclonal protein: A practical framework for interpretation. 2019 , 109, 719	
1280	Laboratory Features of Newly Diagnosed Multiple Myeloma Patients. 2019 , 11, e4716	6
1279	Hypercalcaemia, renal dysfunction, anaemia and bone lesions (CRAB) do not always represent multiple myeloma: diffuse large B cell lymphoma presenting with CRAB symptoms in a 69-year-old man. 2019 , 12,	5
1278	Acquired von Willebrand syndrome associated with plasma cell myeloma - a rare histopathological bone marrow image. 2019 , 70, 311-316	1
1277	PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma. 2019 , 14, 369-381	2
1276	Method comparison of four clinically available assays for serum free light chain analysis. 2019 , 58, 85-94	10
1275	Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders. 2019 , 9, 16769	4
1274	. 2019 ,	10
1273	[Usefulness of free light chain measurement in monoclonal gammopathy, other haematological malignancies and autoimmune diseases]. 2019 , 77, 397-406	
1272	Solitary Plasmacytoma of Bone of the Spine: Results From Surveillance, Epidemiology, and End Results (SEER) Registry. 2019 , 44, E117-E125	5
1271	Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. 2019 , 11,	18
1270	Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study. 2019 , 5, 1-19	10
1269	A Case of Syphilis with High Bone Arsenic Concentration from Early Modern Cemetery (Wroclaw, Poland). 2019 , 14, 427-439	2
1268	Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. 2019 , 20, 39	6

1267	High expression of CHML predicts poor prognosis of multiple myeloma. 2019 , 10, 6048-6056	2
1266	Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma. 2019 , 26, e581-e594	2
1265	Is autologous stem cell transplantation still relevant for multiple myeloma?. 2019 , 26, 386-391	1
1264	Current opinions in nephrology and hypertension: kidney transplantation in patients with plasma cell dyscrasias. 2019 , 28, 573-580	4
1263	POEMS syndrome: a unique presentation and a diagnostic challenge. 2019 , 12,	
1262	Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. 2019 , 2019,	5
1261	Metastatic Multiple Myeloma to the Skin. 2019 , 2019, 7930123	
1260	The Role of Radiology and Radiotherapy for Multiple Myeloma. 2019 ,	1
1259	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. 2019 , 574, 127-131	79
1258	Front-line treatment of multiple myeloma.. 2019 , 3,	3
1257	Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China. 2019 , 98, e17147	3
1256	The Evolution of Monoclonal Gammopathy of Undetermined Significance in Kidney Transplant Recipients. 2019 , 5, e489	5
1255	Rare case of non-producer variant of plasma cell dyscrasias with circulating plasma cells. 2019 , 12,	
1254	A Retrospective Analysis: A Novel Index Predicts Survival and Risk-Stratification for Bone Destruction in 419 Newly Diagnosed Multiple Myelomas. 2019 , 12, 10587-10596	2
1253	Retracted Article: Long non-coding RNA PCAT1 facilitates cell growth in multiple myeloma through an MTDH-mediated AKT/βcatenin signaling pathway by sponging miR-363-3p.. 2019 , 9, 33834-33842	2
1252	Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. 2019 , 19, e43-e50	10
1251	FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients. 2019 , 121, 134-138	1
1250	Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states. 2019 , 48, 773-779	8

1249	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. 2019 , 37, 117-128	7
1248	Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma. 2019 , 76, 58-64	7
1247	Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements. 2019 , 33, 313-318	10
1246	Imaging in multiple myeloma: How? When?. 2019 , 133, 644-651	41
1245	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?. 2019 , 21, 93-105	22
1244	Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI. 2019 , 98, 679-689	9
1243	Imaging in myeloma with focus on advanced imaging techniques. 2019 , 92, 20180768	16
1242	Spine Oncology: Imaging and Intervention. 2019 , 57, 377-395	10
1241	Bone marrow transplant and pediatric multiple myeloma. 2019 , 66, e27528	2
1240	Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study. 2019 , 109, 154-161	3
1239	A Case Report of a Breast Implant-Associated Plasmacytoma and Literature Review of Non-ALCL Breast Implant-Associated Neoplasms. 2019 , 39, NP234-NP239	5
1238	Brief report: Clinical experiences after emergency use of daratumumab monotherapy for relapsed or refractory multiple myeloma in real practice. 2019 , 49, 92-95	8
1237	Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies. 2019 , 121-137	1
1236	Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma. 2019 , 54, 1107-1114	6
1235	Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis. 2019 , 141, 93-106	45
1234	Prevalence and clinical implications of t(11;14) in patients with amyloid light-chain amyloidosis with or without concurrent multiple myeloma. 2019 , 49, 195-198	7
1233	Clinical characteristics and the long-term outcome of patients with atypical POEMS syndrome variant with undetectable monoclonal gammopathy. 2019 , 98, 735-743	5
1232	Clinical features, radiological profiles, and surgical outcomes of primary intracranial solitary plasmacytomas: a report of 17 cases and a pooled analysis of individual patient data. 2019 , 142, 263-272	6

1231	[Diagnosis and treatment of kidney involvement in plasma cell diseases : Renal involvement in multiple myeloma and monoclonal gammopathies]. 2019 , 60, 10-22	2
1230	The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo. 2019 , 98, 691-703	9
1229	Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. 2019 , 60, 619-628	5
1228	Wann sollte bei monoklonaler Gammopathie eine Nierenbiopsie erfolgen?. 2019 , 14, 5-13	2
1227	Discovery and Validation of Clinical Biomarkers of Cancer: A Review Combining Metabolomics and Proteomics. 2019 , 19, e1700448	40
1226	Advances in POEMS treatment and the need to define standardised outcome measures. 2019 , 185, 386-388	
1225	Real-life data on safety and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma. 2019 , 98, 369-379	11
1224	Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. 2019 , 102, 182-190	16
1223	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. 2019 , 15, 45-59	189
1222	Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. 2019 , 98, 1095-1100	4
1221	Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients. 2019 , 102, 70-78	3
1220	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. 2019 , 104, 370-379	40
1219	Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin. 2019 , 44, e13-e15	2
1218	IgM plasma cell myeloma in the era of novel therapy: a clinicopathological study of 17 cases. 2019 , 84, 321-334	8
1217	Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation. 2019 , 109, 98-106	6
1216	Neues zur monoklonalen Gammopathie renaler Signifikanz. 2019 , 14, 14-25	
1215	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. 2019 , 25, 478-486	19
1214	Myeloma light chain cast nephropathy, a review. 2019 , 32, 189-198	22

1213	Eculizumab as a treatment for atypical hemolytic syndrome secondary to carfilzomib. 2019 , 39, 86-88	7
1212	Multiple Myeloma of the Young - a Single Center Experience Highlights Future Directions. 2020 , 26, 419-424	1
1211	Trends in cause of death among patients with multiple myeloma in Puerto Rico and the United States SEER population, 1987-2013. 2020 , 146, 35-43	7
1210	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. 2020 , 105, 1650-1659	9
1209	Solitary plasmacytoma of maxillofacial bones: correlation of CT features with pathological findings. 2020 , 49, 20190277	0
1208	Strategies to improve patient-reported outcome completion rates in longitudinal studies. 2020 , 29, 335-346	11
1207	Deregulated Expression of Long Non-coding RNA HOX Transcript Antisense RNA (HOTAIR) in Egyptian Patients with Multiple Myeloma. 2020 , 36, 271-276	2
1206	Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory. 2020 , 57, 73-85	7
1205	Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma. 2020 , 38, 1126-1137	88
1204	Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. 2020 , 34, 589-603	19
1203	Organ dose and total effective dose of whole-body CT in multiple myeloma patients. 2020 , 49, 549-554	6
1202	Approach to the Diagnosis of Amyloidosis. 2020 , 36, 246-253	2
1201	Haemorrhagic bullous lesions in cutaneous light-chain amyloidosis with smouldering myeloma. 2020 , 34, e13-e15	3
1200	Nonneoplastic Diseases of the Kidney. 2020 , 1-82.e12	
1199	Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. 2020 , 30, 320-327	13
1198	Mature lymphoid neoplasms. 2020 , 603-625	
1197	A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. 2020 , 105, 201-208	20
1196	Role of cell surface proteoglycans in cancer immunotherapy. 2020 , 62, 48-67	35

1195	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. 2020 , 38, 831-843	32
1194	Petrous apex non-secretory plasma cell myeloma with aberrant cytokeratin expression. 2020 , 43, 47-50	1
1193	Oral health status of patients with multiple myeloma. 2020 , 42, 166-172	2
1192	Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients. 2020 , 42, 159-163	4
1191	Treatment of relapsed multiple myeloma: Evidence-based recommendations. 2020 , 39, 100616	29
1190	Calcium state estimation by total calcium: the evidence to end the never-ending story. 2020 , 58, 222-231	8
1189	Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. 2020 , 27, 461-467	15
1188	Solitary Plasmacytoma Treated by Lenalidomide-Dexamethasone in Combination with Radiation Therapy: Clinical Outcomes. 2020 , 106, 589-596	8
1187	The Renal Biopsy in Chronic Kidney Disease. 2020 , 1207-1222	3
1186	Heavy Chain Deposition Disease: Clinicopathologic Characteristics of a Chinese Case Series. 2020 , 75, 736-743	4
1185	New developments in diagnosis, risk assessment and management in systemic amyloidosis. 2020 , 40, 100636	21
1184	Effect factors related to a high probability of hemodialysis independence in newly diagnosed multiple myeloma patients requiring hemodialysis. 2020 , 34, e23057	4
1183	Atlas of Cytopathology and Radiology. 2020 ,	
1182	Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. 2020 , 36, 284-291	1
1181	Light chain only variant of proliferative glomerulonephritis with monoclonal immunoglobulin deposits is associated with a high detection rate of the pathogenic plasma cell clone. 2020 , 97, 589-601	15
1180	Impact of age, sex, ethnicity, socio-economic deprivation and novel pharmaceuticals on the overall survival of patients with multiple myeloma in New Zealand. 2020 , 188, 692-700	5
1179	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. 2020 , 95, 4-9	6
1178	Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis. 2020 , 594, 452-465	9

1177	Successful treatment of marrow failure after CARTs for myeloma by the infusion of cryopreserved stem cells. 2020 , 95, E20-E23	4
1176	Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. 2020 , 26, 1070-1079	1
1175	Prognosis value of RBBP8 expression in plasma cell myeloma. 2020 , 27, 22-29	4
1174	Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. 2019 , 25,	7
1173	Comparison of three different serum-free light-chain assays-implications on diagnostic and therapeutic monitoring of multiple myeloma. 2020 , 10, 2	10
1172	Therapy Response Imaging in Oncology. 2020 ,	
1171	MGUS Predicts Worse Prognosis in Patients with Coronary Artery Disease. 2020 , 13, 806-812	
1170	Multiple Myeloma and Related Disorders. 2020 , 1884-1910.e7	2
1169	In-house age-specific reference ranges for free light chains measured on the SPAPlus [®] analyser. 2020 , 57, 138-143	1
1168	Circulating extracellular vesicle-associated CD163 and CD206 in multiple myeloma. 2020 , 104, 409-419	6
1167	Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome. 2020 , 15, e0227455	11
1166	IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms. 2020 , 44, 151449	3
1165	MRI versus F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance. 2020 , 30, 1927-1937	16
1164	Multiple myeloma: Role of autologous transplantation. 2020 , 82, 101929	21
1163	Use of B-Cell Gene Rearrangement Studies to Establish Clonality in Non-producer Non-secretory Multiple Myeloma. 2020 , 20, e18-e21	1
1162	Multiple myeloma manifesting as an ocular salmon patch - a case report. 2020 , 39, 379-382	0
1161	Trends in myeloma relative survival in Queensland by treatment era, age, place of residence, and socioeconomic status. 2020 , 61, 721-727	2
1160	A Puzzling Case of Hyperviscosity Syndrome. 2020 , 5, 209-213	

1159	Emerging biomarkers in Multiple Myeloma: A review. 2020 , 503, 45-53	15
1158	The 31-nucleotide Y4-RNA fragment in plasma is a potential novel biomarker. 2020 , 5, 37-40	2
1157	Frailty impairs the feasibility of induction therapy but not of maintenance therapy in elderly myeloma patients: final results of the German Maintenance Study (GERMAIN). 2020 , 146, 749-759	5
1156	Paraneoplastic glomerular diseases. 2020 , 205-212.e3	
1155	Monoclonal immunoglobulin deposition disease. 2020 , 76-84.e3	0
1154	A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration. 2020 , 476, 337-351	14
1153	Heparanase promotes myeloma stemness and in vivo tumorigenesis. 2020 , 88, 53-68	16
1152	Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. 2020 , 104, 376-382	3
1151	Impact of 18F-fluorodeoxyglucose PET/CT in the management of patients with plasma cell disorders. 2020 , 41, 34-39	0
1150	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. 2020 , 6, 425-432	25
1149	MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis. 2020 , 72, 314-333	31
1148	Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. 2020 , 104, 230-235	4
1147	Extramedullary multiple myeloma. 2020 , 34, 1-20	69
1146	Validation and Implementation of an Ordering Alert to Improve the Efficiency of Monoclonal Gammopathy Evaluation. 2020 , 153, 396-406	0
1145	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis. 2020 , 61, 875-886	5
1144	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. 2020 , 34, 1135-1143	19
1143	Analytical validation of new ELISAs for the quantitation of polyclonal free light chains and comparison to existing assays for healthy and patient samples. 2020 , 478, 112713	1
1142	Chemokine receptor-4 targeted PET/CT with Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to F-FDG PET/CT. 2020 , 47, 537-546	29

1141	Therapeutic Advances in the Management of Smoldering Myeloma. 2020 , 27, e194-e203	
1140	Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma. 2019 , 12,	0
1139	Integrating Serum Protein Electrophoresis with Mass Spectrometry, A New Workflow for M-Protein Detection and Quantification. 2020 , 19, 2845-2853	7
1138	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. 2020 , 4, e380	2
1137	Clinical characteristics and prognosis of cardiac amyloidosis defined by mass spectrometry-based proteomics in an Australian cohort. 2020 ,	0
1136	Solitary extramedullary plasmacytoma of the larynx: a rare cause of dysphonia. 2020 , 13,	0
1135	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. 2020 , 38, 4030-4041 ²⁵	
1134	Conventional Treatment for Multiple Myeloma Drives Premature Aging Phenotypes and Metabolic Dysfunction in T Cells. 2020 , 11, 2153	7
1133	How we manage smoldering multiple myeloma. 2020 , 12, 8951	0
1132	The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era. 2020 , 37, 103	1
1131	Vertical cutoff methods in serum protein electrophoresis for the measurement of monoclonal protein concentrations: Which is best?. 2020 , 510, 573-580	0
1130	Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images - A proof of principle study. 2020 , 131, 109214	10
1129	Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance. 2020 , 25, 100323	2
1128	Educational Case: Nephrotic Syndrome in Older Adult. 2020 , 7, 2374289520944554	0
1127	Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma. 2020 , 21,	6
1126	Biological properties of bone marrow plasma cells influence their recovery in aspirate specimens: impact on classification of plasma cell disorders and potential bias to evaluation of treatment response. 2020 , 99, 2599-2609	3
1125	Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. 2020 , 20, e910-e925	1
1124	The Role of Low Dose Whole Body CT in the Detection of Progression of Patients with Smoldering Multiple Myeloma. 2020 , 10, 93	7

1123	Multiple myeloma current treatment algorithms. 2020 , 10, 94	59
1122	Systemic Amyloidosis Due to Clonal Plasma Cell Diseases. 2020 , 34, 1009-1026	2
1121	Glucose-regulated protein 78 (GRP78) as a potential novel biomarker and therapeutic target in multiple myeloma. 2020 , 13, 1201-1210	2
1120	High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients. 2020 , 10, 563666	4
1119	Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy. 2020 , 20, 100926	0
1118	Epigenetic Aberrations in Multiple Myeloma. 2020 , 12,	8
1117	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. 2020 , 9, 8895-8901	1
1116	New information flows for cancer registries: testing the use of laboratory data in the province of Reggio Emilia, Italy. 2020 , 29, 548-555	1
1115	Recurrence of paraproteinemic crystalline keratopathy after corneal transplantation: A case of monoclonal gammopathy of ocular significance. 2020 , 19, 100803	4
1114	Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). 2020 , 34, 3111-3125	12
1113	The Spectrum of Monoclonal Immunoglobulin-Associated Diseases. 2020 , 34, 997-1008	
1112	How to quantify monoclonal free light chains in plasma cell disorders: which mass spectrometry technology?. 2020 , 8, 973	1
1111	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). 2020 , 10, 102	45
1110	Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients. 2020 , 9, 649-658	7
1109	Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series. 2020 , 20, e947-e955	4
1108	Differential epigenetic regulation between the alternative promoters, PRDM1 β and PRDM1 α of the tumour suppressor gene PRDM1 in human multiple myeloma cells. 2020 , 10, 15899	1
1107	Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy. 2020 , 13, 89	7
1106	Modern Treatments and Future Directions for Relapsed/Refractory Multiple Myeloma Patients. 2020 , 20, 736-743	2

1105	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. 2020 , 13, 94	76
1104	Pictorial review of whole body MRI in myeloma: emphasis on diffusion-weighted imaging. 2020 , 93, 20200312	2
1103	Impact of age-, cancer-, and treatment-driven inflammation on T cell function and immunotherapy. 2020 , 108, 953-965	7
1102	Identifying predictive factors for vertebral collapse fractures in multiple myeloma patients. 2020 , 20, 1832-1839	3
1101	Accelerated single cell seeding in relapsed multiple myeloma. 2020 , 11, 3617	16
1100	Evaluation of two serum free light chain quantitation methods, Freelite and Seralite, in the clinical laboratory with a view to switching immunoassay. 2020 , 510, 235-241	
1099	Daratumumab and antineoplastic therapy versus antineoplastic therapy only for people with newly diagnosed multiple myeloma ineligible for transplant. 2020 ,	78
1098	Improving real-world myeloma patient access to whole body MRI through "open-access" knowledge sharing: The UK experience. 2020 , 1, 361-363	2
1097	Proteins: analysis and interpretation in serum, urine, and cerebrospinal fluid. 2020 , 365-390	1
1096	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. 2020 , 9,	3
1095	Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. 2020 , 12,	38
1094	Mieloma multiple. 2020 , 13, 1142-1148	
1093	AL Amyloidosis: The Effect of Maintenance Therapy on Autologous Stem Cell Transplantation Outcomes. 2020 , 9,	4
1092	Light Chain Predominant Intact Immunoglobulin Monoclonal Gammopathy Disorders: Shorter Survival in Light Chain Predominant Multiple Myelomas. 2021 , 52, 390-398	4
1091	Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma. 2020 ,	
1090	Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. 2020 , 12,	2
1089	Progressive facial deformity. 2021 , 138, 301-302	
1088	Hypercalcemia caused by humoral effects and bone damage indicate poor outcomes in newly diagnosed multiple myeloma patients. 2020 , 9, 8962-8969	4

1087	A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell transplantation. 2020 , 97, 106441	2
1086	Recent Advances in the Treatment of Patients with Multiple Myeloma. 2020 , 12,	7
1085	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. 2020 , 98, 1407-1418	3
1084	Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo. 2020 , 12,	3
1083	Fat fraction quantification of lumbar spine: comparison of T1-weighted two-point Dixon and single-voxel magnetic resonance spectroscopy in diagnosis of multiple myeloma. 2020 , 26, 492-497	2
1082	Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation. 2021 , 43, 402-409	
1081	Multiple myeloma: the (r)evolution of current therapy and a glance into future. 2020 , 105, 2358-2367	21
1080	Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells. 2020 , 25,	3
1079	Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. 2020 , 34, e23416	3
1078	Ex Vivo Models Simulating the Bone Marrow Environment and Predicting Response to Therapy in Multiple Myeloma. 2020 , 12,	9
1077	Coexistent transthyretin amyloid cardiomyopathy and monoclonal gammopathy: Diagnostic challenges and prognostic implications. 2020 , 1	2
1076	In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma. 2020 , 10, 78	3
1075	A Prospective Study of Circulating Chemokines and Angiogenesis Markers and Risk of Multiple Myeloma and Its Precursor. 2020 , 4, pkz104	5
1074	A rare imaging case of bilateral plasmacytoma of the breast. 2020 , 6, 20190131	
1073	Renal pathology in patients with monoclonal gammopathy or multiple myeloma: monoclonal immunoglobulins are not always the cause. 2020 , 61, 3247-3250	0
1072	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. 2020 , 136, 2513-2523	25
1071	Hematolymphoid neoplasms with a plasma cell phenotype. 2020 , 37, 268-272	1
1070	Characterization of the role of Samsn1 loss in multiple myeloma development. 2020 , 2, 554-572	1

1069	Patients with multiple myeloma over a large catchment of 2.5 million square kilometres: a Western Australia retrospective survival review. 2020 , 50, 869-872	
1068	Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma. 2020 , 21,	5
1067	Multiple Myeloma Associated Bone Disease. 2020 , 12,	17
1066	Free light chain UV quantification compared with immunochemical measurement: How dimers and monomers may influence the results. 2020 , 510, 278-284	1
1065	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. 2020 , 10, 1439	21
1064	Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany. 2020 , 43, 449-459	4
1063	Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma. 2020 , 12,	8
1062	Education level as a predictor of survival in patients with multiple myeloma. 2020 , 20, 737	2
1061	Retrospective analysis of plasmacytoma in Kansai Myeloma Forum Registry. 2020 , 112, 666-673	
1060	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. 2020 , 10, 108	20
1059	Synchronous diagnosis of anaplastic large cell lymphoma and multiple myeloma in a patient: A case report. 2020 , 99, e22931	1
1058	Deep Learning Based Approach for Multiple Myeloma Detection. 2020 ,	4
1057	Kappa Index Versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. 2020 , 10,	10
1056	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. 2020 , 10, 106	20
1055	Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients. 2020 , 4, 4593-4604	8
1054	Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64-labeled daratumumab. 2020 , 4, 5194-5202	9
1053	Giant forehead plasmacytoma as a growing lump in a patient with multiple myeloma. 2020 , 15, 2589-2593	
1052	Somatic Mutations in and Severe Adult-Onset Autoinflammatory Disease. 2020 , 383, 2628-2638	160

1051	Isatuximab for the treatment of relapsed/refractory multiple myeloma. 2020 , 20, 1395-1404	12
1050	Whole-Body Functional MRI and PET/MRI in Multiple Myeloma. 2020 , 12,	7
1049	[Current Recommendations for the First-Line Therapy of Symptomatic Multiple Myeloma]. 2020 , 145, 813-819	0
1048	STAT3 transcription factor as target for anti-cancer therapy. 2020 , 72, 1101-1124	17
1047	Fluorodeoxyglucose-avid focal lesions and extramedullary disease on 18F-FDG PET/computed tomography predict the outcomes of newly diagnosed symptomatic multiple myeloma patients. 2020 , 41, 950-958	1
1046	Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. 2020 , 61, 3484-3492	2
1045	Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma. 2020 , 99, 2869-2880	6
1044	Therapieoptionen beim Multiplen Myelom. 2020 , 41, 231-234	
1043	How I manage frontline transplant-ineligible multiple myeloma. 2020 , 12, 8956	2
1042	Current developments in the combination therapy of relapsed/refractory multiple myeloma. 2020 , 20, 1021-1035	5
1041	Bildgebende Diagnostik des Multiplen Myeloms. 2020 , 41, 246-257	
1040	Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy. 2020 , 8, 1797-1801	
1039	The (Neutrophils + Monocyte)/Lymphocyte Ratio Is an Independent Prognostic Factor for Progression-Free Survival in Newly Diagnosed Multiple Myeloma Patients Treated With BCD Regimen. 2020 , 10, 1617	3
1038	Emerging immunotherapies in multiple myeloma. 2020 , 370, m3176	27
1037	Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. 2020 , 4, 4538-4549	24
1036	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. 2020 , 93, 20200562	12
1035	18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical Features. 2020 , 12,	5
1034	Bone Diseases and Supportive Care. 2020 , 20 Suppl 1, S42-S43	0

1033	Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study. 2020 , 61, 3112-3119	2
1032	The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma. 2020 , 25, 292-298	1
1031	Epigenetic silencing of long non-coding RNA in multiple myeloma: impact on prognosis and myeloma dissemination. 2020 , 20, 403	7
1030	B-Cell Lymphomas. 2020 ,	
1029	Transient Pleural Fluid Infiltration by Clonal Plasma Cells Associated with Pulmonary Tuberculosis. 2020 , 13, 883-891	
1028	Spatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria. 2020 , 12,	3
1027	Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study. 2020 , 99, 2589-2598	7
1026	Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects. 2020 , 12,	12
1025	Detection of monoclonal free light chains by immunofixation electrophoresis and isoelectric focusing - comparison with the quantitative method of determination. 2020 , 80, 556-561	0
1024	Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation. 2020 , 26, 5879-5886	1
1023	Strahlentherapie bei Plasmozytom und multiplem Myelom. 2020 , 23, 18-22	
1022	Surgical Spinal Oncology. 2020 ,	
1021	The FMS like Tyrosine Kinase 3 (FLT3) Is Overexpressed in a Subgroup of Multiple Myeloma Patients with Inferior Prognosis. 2020 , 12,	1
1020	A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests. 2021 , 52, 315-328	5
1019	B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS. 2020 , 11, 602868	2
1018	The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma. 2020 , 13,	1
1017	Recommendations on the management of multiple myeloma in 2020. 2020 , 1-17	1
1016	Outcomes of screening for gammopathies in children and adults with Gaucher disease type 1 in a cohort from Brazil and the United States. 2020 , 184, 1052-1059	

1015	Light-chain amyloid myopathy isolated to skeletal muscles: A case report. 2020 , 8, 2869-2873	
1014	Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma. 2020 , 12,	3
1013	Monoklonale Gammopathie unklarer Signifikanz bei rheumatologischen Erkrankungen. 2020 , 45, 544-549	
1012	Natural Language Processing of Serum Protein Electrophoresis Reports in the Veterans Affairs Health Care System. 2020 , 4, 749-756	1
1011	IgE monoclonal gammopathy: The clinical relevance to perform the immunofixation using IgE antisera. 2020 , 42, e237-e239	3
1010	Deletions and amplifications of the IGH variable and constant regions:a novel prognostic parameter in patients with multiple myeloma. 2020 , 99, 106476	1
1009	Development of a clinical diagnostic tool to differentiate multiple myeloma from bone metastasis in patients with destructive bone lesions (MM-BM DDx). 2020 , 21, 215	1
1008	Plasma cell myeloma with pure lymphocyte-like morphology. 2021 , 100, 3071-3073	
1007	The utility of ADC value in diffusion-weighted whole-body MRI in the follow-up of patients with multiple myeloma. Correlation study with F-FDG PET-CT. 2020 , 133, 109403	3
1006	Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies. 2020 , 5, 1358-1371	9
1005	Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression. 2021 , 106, 1943-1956	28
1004	Incidence and survival of multiple myeloma: a population-based study of 10 524 patients diagnosed 1982-2017. 2020 , 191, 418-425	11
1003	Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. 2020 , 50, 667-679	25
1002	Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?. 2020 , 12,	4
1001	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study. 2020 , 10, 58	3
1000	Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1. 2020 , 12,	4
999	The Spectrum of Rib Neoplasms in Adults: A Practical Approach and Multimodal Imaging Review. 2020 , 215, 165-177	0
998	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. 2020 , 10, 52	4

997	Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. 2020 , 16, 571-578	17
996	Updates in the Diagnosis and Management of AL Amyloidosis. 2020 , 15, 155-167	6
995	Hepatocellular carcinoma and multiple myeloma with elevated globulin: a case report and literature review. 2020 , 48, 300060520920395	
994	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. 2020 , 20, 489	1
993	Cytogenetic abnormalities in patients with newly diagnosed multiple myeloma as a secondary primary malignancy: a retrospective study. 2020 , 25, 176-180	1
992	Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. 2020 , 8,	28
991	Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen. 2020 , 99, 2881-2891	7
990	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. 2020 , 112, 84-95	0
989	Socioeconomic Status Is an Independent Prognostic Factor for Overall Survival in Patients With Multiple Myeloma: Real-World Data From a Cohort of 223 Patients. 2020 , 20, 704-711	1
988	Cardiac calcified amorphous tumour associated with multiple myeloma. 2020 , 13,	1
987	Smoldering Myeloma and the Art of War. 2020 , 38, 2363-2365	7
986	Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. 2020 , 136, 936-945	189
985	Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. 2020 , 135, 1833-1846	18
984	Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. 2020 , 11, 854	5
983	Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma. 2020 , 12,	4
982	Can F-NaF PET/CT before Autologous Stem Cell Transplantation Predict Survival in Multiple Myeloma?. 2020 , 12,	4
981	ImmunoPET in Multiple Myeloma-What? So What? Now What?. 2020 , 12,	4
980	Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. 2020 , 99, 1735-1740	1

979	Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report. 2020 , 112, 741-745	1
978	28 Diffusely Abnormal Marrow Signal within the Vertebrae on MRI. 2020 ,	
977	FDG-PET/CT, a Promising Exam for Detecting High-Risk Myeloma Patients?. 2020 , 12,	1
976	Choline PET/CT in Multiple Myeloma. 2020 , 12,	3
975	Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients. 2020 , 21, 227	3
974	Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All. 2020 , 12,	9
973	Bone marrow particle enrichment analysis for the laboratory diagnosis of multiple myeloma: A case study. 2020 , 34, e23372	1
972	Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019. 2020 , 105, 434-448	
971	Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. 2020 , 22, 66	25
970	Monoclonal gammopathy associated neuropathy: Focusing on IgM M-protein associated neuropathy. 2020 , 109-127	
969	Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?. 2020 , 10, 189	20
968	Response Improvement Rather than Response Status after First Autologous Stem Cell Transplantation Is a Significant Prognostic Factor for Survival Benefit from Tandem Compared with Single Transplantation in Multiple Myeloma Patients. 2020 , 26, 1280-1287	5
967	Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. 2020 , 2020, 4360926	1
966	OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. 2020 , 16, 631-641	20
965	Prevalence of monoclonal gammopathy of undetermined significance in a large population with annual medical check-ups in China. 2020 , 10, 34	2
964	First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. 2020 , 105, 116-125	3
963	Significant differences in access to tests and treatments for multiple myeloma between public and private systems in Latin America. Results of a Latin American survey. GELAMM (Grupo de Estudio Latino Americano de Mieloma Multiple). 2020 , 99, 1025-1030	7
962	The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists. 2020 , 214, 1321-1334	1

961	Limitations of Free Light Chain Assays caused by the Matrix Effect. 2020 , 5, 311-319	1
960	Maximizing the Clinical Benefit of Radiotherapy in Solitary Plasmacytoma: An International Multicenter Analysis. 2020 , 12,	8
959	Prognostic Value and Efficacy Evaluation of Novel Drugs for Multiple Myeloma Patients with 1q21 Amplification (Amp1q21) Only: A Systematic Review of Randomized Controlled Trials. 2020 , 11, 2639-2644	
958	Treatment of Smoldering Multiple Myeloma: Expectant Observation Should Still Be the Standard. 2020 , 40, 1-7	5
957	Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. 2020 , 95, 548-567	235
956	Real world outcomes with Bortezomib Thalidomide dexamethasone and Cyclophosphamide Bortezomib dexamethasone induction treatment for transplant eligible multiple myeloma patients in a Latin American country. A Retrospective Cohort Study from Grupo Argentino de Mieloma Múltiple. 2020 , 26, 363-371	1
955	Untreated plasmacytoma of bone containing macroscopic intralesional fat and mimicking intraosseous lipoma: A case report and review of the literature. 2020 , 64, 18-23	
954	Serum markers alone can define high-risk smoldering multiple myeloma: new insights from the Czech Myeloma Group model. 2020 , 190, 137-138	
953	Computed tomography-based skeletal segmentation for quantitative PET metrics of bone involvement in multiple myeloma. 2020 , 41, 377-382	4
952	Identification of patients with smoldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. 2020 , 190, 189-197	5
951	Unilateral Multiple Extramedullary Plasmacytoma of the Choroid and Conjunctiva: A Case Report. 2020 , 4, 152-156	1
950	Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. 2020 , 10, 28	12
949	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. 2020 , 5, 67-85	1
948	Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review. 2020 , 20, 170	7
947	[Multiple myeloma in old people : Practical skills for geriatricians and general practitioners]. 2020 , 53, 263-272	
946	CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma. 2020 , 213, 108363	2
945	MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. 2020 , 136, 2557-2573	13
944	Multiples Myelom [dynamische Entwicklungen in Krankheitsverständnis und Therapie. 2020 , 26, 661-672	

943	Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. 2020 , 34, e23399	9
942	A report on the syndrome of inappropriate anti-diuretic hormone secretion associated with multiple myeloma. 2020 , 133, 1493-1494	
941	Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. 2020 , 99, 1779-1791	3
940	Serum Lactate Dehydrogenase Can Be Used as a Factor for Re-Evaluating First-Relapsed Multiple Myeloma. 2020 , 143, 559-566	2
939	Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study. 2020 , 95, e268-e279	16
938	Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma. 2020 , 9, 5819-5826	7
937	AL Amyloidosis in Myeloma: Red Flag Symptoms. 2020 , 20, 777-778	3
936	Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. 2020 , 12,	1
935	Immunoglobulin M Paraproteinaemias. 2020 , 12,	3
934	Advanced imaging in evaluation of bone disease of multiple myeloma. 2020 , 3, 76-83	1
933	A Rare Case of Extramedullary Adrenal Plasmacytoma Associated with IVC Thrombus: A Case Report with Review of Literature. 2020 , 2, 792-796	
932	Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients. 2020 , 8, e1363	3
931	Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma. 2020 , 10, 10250	7
930	Real-world data on incidence, clinical characteristics and outcome of patients with macrofocal multiple myeloma (MFMM) in the era of novel therapies: A study of the Greco-Israeli collaborative myeloma working group. 2020 , 95, 465-471	5
929	In Regard to Mignot et al. 2020 , 106, 1109-1110	2
928	In Reply to Sari and Yazici. 2020 , 106, 1110	
927	Light chain proximal tubulopathy with cast nephropathy in monoclonal gammopathy of renal significance. 2020 , 13,	
926	Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?. 2020 , 20, e769-e776	1

925	Phase I/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma. 2020 , 10, 13	3
924	Band Urine free light chains: a new method for quantification. 2020 , 106, 457-463	
923	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). 2020 , 34, 1840-1852	30
922	Mass Spectrometry for Identification, Monitoring, and Minimal Residual Disease Detection of M-Proteins. 2020 , 66, 421-433	20
921	NETs analysed by novel calprotectin-based assays in blood donors and patients with multiple myeloma or rheumatoid arthritis: A pilot study. 2020 , 91, e12870	3
920	Efficient 1-Hour Technetium-99 m Pyrophosphate Imaging Protocol for the Diagnosis of Transthyretin Cardiac Amyloidosis. 2020 , 13, e010249	20
919	Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. 2020 , 125, 110005	6
918	Potential of circular RNA itchy E3 ubiquitin protein ligase as a biomarker and treatment target for multiple myeloma.. 2020 , 9, 335-345	1
917	Imaging of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma. 2020 , 12,	4
916	Assessment of early treatment response on MRI in multiple myeloma: Comparative study of whole-body diffusion-weighted and lumbar spinal MRI. 2020 , 15, e0229607	12
915	Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. 2020 , 13, 375-392	3
914	Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. 2020 , 16, e341-e349	4
913	Prediagnosis dietary pattern and survival in patients with multiple myeloma. 2020 , 147, 1823-1830	10
912	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. 2020 , 190, 249-261	6
911	Treatment and disease-related complications in multiple myeloma: Implications for survivorship. 2020 , 95, 672-690	11
910	Multiple myeloma with primary amyloidosis presenting with digestive symptoms: A case report and literature review. 2020 , 21, 54-58	4
909	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study. 2020 , 17, e1003050	
908	18F-FDG PET or PET/CT role in plasmacytoma: A systematic review. 2020 , 39, 220-224	0

907	A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease. 2020 , 27, 119-127	1
906	Fractures and survival in multiple myeloma: results from a population-based study. 2020 , 105, 1067-1073	12
905	Quantification of tumor burden in multiple myeloma by atlas-based semi-automatic segmentation of WB-DWI. 2020 , 20, 6	3
904	Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencing. 2020 , 11, 400	15
903	NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway. 2020 , 39, 368-378	14
902	Problem Management Plus in the treatment of mental disorders in patients with multiple myeloma. 2020 , 28, 4721-4727	1
901	High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications. 2020 , 33, 101152	7
900	Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. 2020 , 33, 101148	4
899	The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!. 2020 , 33, 101150	4
898	Prognostic role of minichromosome maintenance family in multiple myeloma. 2020 , 27, 819-829	3
897	GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice. 2020 , 15, e0228408	1
896	Modern treatments and future directions for newly diagnosed multiple myeloma patients. 2020 , 33, 101151	4
895	An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. 2020 , 58, 533-546	17
894	How We Approach Smoldering Multiple Myeloma. 2020 , 38, 1119-1125	2
893	Nonsystemic vasculitic neuropathy in a patient with IgG-monoclonal gammopathy of undetermined significance: A case report. 2020 , 99, e19036	
892	Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response. 2020 , 20, 14	15
891	Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. 2020 , 20, e352-e367	12
890	Bone tissue quality in patients with monoclonal gammopathy of uncertain significance. 2020 , 38, 563-569	4

889	Serum Free Light Chain Assay: Shift Toward a Higher κ/λ Ratio. 2020 , 5, 114-125	5
888	Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis. 2020 , 20, 519-525.e1	2
887	Subspecialty Second-Opinion in Multiple Myeloma CT: Emphasis on Clinically Significant Lytic Lesions. 2020 , 56,	2
886	Acquired dysfibrinogenemia: monoclonal κ type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation. 2020 , 112, 96-104	6
885	Development and definition of a simplified scoring system in patients with multiple myeloma undergoing stem cells transplantation on standard computed tomography: myeloma spine and bone damage score (MSBDS). 2020 , 20, 31	5
884	F-FDG and C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. 2020 , 12,	7
883	Role of imaging in multiple myeloma. 2020 , 95, 966-977	8
882	The mediator role of unmet needs on quality of life in myeloma patients. 2020 , 29, 2641-2650	3
881	Serum free light chains and multiple myeloma: Is it time to extend their application?. 2020 , 8, 617-624	2
880	Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma. 2020 , 59, 465-471	1
879	Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects. 2020 , 15, 45-55	3
878	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. 2020 , 20, 596-601	3
877	Pathological hip fractures. 2020 , 34, 64-72	0
876	An in vitro investigation into the protective and genotoxic effects of myricetin bulk and nano forms in lymphocytes of MGUS patients and healthy individuals. 2020 , 327, 33-40	4
875	Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies. 2020 , 12,	9
874	The prognostic value of the controlling nutritional status score in patients with multiple myeloma. 2020 , 61, 1894-1900	7
873	Low absolute CD4 T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. 2020 , 61, 1869-1876	7
872	Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies. 2020 , 11, 762	31

871	Clinicopathological characteristics of light chain proximal tubulopathy in Korean patients and the diagnostic usefulness of immunohistochemical staining for immunoglobulin light chain. 2020 , 21, 146	4
870	PET-FDG: Impetus. 2020 , 12,	5
869	Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. 2020 , 11, 764-768	24
868	Non-cryopreserved peripheral blood stem cells autologous transplantation in multiple myeloma: Bicentric study. 2020 , 27, 152-156	2
867	Osteoclast stimulatory transmembrane protein (OC-STAMP) is a promising molecular prognostic indicator for multiple myeloma. 2020 , 105, 185-195	1
866	Clinical Reasoning: A 59-year-old woman with multiple myeloma and lower extremity weakness and numbness. 2020 , 94, 794-800	
865	Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients. 2020 , 16, 103-110	4
864	Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. 2020 , 105, 2679-2682	15
863	Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. 2020 , 13, 669-686	3
862	Timing the initiation of multiple myeloma. 2020 , 11, 1917	36
861	The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. 2020 , 99, 1709-1725	4
860	Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents. 2020 , 10, 40	7
859	Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence. 2020 , 13, 501-517	3
858	Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains. 2020 , 51, 592-600	5
857	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. 2020 , 104, S11-S103	113
856	Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. 2020 , 190, 555-561	14
855	Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. 2020 , 135, 1101-1110	9
854	Clinical Controversies in the Management of Smoldering Multiple Myeloma. 2020 , 40, 1-6	2

853	Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center. 2021 , 74, 149-158	5
852	Platelet hyperactivation in multiple myeloma is also evident in patients with premalignant monoclonal gammopathy of undetermined significance. 2021 , 192, 322-332	2
851	Multiple Myeloma Presenting in Patients Younger than 50 Years of Age: A Single Institution Experience. 2021 , 144, 58-65	2
850	Marrow uptake on FDG PET/CT is associated with progression from smoldering to symptomatic multiple myeloma. 2021 , 50, 79-85	3
849	Advances & future prospects in newly diagnosed multiple myeloma patients. 2021 , 4,	1
848	Cryoglobulins: Identification, classification, and novel biomarkers of mysterious proteins. 2021 , 104, 299-340	1
847	Standardization of F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. 2021 , 39, 116-125	31
846	Critical role of PET/CT-based novel quantitative techniques for assessing global disease activity in multiple myeloma and other hematological malignancies: why it is time to abandon reliance on examining focal lesions. 2021 , 31, 149-151	1
845	Plasma Cell Proliferation Is Reduced in Myeloma-Induced Hypercalcemia and in Co-Culture with Normal Healthy BM-MSCs. 2021 , 52, 273-289	
844	Ixazomib and lenalidomide maintenance therapy in multiple myeloma. 2021 , 100, 851-853	2
843	Multiple myeloma-A painful disease of the bone marrow. 2021 , 112, 49-58	3
842	Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience. 2021 , 56, 395-399	3
841	Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. 2021 , 192, 869-878	15
840	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. 2021 , 35, 18-30	29
839	Orthopedic Surgical Treatment and Perioperative Complications in Multiple Myeloma Bone Disease: Analysis of a Series (2009-2018). 2021 , 28, 1158-1166	3
838	Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers. 2021 , 147, 205-212	7
837	Fear of cancer recurrence in patients with multiple myeloma: Prevalence and predictors based on a family model analysis. 2021 , 30, 176-184	6
836	Role of computed tomography texture analysis using dual-energy-based bone marrow imaging for multiple myeloma characterization: comparison with histology and established serologic parameters. 2021 , 31, 2357-2367	4

835	Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma. 2021 , 39, 348-361	2
834	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. 2021 , 35, 1732-1744	3
833	Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. 2021 , 75, 60-64	3
832	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. 2021 , 39, 41-50	7
831	Immunoglobulin D-kappa multiple myeloma in a patient with rheumatoid arthritis: a case report and review of the literature. 2021 , 5, 22-28	1
830	Saliva-omics in plasma cell disorders- Proof of concept and potential as a non-invasive tool for monitoring disease burden. 2021 , 231, 104015	6
829	Real-world reproducibility study characterizing patients newly diagnosed with multiple myeloma using Clinical Practice Research Datalink, a UK-based electronic health records database. 2021 , 30, 248-256	3
828	Persistent challenges with treating multiple myeloma early. 2021 , 137, 456-458	8
827	Back to Basics: Parathyroid Adenoma Disguising as 'CRAB'. 2021 , 134, e323-e324	
826	Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. 2021 , 62, 883-890	2
825	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. 2021 , 56, 1144-1150	5
824	Bone Marrow Evaluation. 2021 , 27-39	
823	EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. 2021 , 26, 70-76	14
822	High immunoproteasome concentration in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of longer OS. 2021 , 66, 21-27	0
821	Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?. 2021 , 26, 100338	5
820	DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. 2021 , 192, e73-e77	0
819	Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience. 2021 , 147, 1773-1779	0
818	A new parameter in multiple myeloma: CYP3A4*1B single nucleotide polymorphism. 2021 , 100, 421-427	2

817 Sarcoma. **2021**,

816 Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. *Lancet Oncology, The*, **2021**, 22, 142-154 21.7 22

815 Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma. **2021**, 35, 442-450 5

814 High-Throughput Therapeutic Antibody Interference-Free High-Resolution Mass Spectrometry Assay for Monitoring M-Proteins in Multiple Myeloma. **2021**, 93, 834-842 5

813 Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. **2021**, 56, 928-935 2

812 Myeloma clinical outcomes following the first wave of COVID-19: results from the Thames Valley Cancer Alliance (UK). **2021**, 192, e136-e139 1

811 Effect of high cut-off dialysis for acute kidney injury secondary to cast nephropathy in patients with multiple myeloma: a systematic review and meta-analysis. **2021**, 14, 1894-1900 2

810 Trends in solitary plasmacytoma, extramedullary plasmacytoma, and plasma cell myeloma incidence and myeloma mortality by racial-ethnic group, United States 2003-2016. **2021**, 10, 386-395 6

809 AL amyloidosis presenting as inflammatory polyarthritis: a case report. **2021**, 5, 391-398 0

808 Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? - Literature review. **2021**, 43, 185-190 2

807 Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment. **2021**, 62, 709-715 0

806 EWSR1 overexpression is a pro-oncogenic event in multiple myeloma. **2021**, 113, 381-394 1

805 Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: A population-based study. **2021**, 12, 508-514 1

804 A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy. **2021**, 48, 1487-1497 0

803 Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. **2021**, 21, e220-e226 3

802 Retroperitoneal involvement with light chain amyloidosis- case series and literature review. **2021**, 62, 316-322 1

801 Polymeric IgA paraprotein on agarose gel electrophoresis immunofixation identifies a unique subset of IgA myeloma patients. **2021**, 512, 112-116 4

800 Monoclonal gammopathy of undetermined significance (MGUS): where is the hidden danger? Definition and work-up. **2021**, 14, 76-79

799	Quantitative bone marrow magnetic resonance imaging through apparent diffusion coefficient and fat fraction in multiple myeloma patients. 2021 , 126, 445-452	10
798	Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma. 2021 , 96, 23-30	1
797	Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents. 2021 , 113, 207-213	1
796	Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma. 2021 , 31, 1843-1852	4
795	Diagnostic performance of F-FDG-PET/CT compared to standard skeletal survey for detecting bone destruction in smoldering multiple myeloma: time to move forward. 2021 , 193, 125-128	1
794	Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis. 2021 , 28, 50-55	9
793	Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. 2021 , 99, 410-420	11
792	Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma. 2021 , 137, 1478-1490	9
791	-. 2021 , 14, 156-166	2
790	Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. 2021 , 36, 482-490	4
789	Imaging of Pelvic Bone Tumors. 2021 , 23-32	0
788	Bone diseases and associated therapeutic solutions. 2021 , 89-124	
787	Literaturverzeichnis. 2021 , 503-518	
786	More than Meets the Eye: Bacteremic Pneumococcal Pneumonia as the Initial Presentation of Multiple Myeloma. 2021 , 22, e927904	
785	Diagnostic role of 11C-methionine PET/CT in patients with multiple myeloma and other plasma cell malignancy: a literature review. 2021 , 9, 3-17	0
784	Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. 2021 , 100, 2311-2323	3
783	Oral Conditions of Elders and Middle-aged Individuals with Multiple Myeloma. 2021 , 22, 610-614	
782	What Is New in the Treatment of Smoldering Multiple Myeloma?. 2021 , 10,	2

781 Diagnostic and Therapeutic Challenges. **2021**, 41, 2625-2630

780 PET/CT in Multiple Myeloma: Beyond FDG. **2020**, 10, 622501

6

779 Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma. **2021**, 26, 388-392

0

778 Total diffusion volume in MRI vs. total lesion glycolysis in PET/CT for tumor volume evaluation of multiple myeloma. **2021**, 31, 6136-6144

2

777 Protein Electrophoresis, Serum Free Light Chain Assay and Other Biomarkers in Diagnosis and Monitoring of Monoclonal Protein Associated Disease. **2021**,

776 Lifetime Pesticide Use and Monoclonal Gammopathy of Undetermined Significance in a Prospective Cohort of Male Farmers. **2021**, 129, 17003

5

775 Smoldering multiple myeloma 40 years later: a story of unintended disease. **2021**, 14, 149-153

2

774 Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. **2021**, 192, e115-e120

0

773 Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population. **2021**, 94, 48-52

772 Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015. **2021**, 29, 4501-4511

771 Clinicopathological characteristics and long-term prognosis of monoclonal immunoglobulin light chain associated Fanconi syndrome. **2021**, 12, 2040620720983127

770 Agreement Between 18F-FDG PET/CT and Whole-Body Magnetic Resonance Compared With Skeletal Survey for Initial Staging and Response at End-of-Treatment Evaluation of Patients With Multiple Myeloma. **2021**, 46, 310-322

3

769 IgA- κ Multiple Myeloma with Abnormal Fibrinogen: A Case Report and Literature Review. **2021**, 11, 3113-3116

768 Bone Targeted Therapies. **2021**, 105-127

767 The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. **2021**, 12, 293

20

766 Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. **2021**, 48, 2558-2565

3

765 Oligoclonal Bands: Isoelectric Focusing and Immunoblotting, and Determination of Free Light Chains in the Cerebrospinal Fluid. **2021**, 29-54

764 Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma. **2021**, 19, 79-85

- 763 Monoclonal gammopathy of renal significance. **2021**, 14, 98-102
- 762 Rib Plasmacytoma Presenting as Progressive Muscle Weakness. **2021**, 36, 66-68
- 761 Introduction: Management of Bone Disease and Kidney Failure in Multiple Myeloma. **2021**, 1-5 1
- 760 DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. **2021**, 13, 4
- 759 Underweight as a risk factor of mortality in patients with newly diagnosed multiple myeloma. **2021**, 29, 3991-3999 0
- 758 A rare presentation of myelomatous pleural effusion in immunoglobulin g subtype of multiple myeloma. **2021**, 5, 82
- 757 Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study. **2021**, 15, 100252
- 756 Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5 T. **2021**, 34, 513-521 1
- 755 No Longer Benign: Altered Mental Status and Apparent Coagulopathy in a Woman with Monoclonal Gammopathy of Undetermined Significance. **2021**, 6, 784-789
- 754 Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. **2021**, 106, 380-388 1
- 753 Regulatory role of DEPTOR-mediated cellular autophagy and mitochondrial reactive oxygen species in angiogenesis in multiple myeloma. **2021**, 47, 643-658
- 752 Bone Tumour Pathology. **2021**, 69-92
- 751 Cancer-testis antigen MAGE-C1/ CT7 in multiple myeloma: literature review. **2020**, 15, 29-37
- 750 Smoldering Multiple Myeloma: What Is the Threshold to Start Treatment?. **2020**, 18, 1777-1779 1
- 749 Whole-body magnetic resonance imaging for diagnosis and treatment monitoring in multiple myeloma. **2020**, 65, 431-443 1
- 748 Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (2nd relapse) refractory myeloma: a multicenter real world UK experience. **2021**, 62, 1396-1404 1
- 747 Comparison of Cell Morphology and Flow Cytometry in the Diagnosis of Multiple Myeloma. **2020**, 11, 731-737 0
- 746 Oral medullary plasmacytoma: Rare case reports. **2020**, 24, S55-S58

- 745 Reduced Weekly Subcutaneous Doses of Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma. **2020**, 9, 56-59 1
- 744 Algoritmo de manejo para el síndrome de destrucción vertebral por mieloma múltiple y compresión metastásica de la médula espinal. **2020**, 34, 293-297 1
- 743 Association of Multiple Myeloma and Giant Cell Arteritis - A Case Report. **2020**, 7, 001360 1
- 742 State of the Art for Metastatic Histologies. **2020**, 211-233
- 741 Diagnosis and Treatment of Multiple Myeloma for Spinal Surgeons. **2020**, 34, 134-138
- 740 Multiple myeloma: an update. **2020**, 3, 72 2
- 739 Magnetic resonance imaging versus radiological skeletal survey of the lumbosacral spine in patients with advanced multiple myeloma: A single-institute experience. **2020**, 9, 107
- 738 Amyloidosis masquerading as gastric carcinoma - A case report. **2020**, 63, 119-121 0
- 737 Therapy Response Imaging in Lymphoma and Hematologic Malignancies. **2020**, 177-200
- 736 Plasma Cell Neoplasms (Including Plasma Cell Myeloma). **2020**, 595-614
- 735 ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. **2020**, B-1-B30-3
- 734 MULTIPLE MYELOMA: CHALLENGES OF DIFFERENTIAL DIAGNOSIS (CLINICAL CASE). **2020**, 73, 203-207
- 733 Detection of M-Protein in Acetonitrile Precipitates of Serum using MALDI-TOF Mass Spectrometry.
- 732 Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients.. **2020**, 9, 1495-1505 0
- 731 Acute Kidney Failure: When Multiple Myeloma Doesn't Give Additional Clues. **2020**, 12, e7664 0
- 730 Accurate classification of plasma cell dyscrasias is achieved by combining artificial intelligence and flow cytometry. **2021**, 0
- 729 Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. **2021**, 44, 672-681 6
- 728 Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. **2021**, 8

727	Treatment of multiple myeloma in 2021. 2021 , 35, 70-77	0
726	Identification of patients at high risk of secondary extramedullary multiple myeloma development. 2021 ,	0
725	The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications. 2021 , 22,	0
724	Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. 2021 , 101, 369	0
723	Involvement of MM cell-derived exosomes in T lymphocytes immune responses. 2020 , 20, 31	3
722	F-FDG PET or PET/CT role in plasmacytoma: A systematic review. 2020 , 39, 220-224	1
721	Optimization of workflow and screening panels for the detection of malignant monoclonal gammopathies. 2020 , 1,	
720	Double trouble: A case of synchronous presentation of acute myeloid leukaemia and multiple myeloma. 4,	
719	Simultaneous medication-related osteonecrosis of the jaw and maxillo-mandibular localization of multiple myeloma. 2020 , 70,	
718	The importance of serum immunoglobulin free light chain assessment for predicting outcome in patients with newly diagnosed multiple myeloma in real clinical practice. 2020 , 15, 38-50	1
717	Prognostic value of the modified multiple myeloma comorbidity index in real clinical practice. 2020 , 15, 51-62	
716	Paraneoplastic endocrinopathy in Castleman disease and POEMS syndrome. 2020 , 15, 67-79	
715	Clinical presentation and outcomes of solitary plasmacytoma in a tertiary hospital in the UK. 2020 , 20, e191-e195	0
714	,, and mutations in plasma cell myeloma at a single Korean institute. 2020 , 55, 159-168	
713	Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes (POEMS) Syndrome With IgG Kappa/IgG Lambda Biclonal Gammopathy: A Rare Presentation of a Rare Disease. 2020 , 12, e10232	0
712	[Bone disease as the first manifestation of systemic AL-amyloidosis]. 2020 , 92, 85-89	
711	Prospective Comparison of 18F-Choline Positron Emission Tomography/Computed Tomography (PET/CT) and 18F-Fluorodeoxyglucose (FDG) PET/CT in the Initial Workup of Multiple Myeloma: Study Protocol of a Prospective Imaging Trial. 2020 , 9, e17850	0
710	(F)utility of urine Bence Jones proteins for "routine" screening for plasma cell dyscrasia. 2020 ,	

709	Everyday living with pain – reported by patients with multiple myeloma. 2021 , 21, 127-134	0
708	Differential diagnosis of aggressive neoplasms with plasmablastic and late post-follicular differentiation. 2020 , 26, 421-439	
707	Light chain amyloidosis presenting with autoimmune hepatitis-primary sclerosing cholangitis overlap syndrome. 2020 , 1, e0013	
706	Evaluation of the protein gap for detection of abnormal serum gammaglobulin level: an imperfect predictor. 2021 , 59, 869-874	1
705	Monoclonal components in alpha-2 region should not be neglected in capillary electrophoresis. 2021 , 59, e145-e147	
704	Consenso del Grupo Latinoamericano de estudio de Mieloma Múltiple (MM) GELAMM para el manejo del MM en estado de Pandemia SARS CoV-2 / COVID 19. 24,	2
703	Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma. 2015 , 5, 469-78	42
702	Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. 2015 , 5, 479-92	43
701	Asymptomatic Multiple Myeloma Presenting as a Nodular Hepatic Lesion: A Case Report and Review of the Literature. 2015 , 15, 457-67	3
700	Quantitative analysis of F-NaF dynamic PET/CT cannot differentiate malignant from benign lesions in multiple myeloma. 2017 , 7, 148-156	7
699	Integrating Emerging Data Into Clinical Practice: A Case-Based Approach for Multiple Myeloma. 2017 , 8, 365-377	2
698	Report of the Survey Conducted by RCPAQAP on Current Practice for Paraprotein and Serum Free Light Chain Measurement and Reporting: a Need for Harmonisation. 2019 , 40, 31-42	1
697	The Paraprotein - an Enduring Biomarker. 2019 , 40, 5-22	8
696	Multiple Myeloma: Updates on Diagnosis and Management. 2015 , 32, 49S-56S	4
695	A Rare Case of Non-Secretory Multiple Myeloma: A Case Report and Literature Review. 2019 , 30, 88-94	
694	Clinical relevance of PET/CT in patients with newly diagnosed multiple myeloma. 2019 , 12, 619-627	3
693	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. 2018 , 11, 304-313	7
692	[Advances in the diagnosis and treatment of multiple myeloma]. 2018 , 39, 605-608	

- 691 [Safety and efficacy of chimeric antigen receptor T cell in the treatment of elderly patients with hematological malignancies]. **2018**, 39, 952-955
- 690 [Adverse effects of double-hit combining ISS-III stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma]. **2019**, 40, 912-917
- 689 [Clinical prognosis analysis of patients with "double hit" multiple myeloma]. **2019**, 40, 918-923
- 688 [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center]. **2019**, 40, 453-459
- 687 [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma]. **2019**, 40, 732-737 ○
- 686 [Clinical implication of minimal residual disease monitoring by 10-color flow cytometry in multiple myeloma]. **2019**, 40, 720-725
- 685 [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities]. **2019**, 40, 644-649 ○
- 684 [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation]. **2018**, 39, 496-500
- 683 [Long-term follow-up of multiple myeloma after autologous hematopoietic stem cell transplantation: a single center results]. **2017**, 38, 499-504
- 682 [Myeloid-derived suppressor cells in peripheral blood of multiple myeloma]. **2017**, 38, 545-547
- 681 [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma]. **2016**, 37, 288-91 2
- 680 [Clinical characteristics and prognosis of 56 multiple myeloma patients over 70 years of age complicated with other systemic diseases]. **2018**, 39, 866-869
- 679 [Progress of clonal hematopoiesis of indeterminate potential]. **2016**, 37, 542-4
- 678 [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study]. **2020**, 41, 10-15
- 677 [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. **2019**, 40, 584-588
- 676 Prognostic significance of F-sodium fluoride in newly diagnosed multiple myeloma patients. **2020**, 10, 151-160 1
- 675 [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease]. **2020**, 41, 822-828 1
- 674 VAD Chemotherapy versus Bortezomib Containing Regimens as Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience. **2020**, 14, 248-256

- 673 Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apoptosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein. **2020**, 49, 2078-2086 1
- 672 [Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10]. **2021**, 42, 295-301
- 671 [Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma]. **2021**, 42, 332-337
- 670 A comparison of the efficacy and safety of ixazomib and lenalidomide combined with dexamethasone in the treatment of multiple myeloma. **2021**, 13, 5248-5255
- 669 Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management. **2021**, 11, 2736-2753 1
- 668 Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance. **2021**, 7, e723
- 667 [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients]. **2021**, 42, 390-395
- 666 [Clinical characteristics and outcome of patients with type II cryoglobulinemia]. **2021**, 42, 447-451
- 665 Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. **2021**, 41, 198-205
- 664 [Multiple myeloma and autologous haematopoietic stem-cell transplantation without cryopreservation: experiences of the Clinical Hematology Department of Casablanca, Morocco]. **2021**, 39, 105
- 663 Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. **2021**, 11, 4438-4454
- 662 [A predictive model based on risk factors for early mortality in patients with newly diagnosed multiple myeloma]. **2021**, 42, 666-672
- 661 [Characteristics of immunoglobulin heavy-chain gene clonal rearrangements by next-generation sequencing of patients with multiple myeloma]. **2021**, 42, 683-686 0
- 660 [The efficacy and safety profile of ixazomib/lenalidomide/dexamethasone in relapsed/refractory multiple myeloma: a multicenter real-world study in China]. **2021**, 42, 628-634
- 659 [Autologous stem cell transplantation improves outcomes of patients with multiple myeloma receiving proteasome inhibitors and lenalidomide treatment]. **2021**, 41, 1420-1425
- 658 Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in the Practice of the General Practitioner. **2020**, 98-104
- 657 Compressive Myeloradiculopathies in Multiple Myeloma: Clinical and Radiological Characteristics of a Series of 29 Patients. **2021**, 11, 133-139
- 656 Multiples Myelom. **2022**, 204-211

655 Niere und Elektrolyte, Osteoprotektion. **2022**, 92-99

654 Relationship of tumor load parameters before and after autologous stem cell transplantation with clinical prognosis in transplant-eligible patients with multiple myeloma: A retrospective analysis. **2021**, 112, 106750

653 Outcomes of autologous stem cell transplantation for multiple myeloma in Saudi Arabia. **2021**, 41, 198-205

652 Outcomes of kidney transplant recipients with ESKD due to plasma cell dyscrasia: A case series. **2021**, e14541

651 Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. **2021**, 12, 792609

650 Plasmacytoma of the mandible: A diagnostic conundrum. **2021**, 6, 272-277

649 Spectrum of B-cell neoplasms associated with immunoglobulin G4-related disease. **2021**, 101, 99

648 Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis. **2021**, 11, 766672

647 Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. **2021**, 11, 740796

646 Do Patients With Multiple Myeloma Enrolled in Clinical Trials Live Longer?. **2021**, 44, 603-612

645 Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis. **2021**, 13,

644 Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report. **2021**, 21, 597

643 Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. **2021**, 11, 186

642 Diffusion-Weighted MRI The Way Forward for MRI in Myeloma?. **2021**, 2, 672-679

641 Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma. **2021**, 10,

640 How I Treat Frontline Transplant-eligible Multiple Myeloma. **2021**,

639 Differences and Similarities in Treatment Paradigms and Goals between AL Amyloidosis and Multiple Myeloma. **2021**, 2, 680-691

638 Whole-Body Low-Dose Multidetector-Row CT in Multiple Myeloma: Guidance in Performing, Observing, and Interpreting the Imaging Findings.. **2021**, 11,

637	Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis. 2021,	1
636	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. 2021,	1
635	Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow. 2021,	0
634	Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia.. 2021,	
633	Acquired Bernard-Soulier syndrome and hypodysfibrinogenaemia because of multiple myeloma. 2021,	
632	Genome Instability in Multiple Myeloma: Facts and Factors. 2021, 13,	0
631	Annotating CD38 Expression in Multiple Myeloma with [F]F-Nb1053. 2021,	2
630	The characteristics of patients with kidney light chain deposition disease concurrent with light chain amyloidosis. 2021,	0
629	¹¹ C-acetate positron emission tomography is more precise than ¹⁸ F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma. 2021, 11, 22188	0
628	Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. 2021,	4
627	Theranostics of Hematologic Disorders. 2022, 359-432	
626	Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study. 2021, 13,	0
625	Immunoglobulin Isotype Switch after Anti-BCMA CAR T-Cell Therapy for Relapsed or Refractory Multiple Myeloma. 2021,	0
624	Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. 2021, 11, 178	1
623	Improvement in the Symptoms and VEGF Levels after Resection of an Extramedullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome. 2021, 60, 3625-3630	1
622	Macroglossia reveals multiple myeloma. 2021, 7,	
621	Metachronous Bilateral Testicular Plasmacytoma After an Initial Soft Tissue, Extramedullary Plasmacytoma.. 2021, 13, e19517	1
620	Optimization of whole-body ² -[F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma. 2021, 1	1

619 Spinal Neoplasms. **2022**, 713-721

618 Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. **2021**, 11, 191 0

617 Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. *Lancet Oncology*, **2021**, 21.7 15

616 Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT. **2021**, 11, 190 2

615 Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. **2021**,

614 MRI-Based Bone Marrow Radiomics Nomogram for Prediction of Overall Survival in Patients With Multiple Myeloma.. **2021**, 11, 709813 0

613 Research progress on treatment of extramedullary multiple myeloma. **2021**, 26, 985-994 0

612 Localizaci3n de fracturas en el mieloma m3ltiple en el Hospital Regional "Gral. Ignacio Zaragoza" ISSSTE. **2021**, 19, 497-500

611 Treatment for multiple myeloma in hospital at home: clinical characteristics and patient care pathways.. **2022**, 1-17 0

610 Management of acute kidney injury in frail patients with biopsy-proven cast nephropathy: a combined approach with chemotherapy plus Supra-hemodiafiltration with post-adsorption endogenous reinfusion.. **2022**, 1

609 The development of a home-based therapeutic platform for multiple myeloma.. **2021**,

608 iStopMM: A Monumental Effort. **2022**, 19, 0

607 High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.. **2022**, 41, 2 3

606 VAD Chemotherapy Versus Bortezomib Containing Regimens As Remission Induction For ASCT in Multiple Myeloma: A Single Center Experience. **2020**, 14, 248-256

605 Plasma Cell Neoplasia. **2020**, 283-297

604 Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apop-tosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein. **2020**, 49, 2078-2086 1

603 Multiples Myelom: Die Therapie ist im Umbruch.

602 Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings. 101-110

601	Monoclonal gammopathy of renal significance: Early diagnosis is key. 2021 , 41, 502-502	
600	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.. 2022 , 12, 9	4
599	DNA methylation: a saga of genome maintenance in hematological perspective.. 2022 , 35, 448	1
598	What Do The Elevated Protein Levels Mean In My Patients With Myeloma, Amyloidosis, and Related Disorders?. 2022 ,	
597	Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine.. 2022 ,	10
596	Active Components of Traditional Chinese Medicinal Material for Multiple Myeloma: Current Evidence and Future Directions.. 2022 , 13, 818179	0
595	PET imaging of hematological neoplasia. 2022 ,	
594	Modern radiographic imaging in multiple myeloma, what is the minimum requirement?. 2022 ,	
593	Defining genomic events involved in the evolutionary trajectories of myeloma and its precursor conditions.. 2022 ,	
592	Esophageal Plasmacytoma Revealed by Persistent Hiccups: A Case Report and Literature Review.. 2022 , 2022, 2242768	
591	Applications of noncoding ribonucleic acids in multiple myeloma patients. 2022 , 97-140	
590	Induction of mA methylation in adipocyte exosomal lncRNAs mediates myeloma drug resistance.. 2022 , 41, 4	4
589	Diagnosis of Amyloidosis: From History to Current Tools.	
588	Monoclonal gammopathy in autoimmune diseases: Analysis and follow-up of 160 cases in a tertiary center in China.. 2021 , 234, 108909	
587	How I Treat Relapsed Multiple Myeloma.. 2022 ,	2
586	Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.. 2021 , 12, 797209	1
585	Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?. 2022 , 3, 63-81	0
584	Antibody-drug conjugate therapies in multiple myeloma—what's next on the horizon?. 617-626	1

- 583 The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.. **2022**, 148, 897
- 582 The relationship between bone marrow involvement on 18F-FDG PET/CT and bone marrow biopsy in patients with multiple myeloma and other plasma cell neoplasms. 6,
- 581 Pulmonary amyloidosis and multiple myeloma mimicking lymphoma in a patient with Sjogren's syndrome: A case report.. **2022**, 10, 1016-1023 1
- 580 An Interesting Case of Proteinuria: AL Amyloidosis. 32, 73-76
- 579 Booster BNT162b2 Optimizes SARS-CoV-2 Humoral Response in Myeloma Patients; the Negative Effect of anti-BCMA therapy.. **2022**, 6
- 578 Kidney Transplant Outcomes of Patients With Multiple Myeloma.. **2022**, 7, 752-762 0
- 577 Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.. **2022**, 12, 15 1
- 576 Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. **2022**, 7, 100403 4
- 575 Diagnosis and management of multiple myeloma during pregnancy: case report, review of the literature, and an update on current treatments.. **2022**, 13, 20406207211066173
- 574 The role of KIAA1191 in the necroptotic pathway of multiple myeloma.. **2022**, 101, 359-367
- 573 Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma. **2022**, 1,
- 572 Multiple myeloma in Lebanon: Trend analysis, 10-year projections and comparisons to other countries.. **2022**, 30, 100513 0
- 571 Efficacy and follow-up of humanized anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma patients with extramedullary-extraosseous, extramedullary-bone related, and without extramedullary disease.. **2021**, 0
- 570 A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.. **2022**, 1-10 0
- 569 Risk stratified management approaches for smoldering multiple myeloma: clinical research becomes clinical practice.. **2022**, 9, e162-e165 2
- 568 Diagnosis and Management of Multiple Myeloma: A Review.. **2022**, 327, 464-477 32
- 567 Bone Marrow Findings of Idiopathic Multicentric Castleman Disease: A Histopathologic Analysis and Systematic Literature Review.. **2022**, 1
- 566 Study of Breast Cancer Resistance Protein ABCG2 C421A Single Nucleotide Polymorphism RS2231142 in Multiple Myeloma. 1

- 565 Evaluation of mandibular bone changes in multiple myeloma patients on dental panoramic radiographs.. **2022**, 1
- 564 Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.. **2022**, 22, 147
- 563 Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.. **2022**, 0
- 562 A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma.. **2022**, 1
- 561 Polyclonal hypergammaglobulinaemia: towards definition of a threshold.. **2022**,
- 560 Practical Considerations for the Daratumumab Management in Portuguese Routine Clinical Practice: Recommendations From an Expert Panel of Hematologists.. **2021**, 11, 817762
- 559 Application of super-resolution fluorescence microscopy in hematologic malignancies.
- 558 CD34 myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence.. **2022**,
- 557 In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma.. **2022**, 39, 53 0
- 556 Indications and considerations for kidney biopsy: an overview of clinical considerations for the non-specialist.. **2021**, 0
- 555 Myeloma multiplex treatment and overall survival. **2022**, 67, 79-90
- 554 Treatment of relapsed and refractory multiple myeloma. **2021**, 15, 77-85
- 553 Complement 4 Aids in the Prediction of Newly Diagnosed Multiple Myeloma Outcome in Patients.. **2022**, 16, 11795549221079171
- 552 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2022**, 1-52
- 551 Two Cases of Solitary (Extramedullary) Plasmacytoma of the Soft Tissue in the Nasal Cavity. **2022**, 115, 289-294
- 550 Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma with Renal Impairment. **2022**, 15, 97-106
- 549 Neurological complications of multiple myeloma. **2022**, 415-431
- 548 The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.. **2022**, 14,

547	Diagnostic Value of H NMR-Based Metabolomics in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Breast Cancer.. 2022 , 7, 8128-8140	4
546	Surgical treatment of a frontal bone lesion in a patient with multiple myeloma. 2022 , 16, 46-49	
545	18F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review. 2022 , 1,	o
544	A challenging case of lymphoproliferative disease in a cat.. 2022 ,	
543	Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients.. 2022 , 11, 8	1
542	Comparison of clinical and laboratory characteristics of nonsecretory multiple myeloma and secretory multiple myeloma in a tertiary care hospital.. 2022 ,	
541	Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma.. 2022 , 12, 808290	o
540	Icaritin-elevated circ_0000190 suppresses the malignant progression of multiple myeloma by targeting miR-301a.. 2022 ,	o
539	Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion.. 2022 , 1	
538	Routine blood biomarkers for the detection of multiple myeloma using machine learning.. 2022 ,	o
537	Multisystem Amyloidosis in a Coal Miner with Silicosis: Is Exposure to Silica Dust a Cause of Amyloid Deposition?. 2022 , 19,	o
536	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma.. 2022 , 11,	o
535	Impact of quality of response on survival outcomes among multiple myeloma patients treated with novel agents - a retrospective analysis.. 2022 ,	
534	Global DNA methylation and increased DNMT3A expression in multiple myeloma patients.. 2022 ,	o
533	Molecular Imaging in Multiple Myeloma Novel PET Radiotracers Improve Patient Management and Guide Therapy. 2022 , 2,	o
532	Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials.. 2022 ,	2
531	An Unusual Case of Multiple Myeloma with Light-Chain Cast Nephropathy Secondary to a Very Large Plasmacytoma without Bone Marrow Involvement.. 2022 , 2022, 7531142	
530	Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition.. 2022 ,	o

- 529 Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.. **2022**, 0
- 528 Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥ 100 .. **2022**, 0
- 527 Treatment Resistance Risk in Patients with Newly Diagnosed Multiple Myeloma Is Associated with Blood Hypercoagulability: The ROADMAP-MM Study. **2022**, 3, 188-203
- 526 Clinical Observation and Pharmacoeconomic Evaluations of Original Research Drug and Generic Drug Bortezomib in the Treatment of Multiple Myeloma.. **2022**, 2022, 5201354
- 525 Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.. **2022**, e24375
- 524 A resected case of plasmacytoma of the rib complicated with smoldering multiple myeloma. **2022**, 36, 180-186
- 523 Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.. **2022**, 3
- 522 Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?. **2022**, 1 1
- 521 Bone metabolism parameters and their relation to cytogenetics in multiple myeloma.. **2022**,
- 520 Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma.. **2022**, 11, 0
- 519 Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study.. **2022**,
- 518 Exosomes in Multiple Myeloma: from bench to bedside.. **2022**, 1
- 517 Complete Resolution of Skull Base Solitary Plasmacytoma Using Proton-Beam Radiotherapy: A Case Report.. **2022**, 14, e23130
- 516 Rolle der PET/CT beim multiplen Myelom und anderen Plasmazellerkrankungen. **2022**, 45, 28-34
- 515 The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment.. **2022**, 58, 1
- 514 Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.. **2022**, JCO2101676 2
- 513 Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.. **2022**, 15, 243-250 0
- 512 Genomics of Plasma Cell Leukemia.. **2022**, 14, 0

511	Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting.. 2022 , 12, 830922	2
510	secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics.. 2022 , 12, 39	1
509	An Abnormal Presentation of Multiple Myeloma in Pregnancy: A Case Report.. 2022 , 14, e23363	
508	Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities.. 2022 , 12, 805702	1
507	Extramedullary disease in multiple myeloma: a systematic literature review.. 2022 , 12, 45	3
506	Development of a Risk Assessment Model for Early Grade B Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China.. 2022 , 12, 772015	0
505	Identification of biomarkers for early diagnosis of multiple myeloma by weighted gene co-expression network analysis and their clinical relevance.. 2022 , 27, 322-331	1
504	The Role of the Crosstalk Between Gut Microbiota and Immune Cells in the Pathogenesis and Treatment of Multiple Myeloma.. 2022 , 13, 853540	
503	Case Report: Cavernous Sinus Syndrome as the Initial Presentation of Multiple Myeloma. 2022 , 2,	
502	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma.. 2022 ,	2
501	Current Approaches to Management of Newly Diagnosed Multiple Myeloma.. 2022 ,	2
500	The role of monoclonal antibodies in treatment of refractory multiple myeloma. 2022 , 2, 48-57	
499	NAD ⁺ depletion enhances reovirus-induced oncolysis in multiple myeloma.. 2022 , 24, 695-706	0
498	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.. 2022 , e1614	
497	Amiloidosis AL: conceptos actuales. 2022 , 26, 119-139	
496	¹⁸ F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?. 2022 , 22, 63	0
495	Single-Center Real-World Experience of Multiple Myeloma in the 21st Century. 2022 , 97, 125-140	
494	Clinical Practice Guideline: Patients With Multiple Myeloma or Monoclonal Gammopathy of Undetermined Significance-Diagnosis, Treatment, and Follow Up.. 2022 ,	0

- 493 Comparison of MRI Features of Fat Fraction and ADC for Early Treatment Response Assessment in Participants with Multiple Myeloma.. **2022**, 211388 ○
- 492 Detecting Multiple Myeloma Infiltration of the Bone Marrow on CT Scans in Patients with Osteopenia: Feasibility of Radiomics Analysis.. **2022**, 12, ○
- 491 Intramedullary nailing for pathological fractures of the proximal humerus caused by multiple myeloma: A case report and review of literature. **2022**, 10, 3518-3526
- 490 Monoclonal Gammopathy of Renal Significance (MGRS): Real-World data on outcomes and prognostic factors.. **2022**, ○
- 489 When a Monoclonal Gammopathy Is Not Multiple Myeloma.. **2022**, 42, 1-10
- 488 Correlation between whole skeleton dual energy CT calcium-subtracted attenuation and bone marrow infiltration in multiple myeloma.. **2022**, 149, 110223 1
- 487 Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.. **2022**, 12, 51 ○
- 486 Carfilzomib-induced thrombotic microangiopathy is underestimated in clinical practice: A report of five patients and literature review.. **2022**, 1-9 ○
- 485 Comparison of clinical features of multiple myeloma with paraosseous and extraosseous plasmacytoma in the era of novel drugs: a systemic review and meta-analysis.. **2022**, 1-6
- 484 Māori and Pacific Peoples With Multiple Myeloma in New Zealand are Younger and Have Inferior Survival Compared to Other Ethnicities: A Study From the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).. **2022**,
- 483 Acute Kidney Injury in Patients With Cancer: A Review of Onconeurology.. **2021**, 28, 394-401.e1 ○
- 482 Are African primary physicians suspicious enough? Challenges of multiple myeloma diagnosis in Africa. **2021**, 33, ○
- 481 A Case of POEMS Syndrome Previously Diagnosed with Extramedullary Plasmacytoma. **2021**, 13, 59-63
- 480 Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. **2021**, 2021, 673-681 ○
- 479 The Emerging Role of MicroRNAs in Bone Diseases and Their Therapeutic Potential.. **2021**, 27, 2
- 478 "Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. **2021**, 11, 196 3
- 477 Genomic Instability and Replicative Stress in Multiple Myeloma: The Final Curtain?. **2021**, 14, 1
- 476 A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. **2021**, 22, 1

- 475 Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. **2021**, 27, ○
- 474 Genetic Subtypes of Smoldering Multiple Myeloma are associated with Distinct Pathogenic Phenotypes and Clinical Outcomes.
- 473 Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events. **2021**, 2021, 662-672 1
- 472 Risk Stratification and Treatment in Smoldering Multiple Myeloma.. **2021**, 11, 1
- 471 Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma.. **2021**, 10, 5258-5266 1
- 470 [Radiological diagnosis of multiple myeloma : Role of imaging and the current S3 guideline].. **2021**, 62, 35 ○
- 469 [Positron emission tomography/computed tomography (PET/CT) in multiple myeloma].. **2021**, 62, 20
- 468 Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study.. **2021**,
- 467 Association of loss of spleen visualization on whole-body diffusion-weighted imaging with prognosis and tumor burden in patients with multiple myeloma.. **2021**, 11, 23978 ○
- 466 Allogeneic Stem Cell Transplantation in Multiple Myeloma.. **2021**, 14, 1
- 465 Method comparison of three serum free light chain assays on the Roche Cobas 6000 c501 chemistry analyzer.. **2021**,
- 464 [Potential of radiomics and artificial intelligence in myeloma imaging : Development of automatic, comprehensive, objective skeletal analyses from whole-body imaging data]. **2021**, 62, 44
- 463 [Skeletal changes in plasma cell dyscrasias]. **2021**, 61, 1078-1089 ○
- 462 Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma.. **2021**, 10600280211058388 ○
- 461 Mieloma no secretor. **2020**, 5, 126-128
- 460 Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life.. **2022**, 1
- 459 A phenogenetic axis that modulates clinical manifestation and predicts treatment outcome in primary myeloid neoplasms.
- 458 Real-world evidence of daratumumab monotherapy in relapsed/refractory multiple myeloma patients and efficacy on soft-tissue plasmacytomas. **2022**, ○

- 457 Effectiveness and safety of chemotherapy combined with immunomodulatory therapies for multiple myeloma: A protocol for systematic review and meta-analysis.. **2022**, 101, e29093
- 456 A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.. **2022**, 12, 68 ○
- 455 Atypical multiple myeloma in 3 young dogs.. **2022**, 3009858221087637 ○
- 454 Multiple Myeloma: From Scintigraphy to PET/CT and Importance of Functional Imaging. **2022**, 8, 102-111
- 453 <i>MAGE-C1</i> gene and mage-c1 protein expression comparison in primary multiple myeloma patients. **2022**, 17, 51-59
- 452 Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.. **2022**, 12, ○
- 451 Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?. **2022**, 5, ○
- 450 Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.. **2022**, 12, 63 ○
- 449 Cystatin C-Based Equations Detect Hidden Kidney Disease and Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.. **2022**, 2022, 4282226
- 448 A Case of Systemic AL Amyloidosis Diagnosed by Screening Colonoscopy.. **2022**, 2022, 5562281
- 447 Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.. **2022**, ○
- 446 Image_1.TIFF. **2019**,
- 445 Image_2.TIFF. **2019**,
- 444 Image_3.TIFF. **2019**,
- 443 Table_1.XLSX. **2019**,
- 442 DataSheet_1.pdf. **2020**,
- 441 Table_1.xlsx. **2020**,
- 440 Table_2.xlsx. **2020**,

439 Table_3.xlsx. **2020,**

438 Table_4.xlsx. **2020,**

437 Data_Sheet_1.pdf. **2020,**

436 Presentation_1.PPTX. **2020,**

435 Presentation_2.PPTX. **2020,**

434 Presentation_3.PPTX. **2020,**

433 Presentation_4.PPTX. **2020,**

432 Presentation_5.PPTX. **2020,**

431 Table_1.DOCX. **2020,**

430 Relapse with plasmacytoma after upfront autologous stem cell transplantation in multiple myeloma.. **2022,** 101, 1217

429 Comprehensive bioinformatics analysis reveals the hub genes and pathways associated with multiple myeloma.. **2022,** 27, 280-292

1

428 Clinical impact of spine magnetic resonance imaging as a valuable prognostic tool for patients with multiple myeloma: a retrospective study.. **2022,**

427 [Expert consensus on laboratory standardized technical specifications for monitoring minimal residual disease using next-generation sequencing in multiple myeloma(2021)].. **2021,** 42, 974-977

426 [Immunoglobulin M multiple myeloma: a six-case report and literature review].. **2021,** 42, 1011-1014

425 Evaluation of Heterozygosity Loss in STR-Loci of Tumor DNA in Multiple Myeloma Patients with Plasmacytoma Based on the Molecular Analysis of Complex Archival Tumor Samples. **2022,** 15, 156-166

424 Subacute thyroiditis after SARS-CoV-2 BNT162b2 vaccine in a multiple myeloma patient.. **2022,** 10, 2050313X221091392

423 Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma.. **2022,** 13, 814548

o

422 Update on the POEMS syndrome.. **2022,** 57, 27-31

o

- 421 The Path forward in Multiple Myeloma: 2021 Jan Waldenstrom Award Lecture. **2022**,
- 420 Laboratory-Based Rationale for Targeting the Protein Homeostasis Network in AL Amyloidosis. **2022**, 3, 298-317
- 419 Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance.. **2022**, 13, 876271 ○
- 418 Novel case of primary intracranial solitary plasmacytoma presenting with significant intratumoral hemorrhage.. **2022**, 13, 157 ○
- 417 Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 Gene polymorphisms on Multiple Myeloma Egyptian patients. **2022**, 106854
- 416 CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma.. **2022**, 14, ○
- 415 Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias.. **2022**, 12, 858426
- 414 Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results.. **2022**, 1
- 413 CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.. **2022**, ○
- 412 An Unusual Presentation of Multiple Myeloma: A 71-Year-Old Female With a Single Lytic Lesion of Her Appendicular Skeleton. **2022**,
- 411 Progress of modern imaging modalities in multiple myeloma.. **2022**, ○
- 410 COVID-19 unmasks the critical role of primary healthcare providers in the timely diagnosis of multiple myeloma.. **2022**, 52, 885-886
- 409 Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.. **2022**, ○
- 408 Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know. **2022**, 4, e362-e373 ○
- 407 Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).. **2022**, 1
- 406 Presence of bone marrow fibrosis in multiple myeloma may predict extramedullary disease.. **2022**, 1 ○
- 405 Multiple Myeloma: 2022 update on Diagnosis, Risk-stratification and Management.. **2022**, 12
- 404 Multiple myeloma masquerading as sellar mass: A case report and review of literature. **2021**, 4, 52

403 Protocols. **2022**, 177-206

402 Cancers of the Blood. **2022**, 67-131

401 Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma.. **2022**,

0

400 Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.. **2022**, 20, 225

0

399 Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. **2022**, 1-53

398 How We Approach Smoldering Multiple Myeloma.. **2022**,

0

397 Different roles of urinary light chains and serum light chains as potential biomarkers for monitoring disease activity in systemic lupus erythematosus. 10, e13385

1

396 Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma. **2022**,

395 Extramedullary plasmacytoma: Tumor occurrence and therapeutic concepts-A follow-up.. **2022**,

1

394 Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.. **2022**, 12, 8287

0

393 CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival. **2022**, 11, 2913

0

392 Multiple Myeloma and the Kidney. **2022**, 843-859

391 Lenalidomide-Dexamethasone vs. Observation in High-Risk Smoldering Myeloma after 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study.

390 Mono/polyclonal free light chains as challenging biomarkers for immunological abnormalities. **2022**, 155-209

0

389 Prognostic role of controlling nutritional status score in hematological malignancies. **2022**, 27, 653-658

0

388 Combining Deep Learning and Radiomics for Automated, Objective, Comprehensive Bone Marrow Characterization From Whole-Body MRI. Publish Ahead of Print,

1

387 Die monoklonale Gammopathie (un)klarer Signifikanz. **2022**, 147, 675-682

386 Whole-body magnetic resonance imaging plus serological follow-up for early identification of progression in smoldering myeloma patients to prevent development of end-organ damage.

0

- 385 The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. 18
- 384 Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study REBUILD **2022**, 14, 2768 0
- 383 69-Year-Old Man With Dysuria and Right Lower Abdominal Pain. **2022**, 97, 1182-1187
- 382 The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study. 1
- 381 Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.
- 380 Imaging for Multiple Myeloma according to the Recent International Myeloma Working Group Guidelines: Analysis of Image Acquisition Techniques and Response Evaluation in Whole-Body MRI according to MY-RADS. 83,
- 379 Role of Circulating MicroRNAs in Prognosis and Diagnosis of Cancers. **2022**, 109-132
- 378 Massive splenomegaly as the presenting feature of multiple myeloma in an elderly man. **2022**, 18, 37
- 377 A Case Report of Premalignant Plasma Cell Dyscrasia-Induced Renal Failure in a 31-Year-Old Female. **2022**, 2022, 1-4 0
- 376 CircRNAs: novel therapeutic targets in multiple myeloma. 0
- 375 CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. 13, 3
- 374 Avaliação Radiográfica da Maxila e da Mandíbula de Pacientes Diagnosticados com Mieloma Múltiplo: Estudo Retrospectivo. **2022**, 68,
- 373 Immunoglobulin M Monoclonal Gammopathies of Clinical Significance. 12, 0
- 372 Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders. 0
- 371 Management of Renal Failure in Multiple Myeloma.
- 370 Akutes Nierenversagen nach SARS-CoV-2-Infektion.
- 369 Evaluation of a new ELISA assay for monoclonal free-light chain detection in patients with cardiac amyloidosis. 1
- 368 Cross-Sectional and Longitudinal Associations Between the Serum Globulin Level, and Renal Impairment and All-Cause Deaths in Chinese Patients With Newly Diagnosed Multiple Myeloma. 12,

- 367 Patient-Derived Extracellular Vesicles Proteins as New Biomarkers in Multiple Myeloma - A Real-World Study. 12, 0
- 366 A Cohort Study of Free Light Chain Ratio in Combination with Serum Protein Electrophoresis as a First-Line Test in General Practice. **2022**, 14, 2930 0
- 365 Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. 1-10 0
- 364 Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. **2022**, 13, 1
- 363 Baseline peripheral neuropathy was associated with age and a prognostic factor in newly diagnosed multiple myeloma patients. **2022**, 12, 0
- 362 High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. 1
- 361 ^{99m}Tc-CD3813: A Nanobody-Based Single Photon Emission Computed Tomography Radiotracer with Clinical Potential for Myeloma Imaging and Evaluation of CD38 Expression. 1
- 360 Investigating the potential molecular players and therapeutic drug molecules in carfilzomib resistant multiple myeloma by comprehensive bioinformatics analysis. 1-12
- 359 ¹⁸F-FDG Versus Non-FDG PET Tracers in Multiple Myeloma. **2022**, 17, 415-430 0
- 358 Apical lung mass: A rare presentation of multiple myeloma. **2022**, 17, 2951-2955
- 357 Gamma camera imaging in hematological diseases. **2022**, 318-325
- 356 Hyaluronan in the Extracellular Matrix of Hematological and Solid Tumors. Its Biological Effects. **2022**, 161-196
- 355 Monoclonal Gammopathy-Related Kidney Diseases. **2022**, 29, 86-102.e1
- 354 56/m mit Rückenschmerzen und Konzentrationsstörungen. **2022**, 17, 364-369
- 353 Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. 1
- 352 Quality of Online Information on Multiple Myeloma Available for Laypersons. **2022**, 29, 4522-4540
- 351 Editorial: The Role of Microorganisms in Multiple Myeloma. 13,
- 350 Effect of bortezomib on the treatment of multiple myeloma: a systematic review protocol. **2022**, 12, e061808 0

- 349 What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. 0
- 348 Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease. **2022**, 58,
- 347 Prevalence and risk factors of monoclonal gammopathy in patients with autoimmune inflammatory rheumatic disease: A systematic review and meta-analysis.
- 346 Clinical Characteristics and Outcomes of IgD Myeloma: Experience across UK National Trials. 0
- 345 Multiple Myeloma-Derived Extracellular Vesicles Modulate the Bone Marrow Immune Microenvironment. 13, 1
- 344 Anemia and Other Hematological Problems. **2022**, 493-505
- 343 The Route of the Malignant Plasma Cell in Its Survival Niche: Exploring Multiple Myelomas. **2022**, 14, 3271 1
- 342 Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. 12, 1
- 341 Serum Free Light-Chain Ratio at Diagnosis Is Associated with Early Renal Damage in Multiple Myeloma: A Case Series Real-World Study. **2022**, 10, 1657 0
- 340 Monoclonal gammopathy of unknown significance: Implications of Indian baseline data. 34, 376-378
- 339 A Rare Case of Extra-Medullary Portacaval Plasmacytoma in a Patient With Relapsed Multiple Myeloma. **2022**,
- 338 CKD-581 Downregulates Wnt/ β Catenin Pathway by DACT3 Induction in Hematologic Malignancy. **2022**, 0
- 337 Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy. 0
- 336 CD43 is an adverse prognostic factor in newly diagnosed multiple myeloma. 1-6
- 335 Differentiation of multiple myelomas from osteolytic bone metastases: Diagnostic value of tumor homogeneity on Contrast-Enhanced CT. 1
- 334 Serum free light chain analysis: persisting limitations with new kids on the block. **2022**,
- 333 Molecular Impact of the Tumor Microenvironment on Multiple Myeloma Dissemination and Extramedullary Disease. 12, 1
- 332 Whole body imaging in musculoskeletal oncology: when, why, and how. 0

- 331 Central Nervous System Myeloma and Unusual Extramedullary Localizations: Real Life Practical Guidance. 12, 1
- 330 A rare case of atrial and biventricular thrombi with dilated cardiomyopathy as a delayed presentation in a patient with COVID-19. **2022**, 79, 104057
- 329 Myeloma and Leukemia. **2023**, 503-528
- 328 Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. **2022**, 13,
- 327 Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis. 0
- 326 Lightweight, open source, easy-use algorithm and web service for paraprotein screening using spatial frequency domain analysis of electrophoresis studies. **2022**, 100128 1
- 325 CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
- 324 Chimeric Antigen Receptor T Cell Therapy: A Cutting-Edge Therapy for Multiple Myeloma. **2022**, 475-481
- 323 Secondary Extramedullary Myeloma of the Gallbladder: A Case Report. **2022**, 10, 232470962211178 0
- 322 Breast Plasmacytoma as Extra-Medullary Lesion of Multiple Myeloma: A Case Report. **2022**, 10, 232470962211117
- 321 Posttreatment Persistence of Monoclonal Protein on Immunofixation Electrophoresis but Absence on Serum Protein Electrophoresis in a Case of Solitary Bone Plasmacytoma.
- 320 An unusual ocular manifestation of multiple myeloma. **2022**, 15, e247863 0
- 319 Is RDW a clinically relevant prognostic factor for newly diagnosed multiple myeloma? A systematic review and meta-analysis. **2022**, 22, 1
- 318 Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma. **2022**, 12,
- 317 The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma. 13,
- 316 Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma. **2022**, 14, 1
- 315 Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America. **2022**,
- 314 MULTIPLE MYELOMA: NARRATIVE REVIEW. **2022**, 102-104

- 313 Blood Cancer and the Heart: Light Chain Cardiomyopathy in Refractory Multiple Myeloma. **2022**, 2022, 1-5 0
- 312 Multiple Myeloma Therapy: Emerging Trends and Challenges. **2022**, 14, 4082 1
- 311 Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations. 12,
- 310 Case report: Thoracic and lumbar plasma cell myeloma mimicking hemangiomas on MRI and 18F-FDG PET/CT. 9,
- 309 High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.
- 308 Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling. 12,
- 307 The use of bone-modifying agents in multiple myeloma. **2022**, 100999
- 306 Serum Free Light Chain Quantification Testing: Comparison of Two Methods for Disease Monitoring.
- 305 Impact of the lactate dehydrogenase in association with the International Staging System prognostic score in multiple myeloma patients treated in real life. **2022**,
- 304 Multiple Myeloma Uncovered Under Excessive Antacid and Chronic NSAID Use in a Young Female. **2022**,
- 303 A Novel Integrated Approach for Cytogenomic Evaluation of Plasma Cell Neoplasms. **2022**,
- 302 Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. **2022**, 1
- 301 Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study.
- 300 Reduced CXCR4 expression in associated with extramedullary and predicts poor survival in newly diagnosed multiple myeloma. 1-5
- 299 Early cytopenias and infections after standard of care idcabtagene vicleucel in relapsed or refractory multiple myeloma. 0
- 298 Retinal oxygen saturation in monoclonal gammopathies patients: A pilot study.
- 297 Recent developments on the application of molecular probes in multiple myeloma: Beyond [18F]FDG. 10,
- 296 Deep-learning-based virtual non-calcium imaging in multiple myeloma using dual-energy CT. 0

- 295 Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance. 12,
- 294 Case Report: A rare case of small bowel obstruction secondary to plasma cell myeloma. 12,
- 293 Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?. 12, ○
- 292 The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma. **2022**, 11, 5461 ○
- 291 A method to obtain purified free light chain monomers and dimers from urine samples of patients with multiple myeloma. ○
- 290 Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016. ○
- 289 Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. **2022**, 174, 243-250 ○
- 288 Deep-learned estimation of uncertainty in measurements of apparent diffusion coefficient from whole-body diffusion-weighted MRI. **2022**, 149, 106091 ○
- 287 FDG PET-MRI evaluation of synchronous gallbladder adenocarcinoma and POEMS syndrome. **2022**, 17, 4294-4298 ○
- 286 Radionuclide Therapy of Leukemias and Multiple Myeloma. **2022**, 1329-1380 ○
- 285 Recent Advances in Imaging Studies of Multiple Myeloma. **2022**, 12, 8795-8800 ○
- 284 The Prognostic Value of Immunophenotypic Characteristics of Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Treated with First-Generation Proteasome Inhibitor Bortezomib. **2022**, 15, 377-387 ○
- 283 Diagnostic Applications of Nuclear Medicine: Multiple Myeloma. **2022**, 475-527 ○
- 282 Anti-multiple myeloma potential of resynthesized belinostat derivatives: an experimental study on cytotoxic activity, drug combination, and docking studies. **2022**, 12, 22108-22118 1
- 281 Long follow-up of symptomatic Multiple Myeloma patients after Covid-19 vaccination (BNT162b2): A single-institution retrospective experience. **2022**, 18, 100342 ○
- 280 Multiple Myeloma: Nuances of Minimal Residual Disease Diagnosis and Monitoring with the Use of Multicolor Flow Cytometry. **2022**, 15, 365-376 ○
- 279 The Importance of Complementary Immunological Markers in the Diagnosis of Minimal Residual Disease in Multiple Myeloma. **2022**, 15, 388-395 ○
- 278 ¹¹C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to ¹⁸F-FDG PET/CT and Prognostic Value. **2022**, 23, 9895 ○

- 277 High serum IL-17A is associated with bone destruction in newly diagnosed multiple myeloma patients. 12, ○
- 276 AIMP1 promotes multiple myeloma malignancy through interacting with ANP32A to mediate histone H3 acetylation. ○
- 275 Spinal Lesions as Clinical Manifestations of Plasma Cell Neoplasia. **2022**, 29, 6236-6244 ○
- 274 Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. **2022**, 12, ○
- 273 A phase 1 clinical trial of the repurposable acetyl-lysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. ○
- 272 Optimisation of b-values for the accurate estimation of the apparent diffusion coefficient (ADC) in whole-body diffusion-weighted MRI in patients with metastatic melanoma. ○
- 271 Photon-counting Detector CT with Deep Learning Noise Reduction to Detect Multiple Myeloma. ○
- 270 IGH cytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry. *jclinpath-2022;208230* ○
- 269 The role of serum-free light chain ratios in the prediction of poor prognosis in multiple myeloma patients: a systematic review and meta-analysis. **2022**, 27, 1130-1139 ○
- 268 Integrative Analysis of Enrichment and Prognostic Value of Ferroptosis-related Genes and Pathways in Multiple Myeloma. ○
- 267 Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma. **2022**, 12, ○
- 266 Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma. 9, ○
- 265 Survival in patients with multiple myeloma: evaluation of possible associations with bone marrow fibrosis and investigation of factors independently associated with survival. **2022**, 46, ○
- 264 Smoldering multiple myeloma current treatment algorithms. **2022**, 12, 1
- 263 Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma. **2022**, 11, 1
- 262 Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias. **2022**, 15, ○
- 261 Dysregulated circular RNAs are closely linked to multiple myeloma prognosis, with circ_0026652 predicting bortezomib-based treatment response and survival via the microRNA-608-mediated Wnt/ β -catenin pathway. **2022**, 48, ○
- 260 Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. ○

- 259 Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. ○
- 258 Clinical features, therapy patterns, outcomes and prognostic factors of solitary plasmacytomas: a report of the Israeli Myeloma Study Group. 1-8 ○
- 257 Updates on Multiple Myeloma: What's New in Risk Stratification, Treatment, and Prognosis. ○
- 256 Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance. **2022**, 4, 323-325 ○
- 255 Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma. OF1-OF11 ○
- 254 Comparison of laboratory methods for the detection of neoplastic plasma cells in plasma cell dyscrasias. jcp-2022-208446 ○
- 253 Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study. **2022**, 3, e628-e635 ○
- 252 Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM). 1-10 1
- 251 Advanced Imaging in Multiple Myeloma: New Frontiers for MRI. **2022**, 12, 2182 ○
- 250 Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations. **2022**, ○
- 249 Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE -1 (phase 2) Japanese cohort. ○
- 248 Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation. ○
- 247 Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis. ○
- 246 Role of serum free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma. ○
- 245 Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study. **2022**, 12, e067140 ○
- 244 A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk. ○
- 243 Diagnosis dan Terapi Terkini Multiple Myeloma. **2020**, 33, 3-18 ○
- 242 Multiple Myeloma Plasmacytoid Infiltration of the Gallbladder Presenting as Acute Cholecystitis. **2021**, 8, e2021.00049 ○

- 241 Clinical Characteristics and Prognosis of Multiple Myeloma With Myelomatous Pleural Effusion: A Retrospective Single-Center Study. **2022**, 21, 153303382211323 ○
- 240 Relationship Between Markers of the Acute Phase of Inflammation, Parameters of Blood Lipid Composition and Intracardiac Hemodynamics During Chemotherapy in Patients With Multiple Myeloma. **2022**, 62, 18-26 ○
- 239 Accuracy of determination of free light chains (Kappa and Lambda) in plasma and serum by Swedish laboratories as monitored by external quality assessment. **2022**, ○
- 238 Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina. **2022**, 17, e0274578 ○
- 237 Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine—Are We There Yet?. **2022**, 23, 12888 ○
- 236 The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. 1-12 ○
- 235 Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed. **2022**, 45, 443-449 ○
- 234 L'Electrophorèse des Protéines Sériques : quand ? pourquoi? quels orientation et suivi?. **2022**, ○
- 233 Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. ○
- 232 A Prospective Single-Arm Study of Melphalan, Prednisolone and Lenalidomide (MPL) as First Line Treatment in Elderly Patients with Multiple Myeloma [An Institutional Study]. **2022**, 43, 409-414 ○
- 231 Biochemical profile of Bence-Jones type multiple myeloma. **2022**, 67, 570-574 ○
- 230 Polyneuropathy Associated with IgM Monoclonal Gammopathy; Advances in Genetics and Treatment, Focusing on Anti-MAG Antibodies. **2022**, 3, 663-688 ○
- 229 Plasma cell neoplasms, multiple myeloma, solitary plasmacytoma a plasma cell leukemia. Clinical symptoms, diagnostic criteria and therapy. **2022**, 16, 7-32 ○
- 228 Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification. 10, 1
- 227 High-cutoff hemodialysis in multiple myeloma patients with acute kidney injury. 12, ○
- 226 MUKTweleve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. **2022**, 12, e062504 ○
- 225 CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy. 13, ○
- 224 Plasma Cell Disorders. 1-30 ○

223	Early intervention with a curative intent through an intensive therapy versus immunologic disease control using a minimal intensity approach in the management of high-risk smoldering multiple myeloma: A systematic review of evidence from clinical trials. 2022,	0
222	Flow Cytometric Analysis of Bone Marrow Particle Cells for Measuring Minimal Residual Disease in Multiple Myeloma. 2022, 14, 4937	0
221	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. 12,	0
220	Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal. 2022, 14, 5247	0
219	Deep Learning for Automatic Bone Marrow Apparent Diffusion Coefficient Measurements From Whole-Body Magnetic Resonance Imaging in Patients With Multiple Myeloma. Publish Ahead of Print,	1
218	From iron chelation to overload as a therapeutic strategy to induce ferroptosis in hematologic malignancies. 2022, 27, 1163-1170	0
217	Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma. 2022, 12,	0
216	Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas. 2022, 10, 2535	0
215	Comparison of patient outcomes with two different formulations of melphalan as conditioning chemotherapy for autologous hematopoietic cell transplantation in multiple myeloma.. 2022,	0
214	Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.	0
213	Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. 2022, 14, 5331	0
212	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. 13,	0
211	Necrobiotic xanthogranuloma and monoclonal gammopathy. 2022, 16, 57-60	0
210	Front-line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real-world setting: A multicenter retrospective study in China.	0
209	Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study. 2022, 101, e30988	0
208	Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. 2022, 9, e810-e821	2
207	Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. 2022 , 11, 3365	0
206	SegPC-2021: A challenge & dataset on segmentation of Multiple Myeloma plasma cells from microscopic images. 2022, 102677	0

- 205 An evolutionary machine learning for multiple myeloma using Runge Kutta Optimizer from multi characteristic indexes. **2022**, 150, 106189 ○
- 204 Extramedullary plasmacytoma of the uterine cervix arising in an asymptomatic 46-year-old female. **2022**, 44, 101087 ○
- 203 Advantages and Shortcomings of FISH Technology in Multiple Myeloma. **2022**, 12, 10008-10011 ○
- 202 Monoclonal Gammopathies with Miscellaneous Associations. **2022**, 325-351 ○
- 201 Monoclonal Gammopathy of Renal Significance: An Insight. **2022**, 193-209 ○
- 200 Monoclonal Gammopathy of Undetermined Significance (MGUS) and Highlight on Monoclonal Gammopathy of Neurological Significance (MGNS). **2022**, 177-192 ○
- 199 Immune profiles in Bone marrow to predict induce therapy response for multiple myeloma patients. ○
- 198 Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis. ○
- 197 Multiple myeloma with extramedullary plasmacytoma: pathogenesis and clinical case. **2022**, 17, 67-80 1
- 196 Behandlungsspektrum von Lymphomen und Plasmozytomen der Wirbelsäule. **2022**, 06, 221-224 ○
- 195 Paraproteinämien und Nierenbeteiligung. ○
- 194 Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience. 12, ○
- 193 Experimental design optimization for the synthesis of lenalidomide nitro precursor. ○
- 192 Unusual Diagnosis of Multiple Small Bowel Masses. **2022**, ○
- 191 Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent. ○
- 190 VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience. ○
- 189 Imaging minimal residual disease evaluation in multiple myeloma using [18F]FDG PET/MRI. 1-4 ○
- 188 High-throughput and high-accuracy diagnosis of multiple myeloma with multi-object detection. ○

- 187 Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. **2022**, 40, 1358-1373.e8 ○
- 186 Extracellular Vesicles in Multiple Myeloma—Tracking the Code to a Better Understanding of the Disease. **2022**, 14, 5575 ○
- 185 Dual Negativity of CD56 and CD117 Links to Unfavorable Cytogenetic Abnormalities and Predicts Poor Prognosis in Multiple Myeloma. **2022**, 11, 6524 ○
- 184 Antioxidant and anti-inflammatory activities of *Centratherum anthelminticum* (L.) Kuntze seed oil in diabetic nephropathy via modulation of Nrf-2/HO-1 and NF- κ B pathway. **2022**, 22, ○
- 183 Miscellaneous Etiologies of Acute Kidney Injury. **2022**, 163-184 ○
- 182 Disease-driven engineering of peptide-targeted DM1 loaded liposomal nanoparticles for enhanced efficacy in treating multiple myeloma by exploring DM1 prodrug chemistry. **2022**, 121913 ○
- 181 Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. **2022**, 13, ○
- 180 Multiple myeloma presenting as a lung plasmacytoma: A case report. 1-4 ○
- 179 Paraprotein-associated Kidney Disorders. **2022**, 478-493 ○
- 178 Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myelom. **2022**, ○
- 177 Development of multiple myeloma after 15 years of treatment for polycythemia vera and successful treatment using bortezomib: A case report. **2022**, 10, ○
- 176 High levels of serum IL-10 indicate disease progression, extramedullary involvement, and poor prognosis in multiple myeloma. **2022**, 23, 968-974 ○
- 175 Evaluation of the Therapeutic Management of Hypercalcemia in Myeloma at the Nephrology Department of Louis Pasteur Hospital of Chartres: About 8 Cases. **2022**, 12, 403-409 ○
- 174 A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy. **2023**, 114, 109592 ○
- 173 Renal Involvement in Multiple Myeloma. 46-52 ○
- 172 An Approach to the Diagnosis of Paraproteinemia. **2022**, 79-97 ○
- 171 Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma. **2022**, 23, 14765 ○
- 170 Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy. **2022**, 11, 206-210 ○

- 169 Management of Relapsed and Refractory Multiple Myeloma: Recent advances. **2022**, 43, 458-472 ○
- 168 Clinical Presentation and Outcome of Sinonasal Extranasal Plasmacytoma in Denmark: A Nationwide Cohort From 1980 to 2017. 000348942211393 ○
- 167 Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment. 13, 1 ○
- 166 Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. **2022**, 13, ○
- 165 Plasma cell neoplasms and related entities—evolution in diagnosis and classification. ○
- 164 Peripheral Blood Monocyte Count is a Dynamic Prognostic Biomarker in Multiple Myeloma. ○
- 163 Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. ○
- 162 Renal insufficiency predicts worse prognosis in newly diagnosed IgD multiple myeloma patients. 12, ○
- 161 Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?. 12, ○
- 160 Outcomes after salvage autologous hematopoietic cell transplant for patients with relapsed/refractory multiple myeloma: a single-institution experience. **2022**, ○
- 159 Pathological characteristics of light chain crystalline podocytopathy.. **2022**, ○
- 158 Multiple myeloma and t(11;14): prognostic significance and impact of novel agents on response and survival.. ○
- 157 Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation. **2022**, 22, ○
- 156 Prognosis of hyperviscosity syndrome in newly diagnosed multiple myeloma in modern-era therapy: A real-life study. 13, ○
- 155 Plasmocytome solitaire osseux: caractéristiques et facteurs associés au risque d'évolution vers le myélome multiple, sur une cohorte de 31 patients suivis au CHU de Reims entre janvier 2000 et juin 2022. **2022**, 89, A141 ○
- 154 Identifying monoclonal gammopathy of undetermined significance from electronic health records. ○
- 153 The role of Vertebral Augmentation Procedures in the management of vertebral compression fractures secondary to multiple myeloma. ○
- 152 Solitary hyoid plasmacytoma with unicentric Castleman disease: A case report and review of literature. 10, 13364-13372 ○

151	Newly diagnosed multiple myeloma: making sense of the menu. 2022 , 2022, 539-550	0
150	Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. 2022 ,	0
149	Efficacy and Safety Analysis of VRD-PDCE in Treatment-Native Patients with Multiple Extramedullary Plasmacytomas or Plasma Cell Leukemia.	0
148	Monoclonal Gammopathy of Undetermined Significance. 2022 , 175, ITC177-ITC192	0
147	Onconeurology 2022: An Update. 10.34067/KID.0001582022	0
146	Monoclonal Gammopathy of Renal Significance and Thrombotic Microangiopathy: A Case Report. 2022 ,	0
145	BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3. 2022 , 130299	0
144	Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma. 2022 , 23, 15691	0
143	Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment.	0
142	A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas.	2
141	The consultant's guide to smoldering multiple myeloma. 2022 , 2022, 551-559	0
140	Prognostic value of semi-quantitative parameters of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients.	0
139	Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma.	0
138	Markers for internal neoplasia in the horse.	0
137	Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis. 2022 ,	0
136	Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. 2022 ,	1
135	Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: A retrospective multicenter study from China.	0
134	Geographical and ecological analyses of multiple myeloma in Denmark: Identification of potential hotspot areas and impact of urbanisation.	0

- 133 Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. **2023**, 15, 23-49 ○
- 132 A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. ○
- 131 Computed tomographic findings in dogs with multiple myeloma. ○
- 130 Machine learning-based infection prediction model for newly diagnosed multiple myeloma patients. 16, ○
- 129 Kidney biopsy. **2023**, ○
- 128 Enhanced thrombin generation detected with ST-Genesis analyzer in patients with newly diagnosed multiple myeloma. ○
- 127 Rapid Conversion from Solitary Plasmacytoma with Minimal Skull Marrow Involvement to Symptomatic Multiple Myeloma: a Case Report. **2023**, 5, ○
- 126 Mesenchymal stromal cell senescence in haematological malignancies. ○
- 125 Hematologic imaging. **2023**, 225-244 ○
- 124 Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China. 14, ○
- 123 Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. ○
- 122 Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era. **2023**, 28, ○
- 121 Clinical Relevance of Interferon Regulatory Family-4 (IRF4) Expression in Newly Diagnosed Patients with Multiple Myeloma. ○
- 120 AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. **2023**, 15, 477 ○
- 119 Imaging findings in a case of leptomeningeal myelomatosis, a rare but critical central nervous system complication of multiple myeloma. 197140092211508 ○
- 118 Platelet closure time in the evaluation of efficacy of CAR-T cell therapy in relapsed/refractory multiple myeloma. ○
- 117 Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma. 12, ○
- 116 Genetic analysis of potential biomarkers in cuproptosis from multiple myeloma. ○

- 115 A prognostication system based on clinical parameters and [18F]-FDG PET/CT in patients with newly diagnosed multiple myeloma. ○
- 114 Hepatic Plasmacytoma With DEL13q14 Positive on Fluorescent In Situ Hybridization (FISH) on Tissue Biopsy. **2022**, ○
- 113 How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. **2023**, 15, 155 ○
- 112 Refractory adult-onset Still's disease complicated with monoclonal gammopathy of undetermined significance: A case report. **2022**, 101, e32107 ○
- 111 Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers. **2023**, 15, 95 ○
- 110 Serum free light chains benefit diagnosis of multiple myeloma in orthopaedic patients with normal serum total proteins, creatinine, calcium and hemoglobin. ○
- 109 A repurposed drug combination (VaN) inhibits free light chain secretion and triggers the terminal unfolded protein response (UPR) in multiple myeloma (MM). ○
- 108 XGBoost-based multiparameters from dual-energy computed tomography for the differentiation of multiple myeloma of the spine from vertebral osteolytic metastases. ○
- 107 The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review. **2023**, 13, ○
- 106 Eastern Cooperative Oncology Group, β_2 -microglobulin, hemoglobin, and lactate dehydrogenase can predict early grade B infection in patients with newly diagnosed multiple myeloma: A real-world multicenter study. 14, ○
- 105 Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma. ○
- 104 Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS). **2023**, 84, 51 ○
- 103 Immunophenotypic Profile of Multiple Myeloma: A Tertiary Care Centre Experience. ○
- 102 Development and validation of a chemotherapy tolerance prediction model for Chinese multiple myeloma patients: The TM frailty score. 13, ○
- 101 Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients. ○
- 100 Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. ○
- 99 Orbital Involvement in Multiple Myeloma. Publish Ahead of Print, ○
- 98 Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C. **2023**, 223, 44-52 ○

- 97 Investigation of the Underlying Mechanism of Sclerosteosis Expression in Muscle Tissue in Multiple Myeloma with Sarcopenia. Volume 16, 563-578 ○
- 96 Ocular complications of plasma cell dyscrasias. 112067212311559 ○
- 95 GWAS-Identified Variants for Obesity Do Not Influence the Risk of Developing Multiple Myeloma: A Population-Based Study and Meta-Analysis. **2023**, 24, 6029 ○
- 94 Ixazomib Versus Placebo as Post-Induction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. **2023**, ○
- 93 Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study. 13, ○
- 92 Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study. ○
- 91 Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. **2023**, 23, ○
- 90 The presence of two light chain bands on immunofixation is associated with poor outcomes in newly diagnosed multiple myeloma patients. ○
- 89 Sacrococcygeal spindle cell tumour: A case report. **2023**, 92, 102611 ○
- 88 Obesity and multiple myeloma: Emerging mechanisms and perspectives. **2023**, 92, 45-60 ○
- 87 Plasma Cell Gingivitis and Its Mimics. **2023**, 35, 261-270 ○
- 86 Osteolytic lesions: Multiple myeloma or prostate cancer?. **2023**, 18, 1485-1489 ○
- 85 Rapid detection of serum free light chains by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. **2023**, 29, 132-140 ○
- 84 The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. **2023**, 24, 2938 ○
- 83 Development and Internal Validation of a Risk Prediction Model to Identify Myeloma Based on Routine Blood Tests: A Case-Control Study. **2023**, 15, 975 ○
- 82 Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment. **2023**, 556, 216081 ○
- 81 Prevalence of smoldering multiple myeloma based on nationwide screening. **2023**, 29, 467-472 ○
- 80 The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma. **2023**, 23, ○

- 79 Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. **2023**, 8, ○
- 78 Population screening for smoldering multiple myeloma reveals high prevalence. **2023**, 29, 313-314 ○
- 77 Insuffisance rénale dans le myélome multiple : particularités de la prise en charge. **2023**, ○
- 76 The Expression of Serum lncRNA MIR17HG in Patients with Multiple Myeloma and Its Clinical Significance. **2023**, 2023, 1-7 ○
- 75 A Stepwise Screening Protocol for Multiple Myeloma. **2023**, 12, 1345 ○
- 74 High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics. 13, ○
- 73 Challenges for CAR-T cell therapy in multiple myeloma: overcoming the tumor microenvironment. **2023**, 2, ○
- 72 Daratumumab, Lenalidomide, and Dexamethasone for High-Risk Smoldering Multiple Myeloma. **2023**, 20, ○
- 71 Evaluating the screening value of serum light chain ratio, β_2 microglobulin, lactic dehydrogenase and immunoglobulin in patients with multiple myeloma using ROC curves. **2023**, 18, e0281743 ○
- 70 Presentation and outcomes of patients with multiple myeloma harboring gain or amplification of 1q21 and receiving novel agent therapies: results from a single-center study. **2023**, 28, ○
- 69 Influence of diabetes mellitus on the biochemical parameters and outcomes of multiple myeloma. **2023**, 28, ○
- 68 Biclonal Gammopathies in South Tunisia: Clinical and Biological Characteristics. ○
- 67 The short and long-term characteristics and outcomes of patients with grade 1 myocardial uptake on cardiac scintigraphy. ○
- 66 Differentiating Multiple Myeloma and Osteolytic Bone Metastases on Contrast-Enhanced Computed Tomography Scans: The Feasibility of Radiomics Analysis. **2023**, 13, 755 ○
- 65 Neurofilament light chain levels indicate acute axonal damage under bortezomib treatment. ○
- 64 A case of a Young Multiple Myeloma Patient With Poor Prognostic Cytogenetics. **2023**, 16, 117954762311572 ○
- 63 A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia. **2023**, 2023, 1-4 ○
- 62 The evolving diagnosis and treatment paradigms of multiple myeloma in China: 15 years' experience of 1256 patients in a national medical center. ○

- 61 Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review. **2023**, 23, e195-e212 ○
- 60 The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma. **2023**, 28, ○
- 59 The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients. **2023**, 10, e162-e163 ○
- 58 Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study. **2023**, 10, e203-e212 ○
- 57 Solitary Plasmacytoma of the Jugular Foramen: A Case Report and Review of the Differential Diagnosis. **2023**, ○
- 56 PET/TC con FDG y nuevos radiofármacos en pacientes con mieloma múltiple. **2023**, 42, 129-135 ○
- 55 Urine Protein Immunofixation Electrophoresis: Free Light Chain Urine Immunofixation Electrophoresis Is More Sensitive than Conventional Assays for Detecting Monoclonal Light Chains and Could Serve as a Marker of Minimal Residual Disease. ○
- 54 Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study. **2023**, ○
- 53 Lenalidomide Maintenance and Measurable Residual Disease in a Real-World Multiple Myeloma Transplanted Population Receiving Different Treatment Strategies Guided by Access to Novel Drugs in Brazil. **2023**, 15, 1605 ○
- 52 Anti-CD137 Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial. ○
- 51 Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. ○
- 50 Cyclophosphamide, Thalidomide and Dexamethasone (CTD) as First-Line Therapy in Multiple Myeloma Patients: An Experience in a Clinical Haematology Centre in Dakar, Senegal. **2023**, 13, 43-50 ○
- 49 Clinical Application of PET/MRI. **2023**, 788-813 ○
- 48 Pulmonary hypertension in patients with multiple myeloma: A comprehensive review. **2023**, 13, ○
- 47 Venetoclax in Relapse/Refractory AL Amyloidosis: A Multicenter International Retrospective Real-World Study. **2023**, 15, 1710 ○
- 46 The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies. **2023**, 11, ○
- 45 Squelette. **2022**, 4-16 ○
- 44 Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic. **2023**, 13, ○

- 43 Clinical features of multiple myeloma with bone plasmacytomas. **2023**, 18, 48-56 ○
- 42 Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. **2023**, 24, 5730 ○
- 41 Biological Activity and Prognostic Significance of Common Surface Antigens in Multiple Myeloma. **2023**, 13, 3852-3859 ○
- 40 Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. **2023**, ○
- 39 SOME ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA. **2021**, 23, 395-409 ○
- 38 SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of Biomarker-defined early multiple myeloma: systematic review with meta-analysis. **2023**, 58, 101910 ○
- 37 Multiple myeloma with t(11;14): impact of novel agents on outcome. **2023**, 13, ○
- 36 Spondyloarthritis and nonbacterial thrombotic endocarditis as paraneoplastic manifestations in treatment-naïve Burkitt lymphoma. ○
- 35 The incidence of vertebral compression fractures and spinal instability in newly diagnosed multiple myeloma patients. **2023**, 38, 62-67 ○
- 34 Evaluation of methods to eliminate analytical interference in multiple myeloma patients with spurious hyperphosphatemia. ○
- 33 CT-defined body composition as a prognostic factor in multiple myeloma. **2023**, 28, ○
- 32 Myeloma, Amyloid, and Other Dysproteinemias. **2018**, 274-282.e1 ○
- 31 Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop. **2023**, ○
- 30 Unraveling the Role of Peroxisome Proliferator-Activated Receptor α (PPAR α) in Angiogenesis Associated with Multiple Myeloma. **2023**, 12, 1011 ○
- 29 The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma. **2023**, 12, 1029 ○
- 28 Monoklonale Gammopathie unklarer Signifikanz und Smoldering Multiples Myelom. ○
- 27 Multiple myeloma with acute light chain cast nephropathy. **2023**, 13, ○
- 26 Test-retest, inter- and intra-rater reproducibility of size measurements of focal bone marrow lesions in MRI in patients with multiple myeloma. ○

- 25 Comprehensive analysis of prognosis of cuproptosis-related oxidative stress genes in multiple myeloma. 14, ○
- 24 Prediction of mobilized hematopoietic stem cell yield in patients with multiple myeloma: Usefulness of whole-body MRI-derived indices. **2023**, 18, e0283241 ○
- 23 RiskBenefit ratio of percutaneous kyphoplasty and percutaneous vertebroplasty in patients with newly diagnosed multiple myeloma with vertebral fracture: a single-center retrospective study. ○
- 22 Diagnostic value of machine learning-based computed tomography texture analysis for differentiating multiple myeloma from osteolytic metastatic bone lesions in the peripheral skeleton. ○
- 21 Clinical implication by differential analytical performances of serum free light chain quantitation analysis using fully automated analyzers. **2023**, ○
- 20 A Machine Learning Model to Predict Survival and Therapeutic Responses in Multiple Myeloma. **2023**, 24, 6683 ○
- 19 miR-100-5p is upregulated in multiple myeloma and involves in the pathogenesis of multiple myeloma through targeting MTMR3. **2023**, 28, ○
- 18 Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation. **2023**, 102, 1171-1184 ○
- 17 miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma. **2023**, 21, ○
- 16 Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era. ○
- 15 Hybrid simultaneous whole-body 2-[18F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results. ○
- 14 Encephalitis associated with a monoclonal protein band present in blood, urine and cerebrospinal fluid. **2023**, 34, e00313 ○
- 13 Arginase Inhibition Mitigates Bortezomib-Exacerbated Cardiotoxicity in Multiple Myeloma. **2023**, 15, 2191 ○
- 12 Malignancy diseases and kidneys: A nephrologist prospect and updated review. **2023**, 102, e33505 ○
- 11 Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma. **2023**, 13, 666 ○
- 10 Solitary Plasmacytoma in the Calcaneus. **2023**, ○
- 9 Onco-Nephrology. **2023**, ○
- 8 Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma. 11, ○

- 7 Amyloidosis: a case series and review of the literature. **2023**, 17, ○
- 6 YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma. 1-14 ○
- 5 Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations. **2023**, 13, 85S-93S ○
- 4 Elevated von Willebrand factor levels in multiple myeloma: Dysregulated mechanisms of both secretion and clearance. **2023**, ○
- 3 Chest Pain Caused by Thoracic Spine Plasmacytoma: A Case Report. **2023**, ○
- 2 Thrombosis events in Chinese patients with newly diagnosed multiple myeloma. ○
- 1 A Single Reference Interval for Interpreting Serum Free Light Chains across Patients with Varying Renal Function. ○